<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10Q
__X__ Quarterly report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the quarterly period ended September 30, 1998.
____ Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the transition period from to
------------ ------------
Commission File Number
---------
MEGABIOS CORP.
(Exact name of registrant as specified in its charter)
Delaware 94-3156660
------------------------------- --------------------------------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
863A Mitten Rd., Burlingame, CA 94010
------------------------------- ----------
(Address of principal offices) (Zip Code)
650-697-1900
---------------------------------------------------
(Registrant's telephone number including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
Yes __x__ No ____
The number of outstanding shares of the registrant's Common Stock, $.001 par
value, was 12,895,158 as of September 30, 1998.
<PAGE>
MEGABIOS CORP.
INDEX
PART I: FINANCIAL INFORMATION
<TABLE>
<CAPTION>
Page
----
<S> <C>
ITEM 1: FINANCIAL STATEMENTS
Condensed Balance Sheets 3
Condensed Statements of Operations 4
Condensed Statements of Cash Flows 5
Notes to Condensed Financial Statements 6
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS 9
PART II: OTHER INFORMATION
ITEM 1: LEGAL PROCEEDINGS 13
ITEM 2: CHANGES IN SECURITIES AND USE OF PROCEEDS 13
ITEM 3: DEFAULTS UPON SENIOR SECURITIES 13
ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS 13
ITEM 5: OTHER INFORMATION 13
ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K 15
Signatures 16
Exhibit Index 17
</TABLE>
2
<PAGE>
PART i FINANCIAL INFORMATION
ITEM 1 FINANCIAL STATEMENTS
MEGABIOS CORP.
CONDENSED BALANCE SHEETS
(in thousands)
<TABLE>
<CAPTION>
SEPTEMBER 30, JUNE 30,
1998 1998
------------- ---------
(unaudited) (Note 1)
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 10,657 $ 15,172
Short-term investments 17,033 7,794
Other receivables 1,004 616
Prepaid expenses and other current assets 754 539
----------- -----------
Total current assets 29,448 24,121
Property and equipment, net 8,350 6,151
Long-term investments 17,241 25,460
Other receivables 130 130
Deposits and other assets 39 39
------------ ------------
$ 55,208 $ 55,901
------------ ------------
------------ ------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 564 $ 898
Accrued compensation 573 595
Accrued construction-in-progress 766 589
Other accrued liabilities 186 56
Current portion of long-term debt 805 1,017
----------- ----------
Total current liabilities 2,894 3,155
Long-term debt 4,808 2,464
Commitments - -
Stockholders' equity:
Common stock 13 13
Additional paid-in capital 80,041 79,838
Deferred compensation (899) (976)
Accumulated other comprehensive income (loss) 136 (7)
Accumulated deficit (31,785) (28,586)
------------ ------------
Total stockholders' equity 47,506 50,282
------------ ------------
$ 55,208 $ 55,901
------------ ------------
------------ ------------
</TABLE>
See accompanying notes
3
<PAGE>
MEGABIOS CORP.
CONDENSED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
---------------------------------
1998 1997
----------- -----------
(unaudited) (unaudited)
<S> <C> <C>
Collaborative research and development revenue $ 773 $ 2,287
Operating expenses:
Research and development 3,429 2,758
General and administrative 1,076 675
--------- ---------
Total operating expenses 4,505 3,433
--------- --------
Loss from operations (3,732) (1,146)
Interest income 679 398
Interest expense and other (146) (98)
---------- ----------
Net loss $ (3,199) $ (846)
---------- ----------
---------- ----------
Basic and diluted net loss per share $ (0.25) $ (0.29)
---------- ----------
---------- ----------
Shares used in computing basic and diluted net loss per share 12,736 2,902
---------- ----------
---------- ----------
</TABLE>
See accompanying notes
4
<PAGE>
MEGABIOS CORP.
CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
-----------------------------------
1998 1997
----------- ------------
(unaudited) (unaudited)
<S> <C> <C>
Cash flows from operating activities
Net loss $ (3,199) $ (846)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization 584 425
Amortization of deferred compensation 78 73
Changes in operating assets and liabilities:
Other receivables (388) (155)
Prepaid expenses and other (215) (116)
Deferred revenue -- (186)
Accounts payable (334) (607)
Accrued liabilities 108 105
---------- ----------
Net cash used in operating activities (3,366) (1,307)
---------- ----------
Cash flows from investing activities
Purchase of property and equipment (2,544) (1,163)
Deposits and other assets -- (2)
Purchase of available-for-sale investments (2,010) (4,073)
Maturities of available-for-sale investments 1,070 5,500
--------- ---------
Net cash provided by (used in) investing activities (3,484) 262
--------- ---------
Cash flows from financing activities
Proceeds from issuance of long-term debt 2,502 872
Payments on long-term debt (370) (334)
Proceeds from issuance of common stock, net of repurchases 203 31,770
--------- --------
Net cash provided by financing activities 2,335 32,308
--------- --------
Net increase (decrease) in cash and cash equivalents (4,515) 31,263
Cash and cash equivalents, beginning of period 15,172 9,044
--------- ----------
Cash and cash equivalents, end of period $ 10,657 $ 40,307
--------- ----------
--------- ----------
Supplemental disclosure of cash flow information:
Interest paid $ 143 $ 98
Schedule of non-cash transactions:
Construction in progress included in accrued liabilities $ 177 $ -
</TABLE>
See accompanying notes
5
<PAGE>
MEGABIOS CORP.
NOTES TO THE CONDENSED FINANCIAL STATEMENTS
1. ORGANIZATION AND BASIS OF PRESENTATION
The accompanying condensed financial statements are unaudited and have been
prepared by Megabios Corp. (the "Company") in accordance with the rules and
regulations of the Securities and Exchange Commission for interim financial
information and in accordance with the instructions to Form 10-Q and Article 10
of Regulation S-X. Certain information and footnote disclosures normally
included in the Company's annual financial statements as required by generally
accepted accounting principles have been condensed or omitted. The interim
financial statements, in the opinion of management, reflect all adjustments
(consisting of normal recurring accruals) necessary for a fair statement of the
results for the interim periods ended September 30, 1998 and 1997. The balance
sheet at June 30, 1998 is derived from the audited financial statements at that
date but does not include all the information and footnotes required by
generally accepted accounting principles for complete financial statements.
The results of operations for the interim periods are not necessarily indicative
of the results of operations to be expected for the fiscal year, although the
Company expects to incur a substantial loss for the year ended June 30, 1999.
These interim financial statements should be read in conjunction with the
audited financial statements for the year ended June 30, 1998, which are
contained in the Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission.
2. REVENUE RECOGNITION
Revenue related to collaborative research agreements with the Company's
corporate partners is recognized over the related funding periods for each
contract. The Company is required to perform research and development activities
as specified in each respective agreement on a best-efforts basis. The Company
is reimbursed based on the costs associated with the number of full time
equivalent employees working on each specific contract over the term of the
agreement. Research and development expenses under the collaborative research
agreements approximate or exceed the revenue recognized under such agreements
over the term of the respective agreements. Deferred revenue may result when the
Company does not incur the required level of effort during a specific period in
comparison to funds received under the respective contracts. Milestone payments,
if any, will be recognized pursuant to collaborative agreements upon the
achievement of specified milestones, such as the filing of Investigational New
Drug Applications, commencement of clinical trials or receipt of regulatory
approvals. No milestone payments have been earned or recognized to date.
3. NET LOSS PER SHARE
Basic earnings per share is computed by dividing income or loss applicable to
common stockholders by the weighted-average number of common shares outstanding
for the period net of certain common shares outstanding which are subject to
continued vesting and the Company's right of repurchase. Basic earnings per
share excludes any dilutive effects of options.
6
<PAGE>
MEGABIOS CORP.
NOTES TO FINANCIAL STATEMENTS - (CONTINUED)
Diluted net loss per share has not been presented separately as, given the
Company's net loss position, the result would be anti-dilutive.
The following have been excluded from the calculation of loss per share because
the effect of inclusion would be antidilutive: approximately 136,418 common
shares which are outstanding but are subject to the Company's right of
repurchase which expires ratably over 4 years, and options to purchase
approximately 1,068,408 shares of common stock at a weighted average price of
$5.93 per share. The repurchasable shares and options will be included in the
calculation at such time as the effect is no longer antidilutive, as calculated
using the treasury stock method.
A reconciliation of shares used in the calculation of basic and diluted
and pro forma net loss per share follows:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
SEPTEMBER 30,
----------------------------------------
1998 1997
---- ----
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<S> <C> <C>
Net loss $(3,199) $ (846)
--------------- ---------------
--------------- ---------------
BASIC AND DILUTED
Weighted average shares of common stock 12,872 3,248
Common shares subject to repurchase (136) (346)
--------------- ---------------
Weighted average shares of common stock used in computing net loss per
share 12,736 2,902
--------------- ---------------
--------------- ---------------
Basic and diluted net loss per share $ (0.25) $ (0.29)
--------------- ---------------
--------------- ---------------
PRO FORMA
Shares used in computing net loss per share 2,902
Adjustment to reflect the effect of the assumed conversion from the date
of issuance of preferred stock which automatically converted to common
stock upon the Company's initial public offering 7,180
---------------
Shares used in computing pro forma net loss per share 10,082
---------------
---------------
Pro forma net loss per share $ (0.08)
---------------
---------------
</TABLE>
7
<PAGE>
4. COLLABORATIVE, LICENSE AND RESEARCH AGREEMENTS
In September, 1998, Megabios and DSM Biologics ("DSM") announced the formation
of a broad, strategic partnership focused on the manufacture and supply of DNA
plasmids and DNA:lipid complexes.
Plasmids are circular pieces of DNA that contain a therapeutic gene and
instructional elements that regulate the activity of the gene. The manufacturing
process can be used to produce any plasmid.
The partnership will create the first manufacturing facilities that can produce
high-quality, ultrapure material for plasmid-based therapeutics on every scale,
from preclinical toxicology studies to commercial products. DSM will have full
responsibility for manufacturing material to be marketed to any company or
institution working in the field of gene therapy. The partnership will use
Megabios' proprietary methods for the manufacture of plasmid DNA and complexing
that DNA with lipids. This arrangement could provide revenue for Megabios in
advance of the launch of commercial gene-based products.
Under the agreement, Megabios has exclusively licensed its proprietary
manufacturing technology to DSM for use in its facility in Montreal, Canada and
may be extended to include DSM's facility in Gronigen, The Netherlands. In
return, DSM will pay license and milestone fees to Megabios, and DSM and
Megabios will share in the profits generated by the sale of material produced
using Megabios' process. The initial term of the exclusive partnership is at
least three years and maybe extended.
The Megabios - DSM manufacturing method has already been used to produce
material for a Phase I/II trial for cystic fibrosis conducted by Megabios'
partner, Glaxo Wellcome plc ("Glaxo Wellcome"), and a Phase I/II study for
metastatic melanoma, conducted by Megabios and its academic collaborators at the
University of Colorado Health Sciences Center.
5. SUBSEQUENT EVENT
On October 26, 1998, Megabios and GeneMedicine Inc. announced the signing of a
definitive merger agreement. Under the terms of the agreement, which was
unanimously approved by the boards of both companies, each outstanding share of
GeneMedicine common stock will be exchanged, at a fixed exchange ratio of 0.571,
for newly issued shares of common stock of Megabios Corp. This will result in
the issuance of approximately 9.1 million additional Megabios Corp. shares,
valued at about $38 million based on Megabios Corp.'s closing price of Friday,
October 23, 1998. In addition, all outstanding employee stock options of
GeneMedicine will convert into Megabios options at the same exchange ratio. The
Board of Directors of the combined company will consist of eight directors,
three of whom will be current directors of GeneMedicine, and Benjamin F. McGraw
III will remain as chairman, president and CEO of the combined entity.
The proposed transaction will be accounted for as a purchase. A significant
portion of the excess purchase price is expected to be charged to in-process
research and development in the Company's statement of operations for the
quarter in which the transaction is completed. The merger is subject to the
approval of stockholders of both companies and appropriate governmental
agencies. The transaction is expected to close in the first calendar quarter of
1999.
8
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
THE FOLLOWING MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND
UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE
ANTICIPATED IN THESE FORWARD-LOOKING STATEMENTS AS A RESULT OF CERTAIN FACTORS,
INCLUDING THOSE SET FORTH UNDER "RISK FACTORS" IN THE COMPANY'S ANNUAL REPORT ON
FORM 10-K FOR THE YEAR ENDED JUNE 30, 1998, FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION.
The Company develops proprietary gene delivery systems and provides preclinical
development expertise to create gene-based therapeutics designed for the
treatment or prevention of genetic and acquired diseases. The Company has
developed several IN VIVO, non-viral gene delivery systems to address a number
of potential therapeutic applications using a variety of therapeutic genes. The
Company's clinical development and commercialization strategy is to enter into
corporate partnerships with pharmaceutical and biotechnology companies. The
Company has established corporate partnerships with Glaxo Wellcome, Pfizer Inc.
("Pfizer") and Eli Lilly & Co. ("Lilly"). In December 1997, Pfizer decided to
discontinue its research and development program to develop gene-based
therapeutics to treat cancer via angiogenesis inhibition. Under the terms of the
agreement with Pfizer, Pfizer continued funding the program through May 31,
1998. Megabios intends to continue to advance the angiogenesis inhibition
program and is actively seeking a new corporate partner. The corporate
partnerships with Glaxo Wellcome and Lilly are ongoing.
To date, substantially all revenue has been generated by collaborative research
and development agreements with corporate partners, and no revenue has been
generated from product sales. Under the terms of its corporate collaborations,
the Company receives research and development funding on a quarterly basis in
advance of associated research and development costs. The Company expects that
future revenue will be derived in the short-term from research and development
agreements and milestone payments and in the long-term from royalties on product
sales.
The Company has incurred significant losses since inception and expects to incur
substantial losses for the foreseeable future, primarily due to the expansion of
its research and development programs and because the Company does not expect to
generate revenue from the sale of products in the foreseeable future, if at all.
The Company expects that operating results will fluctuate from quarter to
quarter and that such fluctuations may be substantial. As of September 30, 1998,
the Company's accumulated deficit was approximately $31.8 million.
RESULTS OF OPERATIONS
The Company's collaborative research and development revenue totaled
approximately $773,000, and $2.3 million for the quarters ended September 30,
1998 and 1997, respectively. The 1998 revenue was attributable to amounts earned
for research and development performed under the Company's corporate
collaboration with Lilly. The 1997 revenue was primarily attributable to amounts
earned for research and development performed under the Company's corporate
collaborations with Pfizer and Lilly totaling approximately $1.2 million and
$1.1 million, respectively. No revenue from milestones or royalties from product
sales have been earned under any corporate collaboration to date.
9
<PAGE>
Research and development expenses increased to $3.4 million for the three months
ended September 30, 1998 from $2.8 million for the same period in 1997. The
increase was primarily attributable to increased headcount expenses, increased
purchases of laboratory supplies and materials, increased depreciation from
additional equipment and leasehold improvements and the increased use of
consultants and other services to support the Company's research and development
activities. The Company expects research and development expenses to increase as
the Company continues to expand its independent and collaborative research and
development programs.
General and administrative expenses increased to $1.1 million for the three
months ended September 30, 1998 from $675,000 in the corresponding period of
1997. The increase in 1998 compared to 1997 was primarily attributable to
increased administrative headcount and costs associated with being a newly
public company. The Company expects general and administrative expenses to
increase due to business development activities, expenses incurred as a publicly
traded company, and in support of expanded research and development activities.
Interest income increased to $679,000 for the three months ended September 30,
1998 compared with $398,000 for the same period in 1997. The increase in
interest income resulted primarily from the increase in average cash and
investment balances as a result of $31.4 million in net proceeds from the
Company's initial public offering in September 1997.
Interest expense and other increased to $146,000 for the three months ended
September 30, 1998 compared with $98,000 for the same period in 1997. The
increase was due to additional interest expense on higher outstanding balances
under the Company's equipment financing line of credit.
LIQUIDITY AND CAPITAL RESOURCES
As of September 30, 1998, the Company had $44.9 million in cash, cash
equivalents and investments compared to $48.4 million at June 30, 1998.
Net cash used in the Company's operations was $3.3 million for the quarter ended
September 30, 1998, compared to $1.3 million for the same period in 1997. This
cash was used primarily to fund increasing levels of research and development
and the general and administrative activities. The Company's capital
expenditures were $2.5 million in the quarter ended September 30, 1998 as
compared to $1.2 million in the same quarter of 1997. The majority of the
expenditures made as of September 30, 1998 relate to construction of the
Company's pilot manufacturing facility. The facility is expected to be completed
in December 1998.
In June 1998, the Company obtained an $8.0 million line of credit from a
commercial bank. As of June 30, 1998, the Company had drawn and converted $1.0
million of this line of credit into a term loan bearing interest at the prime
rate plus 0.5%. The loan is payable in 42 equal monthly installments beginning
July 31, 1998. An additional $2.5 million was drawn from the line of credit in
the quarter ended September 30, 1998. Interest on this amount is accrued and
paid monthly and will be converted into a term loan bearing interest at the
prime rate plus 0.5% on December 31, 1998. The $2.5 million draw will be payable
in 42 monthly installments beginning January 31, 1998. The remaining $4.5
million is available to the Company through December 31, 1998.
10
<PAGE>
The Company anticipates that its cash and cash equivalents, committed funding
from existing corporate partnerships, amounts available under its existing line
of credit, and interest income will enable the Company to maintain its current
and planned operations through fiscal 2000. However, there can be no assurance
that the Company will not require additional funding prior to such time. The
Company's future capital requirements will depend on many factors, including
scientific progress in its research and development programs, the size and
complexity of such programs, the scope and results of preclinical studies and
clinical trials, the ability of the Company to establish and maintain corporate
partnerships, the time and costs involved in obtaining regulatory approvals, the
time and costs involved in filing, prosecuting and enforcing patent claims,
competing technological and market developments, the cost of manufacturing
preclinical and clinical materials and other factors not within the Company's
control. The Company is seeking additional collaborative agreements with
corporate partners and may seek additional funding through public or private
equity or debt financing. There can be no assurance, however, that any such
agreements may be entered into or that they will reduce the Company's funding
requirements or that additional funding will be available. The Company expects
that additional equity or debt financing may be required to fund its operations.
There can be no assurance that additional financing to meet the Company's
funding requirements will be available on acceptable terms or at all.
If additional funds are raised by issuing equity securities, substantial
dilution to existing stockholders may result. Insufficient funds may require the
Company to delay, scale back or eliminate some or all of its research or
development programs or to relinquish greater or all rights to products at an
earlier stage of development or on less favorable terms than the Company would
otherwise seek to obtain, which could materially adversely affect the Company's
business, financial condition and results of operations.
IMPACT OF THE YEAR 2000
A major issue currently faced by all industries is the Year 2000 ("Y2K")
computer issue. The problem arises from the use in computer hardware and
software of the last two digits rather than four digits to define the year. As a
result, computer programs are unable to distinguish a year which begins with
"20" or "19". This, can then cause failures in computer systems and
applications, or create erroneous results unless steps are taken to prevent such
failures and errors. The Y2K problem is also compounded by the fact that many
computer and telecommunication systems are interdependent, both within the
United States and throughout the world. Thus, due to interdependence, the
failure of one system may lead other systems to fail, even if these systems are
themselves Y2K compliant.
In order to address this issue, the Company has put a Y2K plan in place to
identify, evaluate and modify its current systems or replace and implement new
systems. Identification includes reviewing and assessing the potential systems
within the Company and at key third party vendors that would be affected by the
Y2K issue. A Y2K Committee, comprised of members of all the Company's
departments and senior management, has been established to evaluate, assess and
prioritize the Company's internal systems and key vendors' systems.
The Company is in the evaluation stage and has determined that it will be
required to upgrade or replace a portion of its accounting software and a
program is underway to evaluate existing or new financial software and
applications.
Completion of the Company's Y2K plan is targeted for the calendar fourth
quarter of 1999. The Company believes that, with upgrades of existing
software and/or conversions to new software, the Y2K issue will not pose
significant operational problems for its business activities. However, if
such upgrades or conversions are
11
<PAGE>
not made, or are not completed in a timely fashion, the Y2K issue could have
a material impact on the operations of the Company, the precise degree of
which cannot be known at this time. The Company currently has no contingency
plans to deal with major Y2K failures, though such plans will be developed
over the coming quarters.
The Company has also initiated communications with its significant suppliers to
determine the extent to which the Company's operations are vulnerable to those
third parties' failure to solve their own Y2K issues. When evaluation is
completed, the Company will modify, or replace if necessary, any other internal
systems and enter into new business relationships with Y2K compliant vendors in
the ordinary course of business. Contingency plans are to be established to
utilize vendors whose systems are Y2K compliant in the event that the Company's
primary vendors fail to adequately address their Y2K issues. However, if such
suppliers or other third parties with which the Company transacts business
experience failures in their computer systems or equipment due to Y2K
non-compliance, it could effect the Company's ability to process transactions or
engage in ordinary business activities.
The financial impact of the required upgrades and/or conversion of computer
software relating to the Y2K issue cannot be known precisely at this time, but
the Company currently anticipates that the cost will be less than $100,000. The
actual financial impact could, however, exceed this estimate. Also, the
estimated costs of implementing the Y2K plan do not take into account the costs,
if any, that might be incurred as a result of Y2K related failures that occur
despite the Company's implementation of its Y2K plan.
Although the Company is not aware of any material operational issues associated
with preparing its internal systems for the Year 2000, or material issues with
respect to the adequacy of third party systems, the Company could experience
material unanticipated negative consequences and/or material costs caused by
undetected errors or defects in such systems or by the Company's failure to
adequately prepare for the results of such errors or defects, including the
costs of related litigation, if any. The impact of such consequences could have
a material adverse effect on the Company's business, financial condition or
results of operations.
12
<PAGE>
PART II: OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
The effective date of the Company's registration statement,
filed on Form S-1 filed under the Securities Act of 1933 (No.
333-32593), was September 15, 1997 (the "Registration
Statement"). The class of securities registered was Common
Stock. The offering commenced on September 15, 1997 and all
securities were sold in the offering. The managing underwriters
for the offering were Montgomery Securities and Hambrecht &
Quist LLP.
Pursuant to the Registration Statement, the Company sold
2,875,000 shares of its Common Stock for an aggregate offering
price of $34,500,000.
The Company incurred expenses of approximately $3.1 million of
which $2.4 million represented underwriting discounts and
commissions and $700,000 represented other expenses. All such
expenses were direct or indirect payments to others. The net
offering proceeds to the Company after total expenses was $31.4
million.
The Company has not used any of the net proceeds from the
offering. All net proceeds have been invested in cash, cash
equivalents and short-term investments. The use of proceeds from
the offering does not represent a material change in the use of
proceeds described in the prospectus.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
ITEM 5. OTHER INFORMATION
Pursuant to an Agreement and Plan of Merger and Reorganization
dated October 24, 1998 (the "Reorganization Agreement") among
Megabios, Montana Acquisition Sub, Inc., a Delaware corporation
and wholly-owned subsidiary of Megabios ("Merger Sub"), and
GeneMedicine, Inc. ("GeneMedicine"), and subject to the
conditions set forth therein (including approval by the
stockholders of Megabios and stockholders of GeneMedicine),
Merger Sub will be merged with and into GeneMedicine (the
"Merger"), with each share of GeneMedicine Common Stock being
converted into the right to receive 0.571 ("Megabios Common
Stock") shares of Megabios' Common Stock. In addition, Megabios
will assume all options outstanding under GeneMedicine's Amended
and Restated Stock Option Plan and all warrants outstanding and
issued by GeneMedicine. If the Merger is consummated,
GeneMedicine Common Stock will be deregistered under the
Exchange Act and delisted from the NASDAQ National Market.
13
<PAGE>
At the effective time of the Merger (the "Effective Time"), the
separate existence of Merger Sub will cease, and GeneMedicine
will continue as the surviving corporation and as a wholly-owned
subsidiary of Megabios ("Surviving Corporation"). The officers
and directors of the Surviving Corporation immediately after the
Effective Time shall be the officers and directors of Merger Sub
immediately prior to the Effective Time and shall serve as the
officers and directors of the Surviving Corporation until their
respective successors are elected and qualified or duly
appointed, as the case may be. The Certificate of Incorporation
of the Surviving Corporation shall be amended and restated as of
the Effective Time to conform to the Certificate of
Incorporation of Merger Sub as in effect immediately prior to
the Effective Time. The Bylaws of the Surviving Corporation shall
be amended and restated as of the Effective Time to conform to
the Bylaws of Merger Sub as in effect immediately prior to the
Effective Time.
REPRESENTATIONS, WARRANTIES, COVENANTS AND CLOSING CONDITIONS.
The Reorganization Agreement contains customary representations
and warranties on the part of GeneMedicine and Megabios, and the
consummation of the Merger is subject to customary closing
conditions, including, without limitation, approval by the
stockholders of GeneMedicine and Megabios, regulatory approval
and the occurrence of no material adverse effect with respect to
a party. The Reorganization Agreement also contains covenants
regarding the activities of GeneMedicine and Megabios prior to
the earlier of the Effective Time and the termination of the
Reorganization Agreement. GeneMedicine and Megabios,
respectively, have agreed to, among other things, conduct their
business in the ordinary course, in accordance with past
practices and in compliance with applicable laws and the
requirements of all of material contracts. In addition, a number
of corporate actions by GeneMedicine and Megabios, respectively,
during the period pending the closing of the Merger require the
other party's approval, including without limitation, dividends,
issuances of capital stock, capital expenditures and stock
options grants above specified minimums.
TERMINATION OF REORGANIZATION AGREEMENT. The Reorganization
Agreement may be terminated prior to the Effective Time, whether
before or after approval of the Reorganization Agreement and the
Merger by the stockholders of GeneMedicine; (i) by mutual
written consent of the Boards of Directors of Megabios and
GeneMedicine; (ii) subject to certain exceptions, by either
Megabios or GeneMedicine if the Merger shall not have been
consummated by February 28, 1999; (iii) by either Megabios or
GeneMedicine in connection with certain legal or governmental
actions having the effect of permanently restraining, enjoining
or otherwise prohibiting the Merger; (iv) subject to certain
limitations, by Megabios or GeneMedicine if the GeneMedicine
Special Meeting shall have been held and the Reorganization
Agreement and the Merger shall not have been approved by the
necessary vote of the GeneMedicine stockholders; (v) by Megabios
if (at any time prior to the adoption and approval of the
Reorganization Agreement and approval of the Merger by the
GeneMedicine stockholders) a "Triggering Event" (as defined in
the Reorganization Agreement) shall have occurred; (vi) by
GeneMedicine, upon satisfaction of certain conditions, if the
Board of Directors of GeneMedicine withdraws, amends, or
modifies its unanimous recommendation in favor of the Merger and
accepts or recommends to GeneMedicine stockholders a Superior
Offer (as defined in the Reorganization Agreement);
14
<PAGE>
(vii) subject to certain limitations, by Megabios or GeneMedicine if
the Megabios Special Meeting shall have been held and the
issuance of Megabios Common stock in the Merger shall not have
been approved by the necessary vote of the Megabios
stockholders; (viii) by Megabios subject to certain limitations,
if any of the representations and warranties of GeneMedicine
contained in the Reorganization Agreement shall be or have
become materially inaccurate, or if any of GeneMedicine's
covenants contained in the Reorganization Agreement shall be
have breached in any material respect and such inaccuracy or
breach (individually and collectively) will cause a Materially
Adverse Effect (as defined in the Reorganization Agreement) on
the Company; or (ix) by GeneMedicine, subject to certain
limitations, if any of the representations and warranties of
Megabios contained in the Reorganization Agreement shall be or
have become materially inaccurate, or if any of Megabios'
covenants contained in the Reorganization have been breached in
any material respect and such inaccuracy or breach (individually
and collectively) will cause a Materially Adverse Effect (as
defined in the Reorganization Agreement) on Megabios.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
a. Exhibits
27 Financial Data Schedule (Exhibit 27 is submitted as
an exhibit only in the electronic format of this
Quarterly Report on Form 10-Q submitted to the
Securities and Exchange Commission).
99.1 Agreement and Plan of Merger and Reorganization by
and among the Company, Montana Acquisition Sub and
GeneMedicine, Inc. dated as of October 24, 1998.
b. Reports on Form 8-K
Filed on October 28, 1998, announcing an agreement between Megabios
Corp. and GeneMedicine Inc. to merge in a transaction intended to
qualify for a tax-free reorganization.
15
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Megabios Corp.
-----------------------------
(registrant)
Date: November 13, 1998 /s/ Benjamin F. McGraw III
-----------------------------
Benjamin F. McGraw III
President, Chief Executive Officer, and
Chairman of the Board of Directors
Date: November 13, 1998 /s/ Bennet Weintraub
-----------------------------
Bennet Weintraub
Chief Financial Officer and Vice President
Finance (Principal Financial and Accounting
Officer)
16
<PAGE>
MEGABIOS CORP.
EXHIBIT INDEX
27 Financial Data Schedule (Exhibit 27 is submitted
as an exhibit only in the electronic format of this
Quarterly Report on Form 10-Q submitted to the
Securities and Exchange Commission).
99.1 Agreement and Plan of Merger and Reorganization by and among the
Company, Montana Acquisition Sub and GeneMedicine, Inc. dated as
of October 24, 1998.
17
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUN-30-1999
<PERIOD-START> JUN-30-1998
<PERIOD-END> SEP-30-1998
<CASH> 10,657
<SECURITIES> 17,033
<RECEIVABLES> 1,004
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 29,448
<PP&E> 13,913
<DEPRECIATION> 5,563
<TOTAL-ASSETS> 55,208
<CURRENT-LIABILITIES> 0
<BONDS> 0
0
0
<COMMON> 80,054
<OTHER-SE> (32,548)
<TOTAL-LIABILITY-AND-EQUITY> 55,208
<SALES> 773
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 4,505
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 143
<INCOME-PRETAX> (3,199)
<INCOME-TAX> 0
<INCOME-CONTINUING> (3,199)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,199)
<EPS-PRIMARY> (.25)
<EPS-DILUTED> (.25)
</TABLE>
<PAGE>
- ------------------------------------------------------------------------------
- ------------------------------------------------------------------------------
AGREEMENT AND PLAN OF MERGER
AND
REORGANIZATION
AMONG
MEGABIOS CORP.
A DELAWARE CORPORATION;
MONTANA ACQUISITION SUB, INC.,
A DELAWARE CORPORATION;
AND
GENEMEDICINE, INC.,
A DELAWARE CORPORATION
--------------------------------------
DATED AS OF OCTOBER 24, 1998
--------------------------------------
- ------------------------------------------------------------------------------
- ------------------------------------------------------------------------------
EXECUTION COPY
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
<S> <C>
SECTION 1. DESCRIPTION OF TRANSACTION . . . . . . . . . . . . . . . . . . . . . 1
1.1 Merger of Merger Sub into the Company. . . . . . . . . . . . . . . . 1
1.2 Effect of the Merger . . . . . . . . . . . . . . . . . . . . . . . . 1
1.3 Closing; Effective Time. . . . . . . . . . . . . . . . . . . . . . . 1
1.4 Certificate of Incorporation and Bylaws; Directors and
Officers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.5 Conversion of Shares . . . . . . . . . . . . . . . . . . . . . . . . 2
1.6 Stock Options and Warrants . . . . . . . . . . . . . . . . . . . . . 3
1.7 Closing of the Company's Transfer Books. . . . . . . . . . . . . . . 3
1.8 Exchange of Certificates . . . . . . . . . . . . . . . . . . . . . . 3
1.9 Tax Consequences . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.10 Further Action . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. . . . . . . . . . . . 5
2.1 Due Organization; Subsidiaries; Etc . . . . . . . . . . . . . . . . 5
2.2 Certificate of Incorporation and Bylaws. . . . . . . . . . . . . . . 6
2.3 Capitalization, Etc. . . . . . . . . . . . . . . . . . . . . . . . . 6
2.4 SEC Filings; Financial Statements. . . . . . . . . . . . . . . . . . 8
2.5 Absence of Changes . . . . . . . . . . . . . . . . . . . . . . . . . 8
2.6 Leasehold; Equipment . . . . . . . . . . . . . . . . . . . . . . . .10
2.7 Title to Assets. . . . . . . . . . . . . . . . . . . . . . . . . . .11
2.8 Payments Under Corporate Partnering Agreements . . . . . . . . . . .11
2.9 Proprietary Assets . . . . . . . . . . . . . . . . . . . . . . . . .11
2.10 Contracts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13
2.11 Year 2000 Liabilities. . . . . . . . . . . . . . . . . . . . . . . .14
2.12 Compliance with Legal Requirements . . . . . . . . . . . . . . . . .15
2.13 Certain Business Practices . . . . . . . . . . . . . . . . . . . . .15
2.14 Governmental Authorizations. . . . . . . . . . . . . . . . . . . . .15
2.15 Tax Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . .15
2.16 Employee and Labor Matters; Benefit Plans. . . . . . . . . . . . . .16
2.17 Environmental Matters . . . . . . . . . . . . . . . . . . . . . . .19
2.18 Insurance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19
i.
<PAGE>
TABLE OF CONTENTS
(CONTINUED)
PAGE
2.19 Transactions with Affiliates . . . . . . . . . . . . . . . . . . . .19
2.20 Legal Proceedings; Orders . . . . . . . . . . . . . . . . . . . . .19
2.21 Authority; Binding Nature of Agreement . . . . . . . . . . . . . . .20
2.22 No Existing Discussions . . . . . . . . . . . . . . . . . . . . . .20
2.23 Vote Required. . . . . . . . . . . . . . . . . . . . . . . . . . . .20
2.24 Non-Contravention; Consents. . . . . . . . . . . . . . . . . . . . .20
2.25 Fairness Opinion . . . . . . . . . . . . . . . . . . . . . . . . . .21
2.26 Financial Advisor. . . . . . . . . . . . . . . . . . . . . . . . . .21
2.27 Full Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . .22
2.28 Rights Agreement . . . . . . . . . . . . . . . . . . . . . . . . . .22
SECTION 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB. . . . . . .22
3.1 Due Organization; Subsidiaries; Etc. . . . . . . . . . . . . . . . .23
3.2 Certificates of Incorporation and Bylaws . . . . . . . . . . . . . .23
3.3 Capitalization, Etc. . . . . . . . . . . . . . . . . . . . . . . . .23
3.4 SEC Filings; Financial Statements. . . . . . . . . . . . . . . . . .25
3.5 Absence of Changes . . . . . . . . . . . . . . . . . . . . . . . . .26
3.6 Leasehold; Equipment . . . . . . . . . . . . . . . . . . . . . . . .27
3.7 Title to Assets. . . . . . . . . . . . . . . . . . . . . . . . . . .28
3.8 Payments Under Corporate Partnering Agreements . . . . . . . . . . .28
3.9 Proprietary Assets . . . . . . . . . . . . . . . . . . . . . . . . .28
3.10 Contracts. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30
3.11 Year 2000 Liabilities. . . . . . . . . . . . . . . . . . . . . . . .31
3.12 Compliance with Legal Requirements . . . . . . . . . . . . . . . . .32
3.13 Certain Business Practices . . . . . . . . . . . . . . . . . . . . .32
3.14 Governmental Authorizations. . . . . . . . . . . . . . . . . . . . .32
3.15 Tax Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . .32
3.16 Employee and Labor Matters; Benefit Plans. . . . . . . . . . . . . .33
3.17 Environmental Matters. . . . . . . . . . . . . . . . . . . . . . . .34
3.18 Insurance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .35
ii.
<PAGE>
TABLE OF CONTENTS
(CONTINUED)
PAGE
3.19 Transactions with Affiliates . . . . . . . . . . . . . . . . . . . .35
3.20 Legal Proceedings; Orders. . . . . . . . . . . . . . . . . . . . . .35
3.21 Authority; Binding Nature of Agreement . . . . . . . . . . . . . . .36
3.22 Non-Contravention; Consents. . . . . . . . . . . . . . . . . . . . .36
3.23 Vote Required. . . . . . . . . . . . . . . . . . . . . . . . . . . .37
3.24 Valid Issuance . . . . . . . . . . . . . . . . . . . . . . . . . . .37
3.25 Fairness Opinion . . . . . . . . . . . . . . . . . . . . . . . . . .37
3.26 Full Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . .37
3.27 Financial Advisor. . . . . . . . . . . . . . . . . . . . . . . . . .38
3.28 Interim Operations of Merger Sub . . . . . . . . . . . . . . . . . .38
SECTION 4. CERTAIN COVENANTS OF THE COMPANY . . . . . . . . . . . . . . . . . .38
4.1 Operation of the Company's Business. . . . . . . . . . . . . . . . .38
4.2 No Solicitation. . . . . . . . . . . . . . . . . . . . . . . . . . .40
4.3 Conversion of Series B Preferred Stock . . . . . . . . . . . . . . .41
SECTION 5. CERTAIN COVENANTS OF PARENT . . . . . . . . . . . . . . . . . . . .41
5.1 Operation of the Parent's Business . . . . . . . . . . . . . . . . .41
SECTION 6. ADDITIONAL COVENANTS OF THE PARTIES. . . . . . . . . . . . . . . . .42
6.1 Registration Statement; Joint Proxy Statement/Prospectus . . . . . .42
6.2 Company Stockholders' Meeting. . . . . . . . . . . . . . . . . . . .43
6.3 Parent Stockholders' Meeting . . . . . . . . . . . . . . . . . . . .44
6.4 Regulatory Approvals . . . . . . . . . . . . . . . . . . . . . . . .45
6.5 Stock Options. . . . . . . . . . . . . . . . . . . . . . . . . . . .45
6.6 Form S-8.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .46
6.7 Indemnification of Officers and Directors. . . . . . . . . . . . . .46
6.8 Tax Free Reorganization. . . . . . . . . . . . . . . . . . . . . . .47
6.9 Additional Agreements. . . . . . . . . . . . . . . . . . . . . . . .47
6.10 Confidentiality. . . . . . . . . . . . . . . . . . . . . . . . . . .47
6.11 Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . .47
6.12 Tax Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . .48
6.13 Resignation of Officers and Directors . . . . . . . . . . . . . . .48
iii.
<PAGE>
TABLE OF CONTENTS
(CONTINUED)
PAGE
6.14 Nasdaq Listing . . . . . . . . . . . . . . . . . . . . . . . . . . .48
6.15 FIRPTA Matters . . . . . . . . . . . . . . . . . . . . . . . . . . .48
6.16 Parent Board of Directors. . . . . . . . . . . . . . . . . . . . . .48
6.17 Access and Investigation . . . . . . . . . . . . . . . . . . . . . .48
6.18 Operation of Business . . . . . . . . . . . . . . . . . . . . . . .49
6.19 Financial Statements . . . . . . . . . . . . . . . . . . . . . . . .50
SECTION 7. CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER
SUB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50
7.1 Accuracy of Representations. . . . . . . . . . . . . . . . . . . . .51
7.2 Performance of Covenants . . . . . . . . . . . . . . . . . . . . . .51
7.3 Effectiveness of Registration Statement. . . . . . . . . . . . . . .51
7.4 Stockholder Approval . . . . . . . . . . . . . . . . . . . . . . . .51
7.5 Consents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51
7.6 Agreements and Documents . . . . . . . . . . . . . . . . . . . . . .51
7.7 No Material Adverse Change . . . . . . . . . . . . . . . . . . . . .52
7.8 FIRPTA Compliance. . . . . . . . . . . . . . . . . . . . . . . . . .52
7.9 Listing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52
7.10 No Governmental Litigation . . . . . . . . . . . . . . . . . . . . .52
7.11 No Other Litigation . . . . . . . . . . . . . . . . . . . . . . . .52
7.12 Conversion of Series B Preferred Stock . . . . . . . . . . . . . . .52
SECTION 8. CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY . . . . . . . . .52
8.1 Accuracy of Representations. . . . . . . . . . . . . . . . . . . . .53
8.2 Performance of Covenants . . . . . . . . . . . . . . . . . . . . . .53
8.3 Effectiveness of Registration Statement . . . . . . . . . . . . . .53
8.4 Stockholder Approval . . . . . . . . . . . . . . . . . . . . . . . .53
8.5 Documents . . . . . . . . . . . . . . . . . . . . . . . . . . . . .53
8.6 No Material Adverse Change . . . . . . . . . . . . . . . . . . . . .53
8.7 Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .53
8.8 No Governmental Litigation . . . . . . . . . . . . . . . . . . . .53
8.9 No Other Litigation . . . . . . . . . . . . . . . . . . . . . . . .54
iv.
<PAGE>
TABLE OF CONTENTS
(CONTINUED)
PAGE
8.10 Directors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54
SECTION 9. TERMINATION . . . . . . . . . . . . . . . . . . . . . . . . . . . .54
9.1 Termination. . . . . . . . . . . . . . . . . . . . . . . . . . . . .54
9.2 Notice of Termination; Effect of Termination . . . . . . . . . . . .55
9.3 Expenses; Termination Fees . . . . . . . . . . . . . . . . . . . . .56
SECTION 10. MISCELLANEOUS PROVISIONS . . . . . . . . . . . . . . . . . . . . .56
10.1 Amendment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56
10.2 Waiver . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56
10.3 No Survival of Representations and Warranties . . . . . . . . . . . .57
10.4 Entire Agreement; Counterparts . . . . . . . . . . . . . . . . . . .57
10.5 Applicable Law; Jurisdiction . . . . . . . . . . . . . . . . . . . .57
10.6 Disclosure Schedule . . . . . . . . . . . . . . . . . . . . . . . . .57
10.7 Attorneys' Fees . . . . . . . . . . . . . . . . . . . . . . . . . . .57
10.8 Assignability . . . . . . . . . . . . . . . . . . . . . . . . . . . .58
10.9 Notices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .58
10.10 Cooperation. . . . . . . . . . . . . . . . . . . . . . . . . . . . .59
10.11 Construction . . . . . . . . . . . . . . . . . . . . . . . . . . . .59
</TABLE>
v.
<PAGE>
AGREEMENT AND PLAN
OF
MERGER AND REORGANIZATION
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION ("AGREEMENT") is
made and entered into as of October 24, 1998, by and among: MEGABIOS CORP.,
a Delaware corporation ("PARENT"); MONTANA ACQUISITION SUB, INC., a Delaware
corporation and a wholly owned subsidiary of Parent ("MERGER SUB"); and
GENEMEDICINE, INC., a Delaware corporation (the "COMPANY"). Certain
capitalized terms used in this Agreement are defined in Exhibit A.
RECITALS
A. Parent, Merger Sub and the Company intend to effect a merger (the
"MERGER") of Merger Sub with and into the Company in accordance with this
Agreement and the Delaware General Corporation Law, as amended (the "DGCL").
Upon consummation of the Merger, Merger Sub will cease to exist, and the
Company will become a wholly-owned subsidiary of Parent.
B. It is intended that the Merger qualify as a tax-free
reorganization within the meaning of Section 368(a) of the Internal Revenue
Code of 1986, as amended (the "CODE").
C. The respective Boards of Directors of Parent, Merger Sub and the
Company have approved this Agreement and the Merger.
AGREEMENT
The parties to this Agreement, intending to be legally bound, agree as
follows:
SECTION 1. DESCRIPTION OF TRANSACTION.
1.1 MERGER OF MERGER SUB INTO THE COMPANY. Upon the terms and
subject to the conditions set forth in this Agreement, at the Effective Time
(as defined in Section 1.3), Merger Sub shall be merged with and into the
Company, and the separate existence of Merger Sub shall cease. The Company
will continue as the surviving corporation in the Merger (the "SURVIVING
CORPORATION").
1.2 EFFECT OF THE MERGER. The Merger shall have the effects set forth
in this Agreement and in the applicable provisions of the DGCL.
1.3 CLOSING; EFFECTIVE TIME. The consummation of the transactions
contemplated by this Agreement (the "CLOSING") shall take place at the
offices of Cooley Godward LLP, Five Palo Alto Square, 3000 El Camino Real,
Palo Alto, California, at 10:00 a.m. on a date to be agreed by Parent and the
Company (the "CLOSING DATE"), which shall be no later than the second
business day after satisfaction or waiver of the conditions set forth in
Sections 7 and 8. Contemporaneously with or as promptly as practicable after
the Closing, a properly executed
1.
<PAGE>
certificate of merger conforming to the requirements of the DGCL shall be
filed with the Secretary of State of the State of Delaware. The Merger shall
take effect at the later of (a) the time the certificate of merger is
accepted for filing by the Secretary of State of the State of Delaware and
(b) at such later time as may be specified in the certificate of merger (the
"EFFECTIVE TIME").
1.4 CERTIFICATE OF INCORPORATION AND BYLAWS; DIRECTORS AND OFFICERS.
Unless otherwise determined by Parent prior to the Effective Time:
(a) the certificate of incorporation and bylaws of the Surviving
Corporation shall be amended and restated as of the Effective Time to conform
to the certificate of incorporation and bylaws substantially in the form
attached hereto as Exhibits B-1 and B-2, respectively; PROVIDED, HOWEVER,
that at the Effective Time the certificate of incorporation of the Surviving
Corporation shall be amended so that the name of the Surviving Corporation
shall be GeneMedicine, Inc.; and
(b) the directors and officers of the Surviving Corporation
immediately after the Effective Time shall be the directors and officers of
Merger Sub immediately prior to the Effective Time, until their respective
successors are elected and qualified or duly appointed, as the case may be.
1.5 CONVERSION OF SHARES.
(a) Subject to Section 1.5(d), at the Effective Time, by virtue
of the Merger and without any further action on the part of Parent, Merger
Sub, the Company or any stockholder of the Company:
(i) any shares of Company Common Stock then held by the
Company or any subsidiary of the Company (or held in the Company's treasury)
shall be canceled;
(ii) any shares of Company Common Stock then held by
Parent, Merger Sub or any other subsidiary of Parent shall be canceled;
(iii) except as provided in clauses "(i)" and "(ii)" above
and subject to Section 1.5(b), each share of Company Common Stock then
outstanding shall be automatically converted into 0.5710 of a fully paid and
non-assessable share of Parent Common Stock; and
(iv) each share of the common stock, no par value per
share, of Merger Sub then outstanding shall be converted into one share of
common stock of the Surviving Corporation.
(b) The fraction of a share of Parent Common Stock into which
each outstanding share of Company Common Stock is to be converted pursuant to
Section 1.5(a)(iii) (as such fraction may be adjusted in accordance with this
Section 1.5(b)) is referred to as the "EXCHANGE RATIO." If, between the date
of this Agreement and the Effective Time, the outstanding shares of Company
Common Stock or Parent Common Stock are changed into a different number or
class of shares by reason of any stock split, stock dividend, reverse stock
2.
<PAGE>
split, reclassification, recapitalization or other similar transaction, then
the Exchange Ratio shall be appropriately adjusted.
(c) If any shares of Company Common Stock outstanding
immediately prior to the Effective Time are unvested or are subject to a
repurchase option, risk of forfeiture or other condition under any applicable
restricted stock purchase agreement or other agreement with the Company, then
the shares of Parent Common Stock issued in exchange for such shares of
Company Common Stock will also be unvested and subject to the same repurchase
option, risk of forfeiture or other condition, and the certificates
representing such shares of Parent Common Stock may accordingly be marked
with appropriate legends. The Company shall take all action that may be
necessary to ensure that, from and after the Effective Time, Parent is
entitled to exercise any such repurchase option or other right set forth in
any such restricted stock purchase agreement or other agreement.
(d) No fractional shares of Parent Common Stock shall be issued
in connection with the Merger, and no certificates for any such fractional
shares shall be issued. In lieu of such fractional shares, any holder of
Company Common Stock who would otherwise be entitled to receive a fraction of
a share of Parent Common Stock (after aggregating all fractional shares of
Parent Common Stock issuable to such holder) shall, upon surrender of such
holder's Company Stock Certificate(s) (as defined in Section 1.7), be paid in
cash the dollar amount (rounded to the nearest whole cent), without interest,
determined by multiplying such fraction by the closing price of a share of
Parent Common Stock on Nasdaq on the Effective Time.
1.6 STOCK OPTIONS AND WARRANTS. At the Effective Time, all Company
Options (as defined in Section 2.3(b)) shall be assumed by Parent in
accordance with Section 6.5.
1.7 CLOSING OF THE COMPANY'S TRANSFER BOOKS. At the Effective Time:
(a) all shares of Company Common Stock outstanding immediately prior to the
Effective Time shall automatically be canceled and retired and shall cease to
exist, and all holders of certificates representing shares of Company Common
Stock that were outstanding immediately prior to the Effective Time shall
cease to have any rights as stockholders of the Company; and (b) the stock
transfer books of the Company shall be closed with respect to all shares of
Company Common Stock outstanding immediately prior to the Effective Time. No
further transfer of any such shares of Company Common Stock shall be made on
such stock transfer books after the Effective Time. If, after the Effective
Time, a valid certificate previously representing any of such shares of
Company Common Stock (a "COMPANY STOCK CERTIFICATE") is presented to the
Exchange Agent (as defined in Section 1.8) or to the Surviving Corporation or
Parent, such Company Stock Certificate shall be canceled and shall be
exchanged as provided in Section 1.8.
1.8 EXCHANGE OF CERTIFICATES.
(a) Prior to the Closing Date, Parent shall select a reputable
bank or trust company reasonably acceptable to the Company to act as exchange
agent in the Merger (the "EXCHANGE AGENT"). At the Effective Time, Parent
shall deposit with the Exchange Agent (i) certificates representing the
shares of Parent Common Stock issuable pursuant to this Section 1 and (ii)
cash sufficient to make payments in lieu of fractional shares in accordance
with Section 1.5(d). The shares of Parent Common Stock and cash amounts so
deposited with the Exchange
3.
<PAGE>
Agent, together with any dividends or distributions received by the Exchange
Agent with respect to such shares, are referred to collectively as the
"EXCHANGE FUND."
(b) As soon as practicable after the Effective Time, the Exchange
Agent will mail to the registered holders of Company Stock Certificates (i) a
letter of transmittal in customary form and containing such provisions as
Parent may reasonably specify (including a provision confirming that delivery
of Company Stock Certificates shall be effected, and risk of loss and title
to Company Stock Certificates shall pass, only upon delivery of such Company
Stock Certificates to the Exchange Agent), and (ii) instructions for use in
effecting the surrender of Company Stock Certificates in exchange for
certificates representing Parent Common Stock. Subject to Section 1.5(d),
upon surrender of a Company Stock Certificate to the Exchange Agent for
exchange, together with a duly executed letter of transmittal and such other
documents as may be reasonably required by the Exchange Agent or Parent, (A)
the holder of such Company Stock Certificate shall be entitled to receive in
exchange therefor a certificate representing the number of shares of Parent
Common Stock that such holder has the right to receive pursuant to the
provisions of Section 1.5(a)(iii) together with any cash in lieu of
fractional share(s) pursuant to the provisions of Section 1.5(d) and any
dividends or distributions to which such holder is entitled, and (B) the
Company Stock Certificate so surrendered shall be canceled. Until
surrendered as contemplated by this Section 1.8(b), each Company Stock
Certificate shall be deemed, from and after the Effective Time, to represent
only the right to receive shares of Parent Common Stock (and cash in lieu of
any fractional share of Parent Common Stock and any dividends or
distributions to which such holder is entitled) as contemplated by Section
1.5. If any Company Stock Certificate shall have been lost, stolen or
destroyed, Parent may, in its discretion and as a condition precedent to the
issuance of any certificate representing Parent Common Stock, require the
owner of such lost, stolen or destroyed Company Stock Certificate to provide
an appropriate affidavit and to deliver a bond (in such sum as Parent may
reasonably direct) as indemnity against any claim that may be made against
the Exchange Agent, Parent or the Surviving Corporation with respect to such
Company Stock Certificate.
(c) No dividends or other distributions declared or made with
respect to Parent Common Stock with a record date after the Effective Time
shall be paid to the holder of any unsurrendered Company Stock Certificate
with respect to the shares of Parent Common Stock represented thereby, until
such holder surrenders such Company Stock Certificate in accordance with this
Section 1.8 (at which time such holder shall be entitled to receive all such
dividends and distributions, without interest).
(d) Any portion of the Exchange Fund that remains undistributed to
holders of Company Stock Certificates as of the date 365 days after the date
on which the Merger becomes effective shall be delivered to Parent upon
demand, and any holders of Company Stock Certificates who have not
theretofore surrendered their Company Stock Certificates in accordance with
this Section 1.8 shall thereafter look only to Parent for satisfaction of
their claims for Parent Common Stock, cash in lieu of fractional shares of
Parent Common Stock and any dividends or distributions with respect to Parent
Common Stock.
(e) Each of the Exchange Agent, Parent and the Surviving
Corporation shall be entitled to deduct and withhold from any consideration
payable or otherwise deliverable pursuant to this Agreement to any holder or
former holder of Company Common Stock such
4.
<PAGE>
amounts as may be required to be deducted or withheld therefrom under the
Code or under any provision of state, local or foreign tax law or under any
other applicable Legal Requirement. To the extent such amounts are so
deducted or withheld, such amounts shall be treated for all purposes under
this Agreement as having been paid to the Person to whom such amounts would
otherwise have been paid.
(f) Neither Parent nor the Surviving Corporation shall be liable
to any holder or former holder of Company Common Stock with respect to any
shares of Parent Common Stock (or dividends or distributions with respect
thereto), or for any cash amounts, delivered to any public official pursuant
to any applicable abandoned property, escheat or similar Legal Requirement.
1.9 TAX CONSEQUENCES. For federal income tax purposes, the Merger is
intended to constitute a reorganization within the meaning of Section 368 of
the Code. The parties to this Agreement hereby adopt this Agreement as a
"plan of reorganization" within the meaning of Sections 1.368-2(g) and
1.368-3(a) of the United States Treasury Regulations.
1.10 FURTHER ACTION. If, at any time after the Effective Time, any
further action is determined by Parent to be necessary or desirable to carry
out the purposes of this Agreement or to vest the Surviving Corporation with
full right, title and possession of and to all rights and property of Merger
Sub and the Company, the officers and directors of the Surviving Corporation
and Parent shall be fully authorized (in the name of Merger Sub, in the name
of the Company and otherwise) to take such action.
SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.
The Company represents and warrants to Parent and Merger Sub that,
except as set forth in the disclosure schedule that has been prepared by the
Company in accordance with the requirements of Section 10.6 and that has been
delivered by the Company to Parent on the date of this Agreement and signed
by the President of the Company (the "COMPANY DISCLOSURE SCHEDULE"):
2.1 DUE ORGANIZATION; SUBSIDIARIES; ETC.
(a) The Company has no Subsidiaries, and does not own any
capital stock of, or any equity interest of any nature in, any other Entity.
The Company has not agreed, is not obligated to make, and is not bound by any
Contract under which it may become obligated to make, any future investment
in or capital contribution to any other Entity. The Company has not, at any
time, been a general partner of any general partnership, limited partnership
or other Entity.
(b) The Company is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
incorporation and has all corporate power and authority: (i) to conduct its
business in the manner in which its business is currently being conducted;
(ii) to own and use its assets in the manner in which its assets are
currently owned and used; and (iii) to perform its obligations under all
Contracts by which it is bound.
5.
<PAGE>
(c) The Company is not and has not been required to be
qualified, authorized, registered or licensed to do business as a foreign
corporation in any jurisdiction other than the jurisdictions identified in
Part 2.1(c) of the Company Disclosure Schedule, except where the failure to
be so qualified, authorized, registered or licensed has not had and will not
have a Material Adverse Effect on the Company. The Company is in good
standing as a foreign corporation in each of the respective jurisdictions
identified in Part 2.1(c) of the Company Disclosure Schedule.
2.2 CERTIFICATE OF INCORPORATION AND BYLAWS. The Company has
delivered to Parent accurate and complete copies of its certificate of
incorporation, bylaws and other charter and organizational documents,
including all amendments thereto. The Company is not in violation of any of
the provisions of its certificate of incorporation or bylaws.
2.3 CAPITALIZATION, ETC.
(a) The authorized capital stock of the Company consists of:
(i) Forty Million (40,000,000) shares of Company Common Stock, $0.001 par
value per share, of which, as of September 30, 1998, 14,579,376 shares (which
amount does not materially differ from the amount issued and outstanding as
of the date of this Agreement) have been issued and are outstanding; and (ii)
Twenty Million (20,000,000) shares of preferred stock, $0.001 par value per
share, of which (A) Six Hundred Thousand (600,000) shares have been
designated Series A Junior Participating Preferred Stock, none of which are
outstanding as of the date of this Agreement, and (B) Three Million Seven
Hundred Fifty Thousand (3,750,000) shares have been designated Series B
Preferred Stock, all of which are outstanding as of the date of this
Agreement. All of the outstanding shares of the Company's capital stock have
been duly authorized and validly issued, and are fully paid and
nonassessable. As of the date of this Agreement, no shares of Company Common
Stock were held in treasury by the Company. None of the outstanding shares
of the Company's capital stock is entitled or subject to any preemptive
right, right of participation, right of maintenance or any similar right.
Except for the shares of Series B Preferred Stock, none of the outstanding
shares of the Company's capital stock is subject to any right of first
refusal in favor of the Company. Except as provided in Part 2.3(a) of the
Company Disclosure Schedule, there is no Company Contract relating to the
voting or registration of, or restricting any Person from purchasing,
selling, pledging or otherwise disposing of (or granting any option or
similar right with respect to), any shares of Company Common Stock. Upon
consummation of the Merger, (A) the shares of Parent Common Stock issued in
exchange for any shares of Company Common Stock that are subject to a
Contract pursuant to which the Company has the right to repurchase, redeem or
otherwise reacquire any shares of Company Common Stock will, without any
further act of Parent, the Company or any other Person, become subject to the
restrictions, conditions and other provisions contained in such Contract, and
(B) Parent will automatically succeed to and become entitled to exercise the
Company's rights and remedies under any such Contract. The Company is not
under any obligation to repurchase, redeem or otherwise acquire any
outstanding shares of the Company's capital stock.
(b) As of September 30, 1998, 3,017,412 shares (which amount
does not materially differ from the amount subject to options outstanding as
of the date of this Agreement) of Company Common Stock are subject to
issuance pursuant to outstanding options
6.
<PAGE>
to purchase Company Common Stock. (Stock options granted by the Company
pursuant to the Company's stock option plans are referred to in this
Agreement as "COMPANY OPTIONS."). Part 2.3(b)(i) of the Company Disclosure
Schedule sets forth the following information with respect to each Company
Option outstanding as of September 30, 1998: (i) the particular plan
pursuant to which such Company Option was granted; (ii) the name of the
optionee; (iii) the number of shares of Company Common Stock subject to such
Company Option; (iv) the exercise price of such Company Option; (v) the date
on which such Company Option was granted; (vi) the applicable vesting
schedule and the extent to which such Company Option is vested and
exercisable as of the date of this Agreement; and (vii) the date on which
such Company Option expires. The Company has delivered to Parent accurate
and complete copies of all stock option plans pursuant to which the Company
has ever granted stock options and the form of all stock option agreements
evidencing such options. Except as set forth in Part 2.3(b) of the Company
Disclosure Schedule, there are no commitments or agreements of any character
to which the Company is bound obligating the Company to accelerate the
vesting of any Company Option.
(c) As of September 30, 1998, 1,204,761 shares (which amount does
not materially differ from the amount subject to warrants outstanding as of
the date of this Agreement) of Company Common Stock are subject to issuance
pursuant to outstanding warrants to purchase Company Common Stock. (Warrants
issued by the Company are referred to in this Agreement as "COMPANY
WARRANTS.") Part 2.3(c)(i) of the Company Disclosure Schedule sets forth
the following information with respect to each Company Warrant outstanding as
of September 30, 1998: (i) the name of the Warrant holder; (ii) the number
of shares of Company Common Stock subject to such Company Warrant; (iii) the
exercise price of such Company Warrant; (iv) the date on which such Company
Warrant was issued; (v) the applicable exercise period and the extent to
which such Company Warrant is exercisable as of the date of this Agreement;
and (vi) the date on which such Company Warrant expires. The Company has
delivered to Parent accurate and complete copies of all agreements and other
documents evidencing such Company Warrants. Except as set forth in Part
2.3(c) of the Company Disclosure Schedule, there are no commitments or
agreements of any character to which the Company is bound obligating the
Company to amend or extend exercisability or term of any Company Warrant.
(d) Except as set forth in Part 2.3(d) of the Company Disclosure
Schedule there is no: (i) outstanding subscription, option, call, warrant or
right (whether or not currently exercisable) to acquire any shares of the
capital stock or other securities of the Company; (ii) outstanding security,
instrument or obligation that is or may become convertible into or
exchangeable for any shares of the capital stock or other securities of the
Company; (iii) stockholder rights plan (or similar plan commonly referred to
as a "poison pill") or Contract under which the Company is or may become
obligated to sell or otherwise issue any shares of its capital stock or any
other securities; or (iv) condition or circumstance that may give rise to or
provide a basis for the assertion of a claim by any Person to the effect that
such Person is entitled to acquire or receive any shares of capital stock or
other securities of the Company.
(e) All outstanding shares of Company Common Stock, all
outstanding shares of Series B Preferred Stock, all outstanding Company
Options, all outstanding Company Warrants and any securities disclosed in
Part 2.3(d) of the Company Disclosure Schedule have been issued and granted
in compliance in all material respects with (i) all applicable securities
7.
<PAGE>
laws and other applicable Legal Requirements, and (ii) all requirements set
forth in applicable Contracts.
2.4 SEC FILINGS; FINANCIAL STATEMENTS.
(a) The Company has delivered to Parent accurate and complete
copies (excluding copies of exhibits) of all registration statements,
definitive proxy statements and other statements, reports, schedules, forms
and other documents filed by the Company with the SEC between July 14, 1994
and the date of this Agreement and will deliver to Parent accurate and
complete copies of all such registration statements, proxy statements and
other statements, reports, schedules, forms and other documents filed after
the date of this Agreement and prior to the Effective Time (collectively, the
"COMPANY SEC DOCUMENTS"), which are all of the forms, reports and documents
required to be filed by the Company with the SEC since July 14, 1994. As of
the time it was filed with the SEC (or, if amended or superseded by a later
filing, then on the date of such filing): (i) each of the Company SEC
Documents filed with the SEC complied in all material respects with the
applicable requirements of the Securities Act or the Exchange Act (as the
case may be) as of the date of such filing and any Company SEC Documents
filed after the date hereof will so comply; and (ii) none of the Company SEC
Documents contained any untrue statement of material fact or omitted to state
a material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were
made, not misleading.
(b) The financial statements (including any related notes)
contained in the Company SEC Documents filed with the SEC (the "COMPANY
FINANCIAL STATEMENTS"): (i) complied as to form in all material respects
with the published rules and regulations of the SEC applicable thereto; (ii)
were prepared in accordance with generally accepted accounting principles
("GAAP") applied on a consistent basis throughout the periods covered (except
as may be indicated in the notes to such financial statements or, in the case
of unaudited statements, as permitted by Form 10-Q of the SEC, and except
that the unaudited financial statements may not contain footnotes and are
subject to normal and recurring year end adjustments which will not,
individually or in the aggregate, be material in amount), and (iii) fairly
present the financial position of the Company as of the respective dates
thereof and the results of operations of the Company and its subsidiaries for
the periods covered thereby. All adjustments (consisting of recurring
accruals) considered necessary for a fair presentation of the financial
statements have been included. The audited balance sheet of the Company
included in the Company's Annual Report on Form 10-K for the year ended
December 31, 1997 is sometimes referred to herein as the "COMPANY BALANCE
SHEET" and the unaudited balance sheet of the Company as of June 30, 1998
included in the Company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 1998 is sometimes referred to herein as the "COMPANY UNAUDITED
INTERIM BALANCE SHEET."
2.5 ABSENCE OF CHANGES. Since the date of the Company Unaudited
Interim Balance Sheet:
(a) there has not been any material adverse change in the
business, assets, liabilities, financial condition or results of operations
of the Company taken as a whole, and no event has occurred that could
reasonably be expected to have a Material Adverse Effect on the Company;
8.
<PAGE>
(b) there has not been any material loss, damage or destruction
to, or any material interruption in the use of, any of the assets of the
Company (whether or not covered by insurance);
(c) the Company has not (i) declared, accrued, set aside or paid
any dividend or made any other distribution in respect of any shares of
capital stock, or (ii) repurchased, redeemed or otherwise reacquired any
shares of capital stock or other securities;
(d) the Company has not sold, issued, granted or authorized the
issuance or grant of (i) any capital stock or other security (except for
Company Common Stock issued upon the exercise of outstanding Company
Options), (ii) any option, call, warrant or right to acquire any capital
stock or any other security (except for Company Options set forth in Parts
2.3(b)(i), 2.3(d) and 2.5(d) of the Company Disclosure Schedule), or (iii)
any instrument convertible into or exchangeable for any capital stock or
other security;
(e) the Company has not amended or waived any of its rights
under, or permitted the acceleration of vesting under, (i) any provision of
the Company's stock option plans, (ii) any provision of any agreement
evidencing any outstanding Company Option, or (iii) any restricted stock
purchase agreement;
(f) there has been no amendment to the certificate of
incorporation, bylaws or other charter or organizational documents of the
Company, and the Company has not effected or been a party to any merger,
consolidation, share exchange, business combination, recapitalization,
reclassification of shares, stock split, reverse stock split or similar
transaction;
(g) the Company has not formed any subsidiary or acquired any
equity interest or other interest in any other Entity;
(h) the Company has not made any capital expenditures which
exceed $100,000 in the aggregate, except as set forth in Part 2.5(h);
(i) except in the ordinary course of business and consistent with
past practices, the Company has not (i) entered into or permitted any of the
assets owned or used by it to become bound by any Company Material Contract
(as defined in Section 2.10), or (ii) amended or prematurely terminated, or
waived any material right or remedy under, any Company Material Contract,
except as set forth in Part 2.5(i);
(j) the Company has not (i) acquired, leased or licensed any
material right or other material asset from any other Person, (ii) sold or
otherwise disposed of, or leased or licensed, any material right or other
material asset to any other Person, or (iii) waived or relinquished any
right, except for rights or other assets acquired, leased, licensed or
disposed of in the ordinary course of business and consistent with past
practices;
(k) the Company has not written off as uncollectible, or
established any extraordinary reserve with respect to, any account receivable
or other indebtedness in excess of $25,000 with respect to any single matter,
or in excess of $50,000 in the aggregate;
9.
<PAGE>
(l) the Company has not made any pledge of any of its assets or
otherwise permitted any of its assets to become subject to any Encumbrance,
except for Permitted Encumbrances;
(m) the Company has not (i) lent money to any Person except as
set forth on Part 2.5(m) of the Company Disclosure Schedule, or (ii) incurred
or guaranteed any indebtedness for borrowed money other than payroll, travel
and other advances made in the ordinary course of business;
(n) the Company has not (i) established or adopted any Company
Plan (as defined in Section 2.16(a)), (ii) caused or permitted any Company
Plan to be amended in any material respect, or (iii) paid any bonus or made
any profit-sharing or similar payment to, or materially increased the amount
of the wages, salary, commissions, fringe benefits or other compensation or
remuneration payable to, any of its directors, officers or employees except
as set forth in Part 2.15(n);
(o) the Company has not changed any of its methods of accounting
or accounting practices in any material respect;
(p) the Company has not made any material election with respect
to Taxes;
(q) the Company has not commenced or settled any Legal Proceeding;
(r) the Company has not entered into any material transaction or
taken any other material action that has had, or could reasonably be expected
to have, a Material Adverse Effect on the Company; and
(s) the Company has not agreed or committed to take any of the
actions referred to in clauses "(c)" through "(r)" above.
2.6 LEASEHOLD; EQUIPMENT.
(a) The Company does not own any real property or any interest in
real property, except for the leaseholds created under the real property
leases identified in Part 2.6 of the Company Disclosure Schedule. All such
real property is being leased pursuant to lease agreements that are in full
force and effect, are valid and effective in accordance with their respective
terms, and there is not, under any of such leases, any existing default or
event of default (or event which with notice or lapse of time, or both, would
constitute a default) that would result in a Material Adverse Effect on the
Company.
(b) Part 2.6 of the Company Disclosure Schedule accurately
identifies all material items of equipment leased by the Company. All
material items of equipment and other tangible assets owned by or leased to
the Company are adequate for the uses to which they are being put, are in
good condition and repair (ordinary wear and tear excepted) and are adequate
for the conduct of the business of the Company in the manner in which such
business is currently being conducted.
10.
<PAGE>
2.7 TITLE TO ASSETS. The Company owns, and has good, valid and
marketable title to, or in the case of leased properties and assets, valid
leasehold interests in, all of their respective tangible properties and
assets, real, personal and mixed, used or held for use in their business,
including: (i) all assets reflected on the Company Unaudited Interim Balance
Sheet; and (ii) all other assets reflected in the books and records of the
Company as being owned or leased by the Company. All of said assets are
owned or leased by the Company free and clear of any Encumbrances, except for
Permitted Encumbrances.
2.8 PAYMENTS UNDER CORPORATE PARTNERING AGREEMENTS.
(a) The Company has received all amounts that are owed and due to
be paid to the Company under agreements with Syntex (USA) Inc. and Corange
International Limited (the "COMPANY CORPORATE PARTNERS") prior to the date of
this Agreement. For each such payment received by the Company under any such
agreement, any revenue that the Company recognized with respect to such
payment was recognized in accordance with GAAP.
(b) The Company has no knowledge that a Company Corporate Partner
is considering, intending or planning to terminate any of the agreements
between any such Company Corporate Partner and the Company, or any research
program under such agreement.
2.9 PROPRIETARY ASSETS.
(a) Part 2.9 of the Company Disclosure Schedule sets forth, with
respect to each Proprietary Asset owned or licensed by the Company and
registered with any Governmental Body or for which an application has been
filed with any Governmental Body, (i) a brief description of such Proprietary
Assets, and (ii) the names of the jurisdictions covered by the applicable
registration or application. Part 2.9 of the Company Disclosure Schedule
identifies and provides a brief description of, and identifies any ongoing
royalty or payment obligations in excess of $50,000 per year with respect to,
each Proprietary Asset that is licensed or otherwise made available to the
Company by any Person (except for any Proprietary Asset that is licensed to
the Company under any third party software license generally available to the
public), and identifies the Contract under which such Proprietary Asset is
being licensed or otherwise made available to the Company. Excluding the
payments required under the Company Contracts set forth in the Company
Disclosure Schedule, the aggregate amounts payable by the Company for ongoing
royalty or license payments do not exceed $100,000 per year. The Company has
good, valid and marketable title to all of the Company Proprietary Assets
(except for licensed assets), free and clear of all Encumbrances, except (i)
as set forth in Part 2.9(a) of the Company Disclosure Schedule, (ii) for any
lien for current taxes not yet due and payable, and (iii) minor liens that
have arisen in the ordinary course of business and that do not (individually
or in the aggregate) materially detract from the value of the assets subject
thereto or materially impair the operations of the Company. To the Company's
knowledge, the Company has a valid right to use, license and otherwise
exploit all Company Proprietary Assets. The Company has not developed
jointly or does not jointly own or have joint rights with any other Person
any Company Proprietary Asset that is material to the business of the
Company. Except as set forth in Part 2.9(a) of the Disclosure Schedule,
there is no Company Contract pursuant to which any Person has any right
(whether or not currently exercisable) to use, license or otherwise exploit
any Company Proprietary Asset.
11.
<PAGE>
(b) The Company has taken all commercially reasonable measures
and precautions to protect and maintain the confidentiality and secrecy of
all Company Proprietary Assets (except Company Proprietary Assets whose value
would be unimpaired by public disclosure) and otherwise to maintain and
protect the value of all Company Proprietary Assets.
(c) To the knowledge of the Company, the Company is not
misappropriating or making any unlawful use of, and the Company has not at
any time misappropriated or made any unlawful use of, or received any notice
or other communication (in writing or otherwise) of any actual, alleged,
possible or potential infringement, misappropriation or unlawful use of, any
Proprietary Asset owned or used by any other Person.
(d) The Company Proprietary Assets constitute all the Proprietary
Assets reasonably necessary to enable the Company to conduct its business in
the manner in which such business has been and is being conducted. Except as
set forth in Part 2.9(d) of the Company Disclosure Schedule, the Company has
not licensed any of the Company Proprietary Assets to any Person on an
exclusive basis.
(e) All current and former employees have executed and delivered
an agreement to the Company (containing no exceptions to or exclusions from
the scope of its coverage) that is substantially identical to the form of
Confidential Information and Invention Assignment Agreement previously
delivered to Parent by the Company. All current and former consultants and
independent contractors to the Company have executed and delivered to the
Company an agreement that contains provisions appropriately restricting the
use and disclosure of Company Proprietary Assets.
(f) The Company has taken reasonably adequate steps to ensure
that all software (and related Company Proprietary Assets) used in its
operations will be Year 2000 Compliant (as defined below) by December 31,
1999. For purposes of this Section 2, "YEAR 2000 COMPLIANT" shall mean that
software that can individually, and in combination and in conjunction with
all other systems, products or processes with which they are required or
designed to interface, continue to be used normally and to operate
successfully (both in functionality and performance in all material respects)
over the transition into the twenty first century when used in accordance
with the documentation relating to all such software (and related Company
Proprietary Assets), including being able to, before, on and after January 1,
2000 substantially conform to the following: (i) use logic pertaining to
dates which allow users to identify and/or use the century portion of any
date fields without special processing; and (ii) respond to all date elements
and date input so as to resolve any ambiguity as to century in a disclosed,
defined and pre-determined manner and provide date information in ways which
are unambiguous as to century, either by permitting or requiring the century
to be specified or where the data element is represented without a century,
the correct century is unambiguous for all manipulations involving that
element.
2.10 CONTRACTS.
(a) Part 2.10 of the Company Disclosure Schedule identifies each
Company Contract that constitutes a "Company Material Contract." For
purposes of this Agreement, each of the following shall be deemed to
constitute a "COMPANY MATERIAL CONTRACT":
12.
<PAGE>
(i) (A) any Contract or outstanding offer relating to the
employment of, or the performance of services by, any employee, and (B) any
Contract pursuant to which the Company is required to make any severance,
termination or similar payment, bonus or relocation payment or any other
payment (other than payments in respect of salary) to any current or former
employee or director of the Company;
(ii) any Contract (A) relating to the acquisition, transfer,
development, sharing, license (to or by the Company), or use of any
Proprietary Asset (except for any Contract pursuant to which any Proprietary
Asset is licensed to the Company under any third party software license
generally available to the public); or (B) with respect to the distribution
or marketing of any products of the Company;
(iii) any Contract which provides for indemnification of any
officer, director, employee or agent of the Company;
(iv) any Contract imposing any restriction on the right or
ability of the Company (A) to compete in any market or geographic area with
any other Person, (B) to acquire any product or other asset or any services
from any other Person, to sell any product or other asset to or perform any
services for any other Person or to transact business or deal in any other
manner with any other Person, or (C) to develop or distribute any technology;
(v) any Contract (A) relating to the acquisition, issuance,
voting, registration, sale or transfer of any securities (other than the
issuance of Company Common Stock upon the valid exercise of Company Options
outstanding as of the date of this Agreement), (B) providing any Person with
any preemptive right, right of participation, right of maintenance or any
similar right with respect to any securities, or (C) providing the Company
with any right of first refusal with respect to, or right to repurchase or
redeem, any securities;
(vi) any Contract requiring that the Company give any notice
or provide any information to any Person prior to accepting any Acquisition
Proposal;
(vii) any Contract that (A) contemplates or involves payment
or delivery of cash or other consideration in an amount or having a value in
excess of $20,000 per month and (B) has a term of more than 90 days and that
may not be terminated by the Company within 90 days after the delivery of a
termination notice by the Company;
(viii) any Contract that contemplates or involves payment
or delivery of cash or other consideration by the Company in an amount or
having a value in excess of $75,000 in the aggregate;
(ix) any Contract or Company Plan (including, without
limitation, any stock option plan, stock appreciation plan or stock purchase
plan), any of the benefits of which will be increased, or the vesting of
benefits of which will be accelerated, by the execution of this Agreement or
the consummation of any of the transactions contemplated by this Agreement or
the value of any of the benefits of which will be calculated on the basis of
any of the transactions contemplated by this Agreement;
13.
<PAGE>
(x) any Contract (not otherwise identified in clauses "(i)"
through "(ix)" of this sentence) that is or would be material to the Company,
to the business, condition, capitalization or operations of the Company or to
any of the transactions contemplated by this Agreement; and
(xi) any other Contract, if a breach of such Contract could
reasonably be expected to have a Material Adverse Effect on the Company.
(b) Each Company Material Contract is valid and in full force and
effect, and is enforceable by an Acquired Corporation in accordance with its
terms, subject to (i) laws of general application relating to bankruptcy,
insolvency and the relief of debtors, and (ii) rules of law governing
specific performance, injunctive relief and other equitable remedies
(c) Except where the following would not have a Material Adverse
Effect on the Company: (i) the Company has not violated or breached, or
committed any default under, any Company Contract, and, to the knowledge of
the Company, no other Person has violated or breached, or committed any
default under, any Company Contract; (ii) to the knowledge of the Company, no
event has occurred, and no circumstance or condition exists, that (with or
without notice or lapse of time) will, or could reasonably be expected to,
(A) result in a violation or breach of any of the provisions of any Company
Contract, (B) give any Person the right to declare a default or exercise any
remedy under any Company Contract, (C) give any Person the right to a rebate,
chargeback, penalty or change in delivery schedule under any Company
Contract, (D) give any Person the right to accelerate the maturity or
performance of any Company Contract, or (E) give any Person the right to
cancel, terminate or modify any Company Contract; and (iii) neither the
Company, nor any of its Representatives, has received any notice or other
communication regarding any actual or possible violation or breach of, or
default under any Company Contract.
(d) There is no Company Contract to which any Governmental Body is
a party or under which any Governmental Body has any rights or obligations,
or directly or indirectly benefiting any Governmental Body (including any
subcontract or other Contract between the Company and any contractor or
subcontractor to any Governmental Body).
(e) No Person is renegotiating, or has a right pursuant to the
terms of any Company Material Contract to renegotiate, any amount paid or
payable to the Company under any Company Material Contract or any other
material term or provision of any Company Material Contract.
2.11 YEAR 2000 LIABILITIES. The Company does not have any accrued,
contingent or other liabilities of any nature, either matured or unmatured,
including, without limitation, any liabilities relating to costs associated
with insuring that all software (and related Company Proprietary Assets)
utilized by the Company or other components of the Company's information
technology infrastructure are Year 2000 Compliant (whether or not required to
be reflected in financial statements in accordance with GAAP, and whether due
or to become due), except for: (a) liabilities identified as such in the
"liabilities" column of the Company Unaudited Interim Balance Sheet; and (b)
normal and recurring liabilities that have been incurred by the Company
14.
<PAGE>
since the date of the Company Unaudited Interim Balance Sheet in the ordinary
course of business and consistent with past practices.
2.12 COMPLIANCE WITH LEGAL REQUIREMENTS. The Company is, and has at
all times since July 14, 1994 been, in compliance with all applicable Legal
Requirements, except where the failure to comply with such Legal Requirements
has not had and will not have a Material Adverse Effect on the Company.
Since July 14, 1994, the Company has not received any notice or other
communication from any Governmental Body regarding any actual or possible
violation of, or failure to comply with, any Legal Requirement.
2.13 CERTAIN BUSINESS PRACTICES. Neither the Company nor any
director, officer, agent or employee of the Company has, on behalf of the
Company, (i) used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses relating to political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or
to foreign or domestic political parties or campaigns or violated any
provision of the Foreign Corrupt Practices Act of 1977, as amended, or (iii)
made any other unlawful payment.
2.14 GOVERNMENTAL AUTHORIZATIONS. The Company holds all Governmental
Authorizations necessary to enable it to conduct its business in the manner
in which such business is currently being conducted. All such Governmental
Authorizations are valid and in full force and effect. The Company is, and
at all times since July 14, 1994 has been, in substantial compliance with the
terms and requirements of such Governmental Authorizations. Since July 14,
1994, the Company has not received any notice or other communication from any
Governmental Body regarding (a) any actual or possible violation of or
failure to comply with any term or requirement of any Governmental
Authorization, or (b) any actual or possible revocation, withdrawal,
suspension, cancellation, termination or modification of any Governmental
Authorization.
2.15 TAX MATTERS.
(a) All Tax Returns required to be filed by or on behalf of the
Company with any Governmental Body with respect to any taxable period ending
on or before the Closing Date (the "COMPANY RETURNS") (i) have been or will
be filed on or before the applicable due date (including any extensions of
such due date if properly obtained), and (ii) have been, or will be when
filed, prepared in all material respects in compliance with all applicable
Legal Requirements. All amounts shown on the Company Returns to be due on or
before the Closing Date have been or will be paid on or before the Closing
Date.
(b) The Company Financial Statements fully accrue all actual and
contingent liabilities for Taxes with respect to all periods through the
dates thereof in accordance with GAAP. The Company will establish, in the
ordinary course of business and consistent with its past practices, reserves
adequate for the payment of all Taxes for the period from June 30, 1998
through the Closing Date.
(c) Except as set forth in Part 2.15(c) of the Company Disclosure
Schedule, the Company Returns have never been examined or audited by any
Governmental Body. No
15.
<PAGE>
extension or waiver of the limitation period applicable to any of the Company
Returns has been granted (by the Company or any other Person), and no such
extension or waiver has been requested from the Company.
(d) No claim or Legal Proceeding is pending or, to the knowledge
of the Company, has been threatened against or with respect to the Company in
respect of any material Tax. There are no unsatisfied liabilities for
material Taxes (including liabilities for interest, additions to tax and
penalties thereon and related expenses) with respect to any notice of
deficiency or similar document received by the Company with respect to any
material Tax (other than liabilities for Taxes asserted under any such notice
of deficiency or similar document which are being contested in good faith by
the Company and with respect to which adequate reserves for payment have been
established). There are no liens for material Taxes upon any of the assets
of the Company except liens for current Taxes not yet due and payable. The
Company has not entered into or become bound by any agreement or consent
pursuant to Section 341(f) of the Code. The Company has not been, and it
will not be, required to include any material adjustment in taxable income
for any tax period (or portion thereof) pursuant to Section 481 of the Code
or any comparable provision under state or foreign Tax laws as a result of
transactions or events occurring, or accounting methods employed, prior to
the Closing.
(e) Except as set forth in Part 2.15(e) of the Company Disclosure
Schedule, there is no agreement, plan, arrangement or other Contract covering
any employee or independent contractor or former employee or independent
contractor of the Company that, considered individually or considered
collectively with any other such Contracts, will, or could reasonably be
expected to, give rise directly or indirectly to the payment of any amount
that would not be deductible pursuant to Section 280G or Section 162 of the
Code. The Company is not and has never been, a party to or bound by any tax
indemnity agreement, tax sharing agreement, tax allocation agreement or
similar Contract.
2.16 EMPLOYEE AND LABOR MATTERS; BENEFIT PLANS.
(a) Part 2.16(a) of the Company Disclosure Schedule identifies
each salary, bonus, deferred compensation, incentive compensation, stock
purchase, stock option, severance pay, termination pay, hospitalization,
medical, life or other insurance, supplemental unemployment benefits,
profit-sharing, pension or retirement plan, program or agreement
(collectively, the "COMPANY PLANS") sponsored, maintained, contributed to or
required to be contributed to by the Company for the benefit of any current
or former employee of the Company.
(b) Except as set forth in Part 2.16(a) of the Company Disclosure
Schedule, the Company does not maintain, sponsor or contribute to, and it has
not at any time in the past maintained, sponsored or contributed to, any
employee pension benefit plan (as defined in Section 3(2) of the Employee
Retirement Income Security Act of 1974, as amended ("ERISA"), whether or not
excluded from coverage under specific Titles or Subtitles of ERISA) for the
benefit of employees or former employees of the Company (a "COMPANY PENSION
PLAN"). None of the Plans identified in Part 2.16(a) of the Company
Disclosure Schedule is subject to Title IV of ERISA or Section 412 of the
Code.
16.
<PAGE>
(c) Except as set forth in Part 2.16(a) of the Company Disclosure
Schedule, the Company does not maintain, sponsor or contribute to any
employee welfare benefit plan (as defined in Section 3(1) of ERISA, whether
or not excluded from coverage under specific Titles or Subtitles of ERISA)
for the benefit of any employees or former employees of the Company including
any self-funded medical, dental, or other similar Company Plan (a "COMPANY
WELFARE PLAN"). None of the Company Plans identified in Part 2.16(a) of the
Company Disclosure Schedule is a multi-employer plan (within the meaning of
Section 3(37) of ERISA).
(d) With respect to each Company Plan, the Company has delivered
to Parent: (i) an accurate and complete copy of such Company Plan (including
all amendments thereto); (ii) an accurate and complete copy of the annual
report, if required under ERISA, with respect to such Plan for the last two
years; (iii) an accurate and complete copy of the most recent Summary Plan
Description, together with each Summary of Material Modifications, if
required under ERISA, with respect to such Company Plan, (iv) if such Company
Plan is funded through a trust or any third party funding vehicle, an
accurate and complete copy of the trust or other funding agreement (including
all amendments thereto) and accurate and complete copies of the most recent
financial statements thereof; (v) accurate and complete copies of all
Contracts relating to such Company Plan, including service provider
agreements, insurance contracts, minimum premium contracts, stop-loss
agreements, investment management agreements, subscription and participation
agreements and recordkeeping agreements; and (vi) an accurate and complete
copy of the most recent determination letter received from the Internal
Revenue Service with respect to such Company Plan (if such Company Plan is
intended to be qualified under Section 401(a) of the Code).
(e) The Company is not and has never been required to be treated
as a single employer with any other Person under Section 4001(b)(1) of ERISA
or Section 414(b), (c), (m) or (o) of the Code. The Company has never made a
complete or partial withdrawal from a multiemployer plan, as such term is
defined in Section 3(37) of ERISA, resulting in "withdrawal liability," as
such term is defined in Section 4201 of ERISA (without regard to subsequent
reduction or waiver of such liability under either Section 4207 or 4208 of
ERISA).
(f) The Company has no plans or commitment to create any
additional Company Plan, or to modify or change any existing Company Plan
(other than to comply with applicable law) in a manner that would affect any
employee of the Company.
(g) No Company Plan provides death, medical or health benefits
(whether or not insured) with respect to any current or former employee of
the Company after any such employee's termination of service (other than (i)
benefit coverage mandated by applicable law, including coverage provided
pursuant to Section 4980B of the Code, (ii) deferred compensation benefits
accrued as liabilities on the Company Balance Sheet, and (iii) benefits the
full cost of which are borne by current or former employees of the Company
(or the employees' beneficiaries)).
(h) With respect to any Company Plan constituting a group health
plan within the meaning of Section 4980B(g)(2) of the Code, the provisions of
Section 4980B of the Code ("COBRA") have been complied with in all material
respects. Part 2.16(h) of the Company
17.
<PAGE>
Disclosure Schedule describes all obligations of the Company as of the date
of this Agreement under any of the provisions of COBRA.
(i) Each of the Company Plans complies with and has been operated
and administered in all material respects in accordance with applicable Legal
Requirements, including but not limited to ERISA and the Code.
(j) Each of the Company Plans intended to be qualified under
Section 401(a) of the Code has received a favorable determination from the
Internal Revenue Service, and the Company is not aware of any reason why any
such determination letter should be revoked.
(k) Part 2.16(k) of the Company Disclosure Schedule sets forth
each plan and arrangement of the Company including (i) the aggregate amount
of payments thereunder (including any bonus, golden parachute or severance
payment), (ii) any material increase in benefits payable thereunder and (iii)
acceleration of the time of payment or vesting any such benefits referred to
in (ii), which may result in any payment to any current or former employee or
director of the Company as a result of the execution, delivery or performance
of this Agreement, the consummation of the Merger or any other transactions
contemplated by this Agreement, or the termination of any employee.
(l) Part 2.16(l) of the Company Disclosure Schedule contains a
list of all salaried employees of the Company as of the date of this
Agreement, and correctly reflects, in all material respects, their base
salaries, their targeted annual bonus amounts, their dates of employment and
their positions. The Company is not a party to any collective bargaining
contract or other Contract with a labor union involving any of its employees.
All of the employees of the Company are "at will" employees.
(m) Part 2.16(m) of the Company Disclosure Schedule identifies
each employee who is not fully available to perform work because of
disability or other leave and sets forth the basis of such leave and the
anticipated date of return to full service.
(n) The Company is in compliance in all material respects with
all Contracts relating to employment, employment practices, wages, bonuses
and terms and conditions of employment, including employee compensation
matters.
(o) The Company has good labor relations, and it has no knowledge
of any facts indicating that (i) the consummation of the Merger or any of the
other transactions contemplated by this Agreement will have a material
adverse effect on the labor relations of the Company, or (ii) any of the
employees of the Company intends to terminate his or her employment with the
Company with which such employee is employed.
2.17 ENVIRONMENTAL MATTERS. The Company is in compliance with all
applicable Environmental Laws, except where failure to comply would not have
a Material Adverse Effect on the Company. The Company possesses all permits
and other Governmental Authorizations required under applicable Environmental
Laws to conduct its current operations. The Company has not received any
notice or other communication (in writing or otherwise) from a Governmental
Body or citizens group that alleges that the Company is not in compliance
with any Environmental Law. To the knowledge of the Company, there are no
circumstances that
18.
<PAGE>
may prevent or interfere with the compliance by the Company with any
Environmental Law in the future, except where failure to comply would not
have a Material Adverse Effect on the Company. To the knowledge of the
Company without further inquiry, no current or prior owner of any property
leased or controlled by the Company has received any notice or other
communication (in writing or otherwise) from a Governmental Body or citizens
group that alleges that such current or prior owner or the Company is not in
compliance with any Environmental Law. To the knowledge of the Company, all
property that is leased to, controlled by or used by the Company, and all
surface water, groundwater and soil associated with or adjacent to such
property is in clean and healthful condition and is free of environmental
contamination of any nature.
2.18 INSURANCE. Part 2.18 of the Company Disclosure Schedule sets
forth each insurance policy relating to the business, assets or operations of
the Company and with respect to each such policy, the insurer, the amount of
coverage, the type of insurance and the period of coverage. Each such
insurance policy is in full force and effect. Part 2.18 of the Company
Disclosure Schedule also sets forth each self insurance program relating to
the business, assets or operations of the Company. Since July 14, 1994, the
Company has not received any notice or other communication regarding any
actual or possible (a) cancellation or invalidation of any insurance policy,
(b) refusal of any coverage or rejection of any material claim under any
insurance policy, or (c) material adjustment in the amount of the premiums
payable with respect to any insurance policy. There is no pending claim
(including any workers' compensation claim) under or based upon any insurance
policy of the Company; and, to the knowledge of the Company, no event has
occurred that could reasonably be expected to (with or without notice or
lapse of time) directly or indirectly give rise to or serve as a basis for
any such claim.
2.19 TRANSACTIONS WITH AFFILIATES. Except as set forth in the Company
SEC Documents, since the date of the Company's last proxy statement filed
with the SEC, no event has occurred that would be required to be reported by
the Company pursuant to Item 404 of Regulation S-K promulgated by the SEC.
Part 2.19 of the Company Disclosure Schedule identifies each person who is an
"affiliate" (as that term is used in Rule 145 promulgated under the
Securities Act) of the Company as of the date of this Agreement.
2.20 LEGAL PROCEEDINGS; ORDERS.
(a) Except as set forth in Part 2.20(a) of the Company Disclosure
Schedule, there is no pending Legal Proceeding and, to the knowledge of the
Company, no Person has threatened to commence any Legal Proceeding: (i) that
involves the Company or any of the assets owned or used by the Company,
including, without limitation, Company Proprietary Assets; or (ii) that
challenges, or that may have the effect of preventing, delaying, making
illegal or otherwise interfering with, the Merger or any of the other
transactions contemplated by this Agreement. To the knowledge of the
Company, no event has occurred, and no claim, dispute or other condition or
circumstance exists, that will, or that could reasonably be expected to, give
rise to or serve as a basis for the commencement of any such Legal
Proceeding. To the knowledge of the Company, no event has occurred, and no
claim, dispute or other condition or circumstance exists, that will, or that
could reasonably be expected to, cause or provide a basis for a director,
officer or other Representative of the Company to seek indemnification from,
or commence a Legal Proceeding against or involving, the Company.
19.
<PAGE>
(b) There is no order, writ, injunction, judgment or decree to
which the Company, or any of the assets owned or used by the Company, is
subject. To the knowledge of the Company, no officer or other employee of
the Company is subject to any order, writ, injunction, judgment or decree
that prohibits such officer or other employee from engaging in or continuing
any conduct, activity or practice relating to the business of the Company.
2.21 AUTHORITY; BINDING NATURE OF AGREEMENT. The Company has the
absolute and unrestricted right, power and authority to enter into and to
perform its obligations under this Agreement. The Board of Directors of the
Company (at a meeting duly called and held) has (a) unanimously determined
that the Merger is advisable and fair and in the best interests of the
Company and its stockholders, (b) unanimously approved the execution,
delivery and performance of this Agreement by the Company and has unanimously
approved the Merger, and (c) unanimously recommended the adoption and
approval of this Agreement and the Merger by the holders of Company Common
Stock and directed that this Agreement and the Merger be submitted for
consideration by the Company's stockholders at the Company Stockholders'
Meeting (as defined in Section 6.2). This Agreement constitutes the legal,
valid and binding obligation of the Company, enforceable against the Company
in accordance with its terms, subject to (i) laws of general application
relating to bankruptcy, insolvency and the relief of debtors, and (ii) rules
of law governing specific performance, injunctive relief and other equitable
remedies.
2.22 NO EXISTING DISCUSSIONS. As of the date hereof, neither the
Company nor any Representative of the Company is engaged, directly or
indirectly, in any discussions or negotiations with any other Person relating to
any Acquisition Proposal.
2.23 VOTE REQUIRED. Upon the conversion of the Company's Series B
Preferred Stock, the affirmative vote of the holders of a majority of the
shares of Company Common Stock outstanding on the record date for the Company
Stockholder Meeting (the "REQUIRED COMPANY STOCKHOLDER VOTE") is the only
vote of the holders of any class or series of the Company's capital stock
necessary to adopt and approve this Agreement, the Merger and the other
transactions contemplated by this Agreement.
2.24 NON-CONTRAVENTION; CONSENTS. Neither (i) the execution, delivery
or performance of this Agreement or any of the other agreements referred to
in this Agreement, nor (ii) the consummation of the Merger or any of the
other transactions contemplated by this Agreement, will directly or
indirectly (with or without notice or lapse of time):
(a) contravene, conflict with or result in a violation of (i) any
of the provisions of the certificate of incorporation, bylaws or other
charter or organizational documents of the Company, or (ii) any resolution
adopted by the stockholders, the Board of Directors or any committee of the
Board of Directors of the Company;
(b) contravene, conflict with or result in a violation of, or
give any Governmental Body or other Person the right to challenge the Merger
or any of the other transactions contemplated by this Agreement or to
exercise any remedy or obtain any relief under, any Legal Requirement or any
order, writ, injunction, judgment or decree to which the Company, or any of
the assets owned or used by the Company, is subject;
20.
<PAGE>
(c) contravene, conflict with or result in a violation of any of
the terms or requirements of, or give any Governmental Body the right to
revoke, withdraw, suspend, cancel, terminate or modify, any Governmental
Authorization that is held by the Company or that otherwise relates to the
business of the Company or to any of the assets owned or used by the Company;
(d) contravene, conflict with or result in a violation or breach
of, or result in a default under, any provision of any Company Material
Contract or (except as set forth in Part 2.24(d) of the Company Disclosure
Schedule), give any Person the right to (i) declare a default or exercise any
remedy under any such Company Material Contract, (ii) a rebate, chargeback,
penalty or change in delivery schedule under any such Company Material
Contract, (iii) accelerate the maturity or performance of any such Company
Material Contract, or (iv) cancel, terminate or modify any term of such
Company Material Contract; or
(e) result in the imposition or creation of any Encumbrance upon,
or with respect to any asset owned or used by the Company (except for
Permitted Encumbrances).
Except as set forth in Part 2.24(d) of the Company Disclosure Schedule, or
except as may be required by the Exchange Act, the DGCL and the rules of the
National Association of Securities Dealers, Inc. ("NASD") (as they relate to
the S-4 Registration Statement and the Joint Proxy Statement/Prospectus, as
defined in Section 2.27(b)), the Company was not, is not and will not be
required to make any filing with or give any notice to, or to obtain any
Consent from, any Person in connection with (x) the execution, delivery or
performance of this Agreement or any of the other agreements referred to in
this Agreement, or (y) the consummation of the Merger or any of the other
transactions contemplated by this Agreement.
2.25 FAIRNESS OPINION. The Company's Board of Directors has received
the written opinion of PaineWebber Incorporated, financial advisor to the
Company, dated the date of this Agreement, to the effect that the Exchange
Ratio is fair to the stockholders of the Company from a financial point of
view. The Company has furnished an accurate and complete copy of said
written opinion to Parent.
2.26 FINANCIAL ADVISOR. Except for PaineWebber Incorporated, or any
Person set forth on Part 2.26 of the Company Disclosure Schedule no broker,
finder or investment banker is entitled to any brokerage, finder's or other
fee or commission in connection with the Merger or any of the other
transactions contemplated by this Agreement based upon arrangements made by
or on behalf of the Company. The Company has disclosed to Parent the fee
formula pursuant to which fees, commissions and other payments will be paid
by the Company to PaineWebber Incorporated and any such other Person if the
Merger is consummated. The Company furnished to Parent accurate and complete
copies of all agreements under which any such fees, commissions or other
amounts have been paid or may become payable and all indemnification and
other agreements relating to the engagement of PaineWebber Incorporated or
any such other Person.
21.
<PAGE>
2.27 FULL DISCLOSURE.
(a) This Agreement (including the Company Disclosure Schedule)
does not, and the certificate referred to in Section 7.6(c) will not, (i)
contain any representation, warranty or information that is false or
misleading with respect to any material fact, or (ii) omit to state any
material fact necessary in order to make the representations, warranties and
information contained and to be contained herein and therein (in the light of
the circumstances under which such representations, warranties and
information were or will be made or provided) not false or misleading.
(b) None of the information supplied or to be supplied by or on
behalf of the Company for inclusion or incorporation by reference in the
registration statement on Form S-4 to be filed with the SEC by Parent in
connection with the issuance of Parent Common Stock in the Merger (the "S-4
REGISTRATION STATEMENT") will, at the time the S-4 Registration Statement is
filed with the SEC or at the time it becomes effective under the Securities
Act, contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they are
made, not misleading. None of the information supplied or to be supplied by
or on behalf of the Company for inclusion or incorporation by reference in
the Joint Proxy Statement/Prospectus to be filed with the SEC as part of the
S-4 Registration Statement (the "JOINT PROXY STATEMENT/PROSPECTUS"), will, at
the time the Joint Proxy Statement/Prospectus is mailed to the stockholders
of the Company, at the time of the Company Stockholders' Meeting or as of the
Effective Time, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order
to make the statements therein, in the light of the circumstances under which
they are made, not misleading. The Joint Proxy Statement/Prospectus will
comply as to form in all material respects with the provisions of the
Exchange Act and the rules and regulations promulgated by the SEC thereunder.
2.28 RIGHTS AGREEMENT. The Company has taken all action necessary to
provide that the execution and delivery of this Agreement and the consummation
of the transactions contemplated by this Agreement will not enable or require
any Rights (as such term is defined in the Rights Agreement) to be exercised or
distributed.
SECTION 3. REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB.
Parent and Merger Sub represent and warrant to the Company that, except
as set forth in the Parent SEC Documents (as defined in Section 3.4(a)) or in
the disclosure schedule delivered to the Company on the date of this
Agreement and signed by an executive officer of Parent (the "PARENT
DISCLOSURE SCHEDULE"):
3.1 DUE ORGANIZATION; SUBSIDIARIES; ETC.
(a) Parent has no Subsidiaries, except for the corporations
identified in Part 3.1(a) of the Parent Disclosure Schedule; and neither the
Parent nor any of the other corporations identified in Part 3.1(a) of the Parent
Disclosure Schedule owns any capital stock of, or any equity interest of any
nature in, any other Entity. (Parent and each of its Subsidiaries are referred
22.
<PAGE>
to collectively in this Agreement as the "PARENT CORPORATIONS".) None of the
Parent Corporations has agreed to or is obligated to make, or is bound by any
Contract under which it may become obligated to make, any future investment
in or capital contribution to any other Entity. None of the Parent
Corporations has, at any time, been a general partner of any general
partnership, limited partnership or other Entity.
(b) Each of the Parent Corporations is a corporation duly
organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation and has all corporate power and authority:
(i) to conduct its business in the manner in which its business is currently
being conducted; (ii) to own and use its assets in the manner in which its
assets are currently owned and used; and (iii) to perform its obligations
under all Contracts by which it is bound.
(c) None of the Parent Corporations is or has been required to
be qualified, authorized, registered or licensed to do business as a foreign
corporation in any jurisdiction other than the jurisdictions identified in
Part 3.1(c) of the Parent Disclosure Schedule, except where the failure to be
so qualified, authorized, registered or licensed has not had and will not
have a Material Adverse Effect on the Parent Corporations. Each of the
Parent Corporations is in good standing as a foreign corporation in each of
the respective jurisdictions identified in Part 3.1(c) of the Parent
Disclosure Schedule.
3.2 CERTIFICATES OF INCORPORATION AND BYLAWS. The Parent has
delivered to the Company accurate and complete copies of the certificates of
incorporation, bylaws and other charter and organizational documents of the
respective Parent Corporations, including all amendments thereto. None of
the Parent Corporations is in violation of any of the provisions of its
respective certificate of incorporation or bylaws.
3.3 CAPITALIZATION, ETC.
(a) The authorized capital stock of Parent consists of: (i)
thirty million (30,000,000) shares of Parent Common Stock, $.001 par value
per share, of which, as of September 30, 1998, 12,895,163 shares (which
amount does not materially differ from the amount issued and outstanding as
of the date of this Agreement) were issued and outstanding; and (ii) ten
million (10,000,000) shares of preferred stock, $.001 par value per share, of
which no shares are outstanding as of the date of this Agreement. As of the
date of this Agreement, there are no outstanding subscriptions, options,
calls, warrants or rights to acquire shares of Parent Common Stock other than
pursuant to stock issuance or stock option plans or other arrangements
disclosed in the Parent SEC Documents. The authorized capital stock of Merger
Sub consists of one hundred (100) shares of Common Stock ("MERGER SUB COMMON
STOCK"), $.001 par value per share, all of which have been issued and are
outstanding as of the date of this Agreement and are held by Parent. As of
the date of this Agreement, there are no shares of Parent Common Stock held
in treasury by Parent. None of the outstanding shares of Parent Common Stock
is entitled or subject to any preemptive right, right of participation, right
of maintenance or any similar right. None of the outstanding shares of the
Parent's capital stock is entitled or subject to any preemptive right, right
of participation, right of maintenance or any similar right. None of the
outstanding shares of the Parent's capital stock is subject to any right of
first refusal in favor of the Parent. Except as provided in Part 3.3(a) of
the Parent Disclosure Schedule, there is no
23.
<PAGE>
Parent Contract relating to the voting or registration of, or restricting any
Person from purchasing, selling, pledging or otherwise disposing of (or
granting any option or similar right with respect to), any shares of Parent
Common Stock. The Parent is not under any obligation to repurchase, redeem
or otherwise acquire any outstanding shares of the Parent's capital stock.
(b) As of September 30, 1998, 1,068,408 shares (which amount
does not materially differ from the amount subject to options outstanding as
of the date of this Agreement) of Parent Common Stock are subject to issuance
pursuant to outstanding options to purchase Parent Common Stock. (Stock
options granted by the Parent pursuant to Parent's stock option plans are
referred to in this Agreement as "PARENT OPTIONS"). Part 3.3(b) of the
Parent Disclosure Schedule sets forth the following information with respect
to each Parent Option outstanding as of September 30, 1998: (i) the
particular plan pursuant to which such Parent Option was granted; (ii) the
name of the optionee; (iii) the number of shares of Parent Common Stock
subject to such Parent Option; (iv) the exercise price of such Parent Option;
(v) the date on which such Parent Option was granted; (vi) the applicable
vesting schedule and the extent to which such Parent Option is vested and
exercisable as of the date of this Agreement; and (vii) the date on which
such Parent Option expires. Parent has delivered to the Company accurate and
complete copies of all stock option plans pursuant to which the Company has
ever granted stock options and the form of all stock option agreements
evidencing such options. Except as set forth in Part 3.3(b) of the Parent
Disclosure Schedule, there are no commitments or agreements of any character
to which Parent is bound obligating Parent to accelerate the vesting of any
Parent Option.
(c) As of September 30, 1998, 62,378 shares (which amount does
not materially differ from the amount subject to warrants outstanding as of
the date of this Agreement) of Parent Common Stock are subject to issuance
pursuant to outstanding warrants to purchase Parent Common Stock. (Warrants
issued by Parent are referred to in this Agreement as "PARENT WARRANTS.")
Part 3.3(c) of Parent Disclosure Schedule sets forth the following
information with respect to each Parent Warrant outstanding as of September
30, 1998: (i) the name of the warrant holder; (ii) the number of shares of
Parent Common Stock subject to such Parent Warrant; (iii) the exercise price
of such Parent Warrant; (iv) the date on which such Parent Warrant was
issued; (v) the applicable exercise period and the extent to which such
Parent Warrant is exercisable as of the date of this Agreement; and (vi) the
date on which such Parent Warrant expires. Parent has delivered to Parent
accurate and complete copies of all agreements and other documents evidencing
such Parent Warrants. Except as set forth in Part 3.3(c) of Parent
Disclosure Schedule, there are no commitments or agreements of any character
to which Parent is bound obligating Parent to amend or extend exercisability
or term of any Parent Warrant.
(d) Except as set forth in this Section 3.3 there is no: (i)
outstanding subscription, option, call, warrant or right (whether or not
currently exercisable) to acquire any shares of the capital stock or other
securities of Parent; (ii) outstanding security, instrument or obligation that
is or may become convertible into or exchangeable for any shares of the capital
stock or other securities of Parent; (iii) stockholder rights plan (or similar
plan commonly referred to as a "poison pill") or Contract under which Parent is
or may become obligated to sell or otherwise issue any shares of its capital
stock or any other securities; or (iv) condition or circumstance that may give
rise to or provide a basis for the assertion of a claim by any Person to
24.
<PAGE>
the effect that such Person is entitled to acquire or receive any shares of
capital stock or other securities of Parent.
(e) All outstanding shares of Parent Common Stock, all
outstanding shares of Preferred Stock, all outstanding Parent Options, all
outstanding Parent Warrants and all outstanding shares of capital stock of
Parent have been issued and granted in compliance in all material respects
with (i) all applicable securities laws and other applicable Legal
Requirements, and (ii) all requirements set forth in applicable Contracts.
3.4 SEC FILINGS; FINANCIAL STATEMENTS.
(a) Parent has delivered to the Company accurate and complete
copies (excluding copies of exhibits) of all registration statements,
definitive proxy statements and other statements, reports, schedules, forms
and other documents filed by Parent with the SEC between September 15, 1997
and the date of this Agreement and will deliver to the Company accurate and
complete copies of all such registration statements, proxy statements and
other statements, reports, schedules, forms and other documents filed after
the date of this Agreement and prior to the Effective Time (collectively, the
"PARENT SEC DOCUMENTS"), which are all of the forms, reports and documents
required to be filed by Parent with the SEC since September 15, 1997. As of
the time it was filed with the SEC (or, if amended or superseded by a later
filing, then on the date of such filing): (i) each of Parent SEC Documents
filed with the SEC was timely filed and complied in all material respects
with the applicable requirements of the Securities Act or the Exchange Act
(as the case may be) as of the date of such filing and any Parent SEC
Documents filed after the date hereof and prior to the Effective Time will so
comply; and (ii) none of Parent SEC Documents contained any untrue statement
of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading.
(b) The financial statements (including any related notes)
contained in the Parent SEC Documents: (i) complied as to form in all
material respects with the published rules and regulations of the SEC
applicable thereto; (ii) were prepared in accordance with GAAP applied on a
consistent basis throughout the periods covered (except as may be indicated
in the notes to such financial statements and, in the case of unaudited
statements, as permitted by Form 10-Q of the SEC, and except that unaudited
financial statements may not contain footnotes and are subject to normal and
recurring year end adjustments which will not, individually or in the
aggregate, be material in amount); and (iii) fairly present the financial
position of Parent and its subsidiaries as of the respective dates thereof
and the consolidated results of operations of Parent and its subsidiaries for
the periods covered thereby. All adjustments (consisting of recurring
accruals) considered necessary for a fair presentation of the financial
statements have been included. The audited balance sheet of Parent and its
subsidiaries for the year ended June 30, 1998 is sometimes referred to herein
as the "PARENT BALANCE SHEET."
3.5 ABSENCE OF CHANGES. Since the date of the Parent Balance Sheet:
(a) there has not been any material adverse change in the
business, assets, liabilities, financial condition or results of operations
of Parent taken as a whole, and no event has occurred that could reasonably
be expected to have a Material Adverse Effect on Parent;
25.
<PAGE>
(b) there has not been any material loss, damage or destruction
to, or any material interruption in the use of, any of the assets of Parent
(whether or not covered by insurance);
(c) Parent has not (i) declared, accrued, set aside or paid any
dividend or made any other distribution in respect of any shares of capital
stock, or (ii) repurchased, redeemed or otherwise reacquired any shares of
capital stock or other securities;
(d) except for formation of Merger Sub, Parent has not sold,
issued, granted or authorized the issuance or grant of (i) any capital stock
or other security (except for Parent Common Stock issued upon the exercise of
outstanding Parent Options), (ii) any option, call, warrant or right to
acquire any capital stock or any other security (except for Parent Options
described in Part 3.3(b)(i) and 3.5(d) of the Parent Disclosure Schedule), or
(iii) any instrument convertible into or exchangeable for any capital stock
or other security;
(e) Parent has not amended or waived any of its rights under, or
permitted the acceleration of vesting under, (i) any provision of Parent's
stock option plans, (ii) any provision of any agreement evidencing any
outstanding Parent Option, or (iii) any restricted stock purchase agreement;
(f) there has been no amendment to the certificate of
incorporation, bylaws or other charter or organizational documents of Parent,
and Parent has not effected or been a party to any merger, consolidation,
share exchange, business combination, recapitalization, reclassification of
shares, stock split, reverse stock split or similar transaction;
(g) Parent has not formed any subsidiary or acquired any equity
interest or other interest in any other Entity;
(h) except as set forth on Part 3.5(h) of the Parent Disclosure
Schedule, Parent has not made any capital expenditures which exceed $100,000
in the aggregate;
(i) except in the ordinary course of business and consistent
with past practices, Parent has not (i) entered into or permitted any of the
assets owned or used by it to become bound by any Parent Material Contract
(as defined in Section 3.10), or (ii) amended or prematurely terminated, or
waived any material right or remedy under, any Parent Material Contract;
(j) Parent has not (i) acquired, leased or licensed any material
right or other material asset from any other Person, (ii) sold or otherwise
disposed of, or leased or licensed, any material right or other material
asset to any other Person, or (iii) waived or relinquished any right, except
for rights or other assets acquired, leased, licensed or disposed of in the
ordinary course of business and consistent with past practices;
(k) Parent has not written off as uncollectible, or established
any extraordinary reserve with respect to, any account receivable or other
indebtedness in excess of $25,000 with respect to any single matter, or in
excess of $50,000 in the aggregate;
26.
<PAGE>
(l) Parent has not made any pledge of any of its assets or
otherwise permitted any of its assets to become subject to any Encumbrance,
except for Permitted Encumbrances;
(m) Parent has not (i) lent money to any Person, or (ii)
incurred or guaranteed any indebtedness for borrowed money other than
payroll, travel and other advances made in the ordinary course of business;
(n) Parent has not (i) established or adopted any Parent Plan
(as defined in Section 3.16(a)), (ii) caused or permitted any Parent Plan to
be amended in any material respect, or (iii) paid any bonus or made any
profit-sharing or similar payment to, or materially increased the amount of
the wages, salary, commissions, fringe benefits or other compensation or
remuneration payable to, any of its directors, officers or employees;
(o) Parent has not changed any of its methods of accounting or
accounting practices in any material respect;
(p) Parent has not made any material election with respect to
Taxes;
(q) Parent has not commenced or settled any Legal Proceeding;
(r) Parent has not entered into any material transaction or
taken any other material action that has had, or could reasonably be expected
to have, a Material Adverse Effect on Parent; and
(s) Parent has not agreed or committed to take any of the
actions referred to in clauses "(c)" through "(r)" above.
3.6 LEASEHOLD; EQUIPMENT.
(a) Parent does not own any real property or any interest in
real property, except for the leaseholds created under the real property
leases identified in Part 3.6(a) of the Parent Disclosure Schedule. All such
real property is being leased pursuant to lease agreements that are in full
force and effect, are valid and effective in accordance with their respective
terms, and there is not, under any of such leases, any existing default or
event of default (or event which with notice or lapse of time, or both, would
constitute a default) that would result in a Material Adverse Effect on
Parent.
(b) Part 3.6(b) of Parent Disclosure Schedule accurately
identifies all material items of equipment leased by Parent. All material
items of equipment and other tangible assets owned by or leased to Parent are
adequate for the uses to which they are being put, are in good condition and
repair (ordinary wear and tear excepted) and are adequate for the conduct of
the business of Parent in the manner in which such business is currently
being conducted.
3.7 TITLE TO ASSETS. Parent owns, and has good, valid and marketable
title to, or in the case of leased properties and assets, valid leasehold
interests in, all of their respective tangible properties and assets, real,
personal and mixed, used or held for use in their business, including: (i)
all assets reflected on the Parent Balance Sheet; and (ii) all other assets
reflected in the books
27.
<PAGE>
and records of Parent as being owned or leased by Parent. All of said assets
are owned or leased by Parent free and clear of any Encumbrances, except for
Permitted Encumbrances.
3.8 PAYMENTS UNDER CORPORATE PARTNERING AGREEMENTS.
(a) All amounts charged to Glaxo Wellcome PLC and Eli Lilly and
Company (the "PARENT CORPORATE PARTNERS") and Pfizer, Inc. for reimbursement
or payments in accordance with the agreements between Parent and such Persons
represent amounts due to Parent under the terms of such agreements for actual
work or services performed or, in the case of advance payments, work or
services to be performed or milestones met.
(b) Parent has received all amounts that are owed and due to be
paid to Parent under such agreements prior to the date of this Agreement.
For each such payment received by Parent under any such agreement, any
revenue that Parent recognized with respect to such payment was recognized in
accordance with GAAP.
(c) Parent has no knowledge that a Parent Corporate Partner is
considering, intending or planning to terminate any of the agreements between
any such Parent Corporate Partner and Parent, or any research program under
such agreement.
3.9 PROPRIETARY ASSETS.
(a) Part 3.9(a) of Parent Disclosure Schedule sets forth, with
respect to each Proprietary Asset owned or licensed by Parent and registered
with any Governmental Body or for which an application has been filed with
any Governmental Body, (i) a brief description of such Proprietary Assets,
and (ii) the names of the jurisdictions covered by the applicable
registration or application. Part 3.9(a) of Parent Disclosure Schedule
identifies and provides a brief description of, and identifies any ongoing
royalty or payment obligations in excess of $50,000 per year with respect to,
each Proprietary Asset that is licensed or otherwise made available to Parent
by any Person (except for any Proprietary Asset that is licensed to Parent
under any third party software license generally available to the public),
and identifies the Contract under which such Proprietary Asset is being
licensed or otherwise made available to Parent. Excluding the payments
required under the Parent Contracts set forth in the Parent Disclosure
Schedule, the aggregate amounts payable by Parent for ongoing royalty or
license payments do not exceed $100,000 per year. Parent has good, valid and
marketable title to all of Parent Proprietary Assets (except for licensed
assets), free and clear of all Encumbrances, except (i) as set forth in Part
3.9(a) of the Parent Disclosure Schedule, (ii) for any lien for current taxes
not yet due and payable, and (iii) for minor liens that have arisen in the
ordinary course of business and that do not (individually or in the
aggregate) materially detract from the value of the assets subject thereto or
materially impair the operations of Parent. To Parent's knowledge, Parent
has a valid right to use, license and otherwise exploit all Parent
Proprietary Assets. Except as set forth in Part 3.9(a) of Parent Disclosure
Schedule, Parent has not developed jointly or does not jointly own or have
joint rights with any other Person any Parent Proprietary Asset that is
material to the business of Parent. Except as set forth in Part 3.9(a) of
the Disclosure Schedule, there is no Parent Contract pursuant to which any
Person has any right (whether or not currently exercisable) to use, license
or otherwise exploit any Parent Proprietary Asset.
28.
<PAGE>
(b) Parent has taken all commercially reasonable measures and
precautions to protect and maintain the confidentiality and secrecy of all
Parent Proprietary Assets (except Parent Proprietary Assets whose value would
be unimpaired by public disclosure) and otherwise to maintain and protect the
value of all Parent Proprietary Assets.
(c) To the knowledge of Parent, Parent is not misappropriating
or making any unlawful use of, and Parent has not at any time misappropriated
or made any unlawful use of, or received any notice or other communication
(in writing or otherwise) of any actual, alleged, possible or potential
infringement, misappropriation or unlawful use of, any Proprietary Asset
owned or used by any other Person.
(d) Parent Proprietary Assets constitute all the Proprietary
Assets reasonably necessary to enable Parent to conduct its business in the
manner in which such business has been and is being conducted. Except as set
forth in Part 3.9(d) of the Parent Disclosure Schedule, Parent has not
licensed any of the Company Proprietary Assets to any Person on an exclusive
basis.
(e) All current and former employees have executed and delivered
an agreement to Parent (containing no exceptions to or exclusions from the
scope of its coverage) that is substantially identical to the form of
Confidential Information and Invention Assignment Agreement previously
delivered to the Company by Parent. All current and former consultants and
independent contractors to Parent have executed and delivered to Parent an
agreement that contains provisions appropriately restricting the use and
disclosure of Parent Proprietary Assets.
(f) Parent has taken reasonably adequate steps to ensure that
all software (and related Proprietary Assets) used in its operations will be
Year 2000 Compliant (as defined below) by December 31, 1999. For purposes of
this Section 3, "YEAR 2000 COMPLIANT" shall mean that software that can
individually, and in combination and in conjunction with all other systems,
products or processes with which they are required or designed to interface,
continue to be used normally and to operate successfully (both in
functionality and performance in all material respects) over the transition
into the twenty first century when used in accordance with the documentation
relating to all such software (and related Parent Proprietary Assets),
including being able to, before, on and after January 1, 2000 substantially
conform to the following: (i) use logic pertaining to dates which allow users
to identify and/or use the century portion of any date fields without special
processing; and (ii) respond to all date elements and date input so as to
resolve any ambiguity as to century in a disclosed, defined and
pre-determined manner and provide date information in ways which are
unambiguous as to century, either by permitting or requiring the century to
be specified or where the data element is represented without a century, the
correct century is unambiguous for all manipulations involving that element.
3.10 CONTRACTS.
(a) Part 3.10 of the Parent Disclosure Schedule identifies each
Parent Contract that constitutes a "Parent Material Contract." For purposes
of this Agreement, each of the following shall be deemed to constitute a
"PARENT MATERIAL CONTRACT":
29.
<PAGE>
(i) (A) any Contract or outstanding offer relating to the
employment of, or the performance of services by, any employee, and (B) any
Contract pursuant to which the Company is required to make any severance,
termination or similar payment, bonus or relocation payment or any other
payment (other than payments in respect of salary) to any current or former
employee or director of the Company;
(ii) any Contract (A) relating to the acquisition,
transfer, development, sharing, license (to or by Parent), or use of any
Proprietary Asset (except for any Contract pursuant to which any Proprietary
Asset is licensed to the Company under any third party software license
generally available to the public); or (B) with respect to the distribution
or marketing of any products of Parent;
(iii) any Contract which provides for indemnification of any
officer, director, employee or agent of Parent;
(iv) any Contract imposing any restriction on the right or
ability of Parent (A) to compete in any market or geographic area with any
other Person, (B) to acquire any product or other asset or any services from
any other Person, to sell any product or other asset to or perform any
services for any other Person or to transact business or deal in any other
manner with any other Person, or (C) to develop or distribute any technology;
(v) any Contract (A) relating to the acquisition,
issuance, voting, registration, sale or transfer of any securities (other
than the issuance of Parent Common Stock upon the valid exercise of Parent
Options outstanding as of the date of this Agreement), (B) providing any
Person with any preemptive right, right of participation, right of
maintenance or any similar right with respect to any securities, or (C)
providing Parent with any right of first refusal with respect to, or right to
repurchase or redeem, any securities;
(vi) any Contract that (A) contemplates or involves payment
or delivery of cash or other consideration in an amount or having a value in
excess of $20,000 per month and (B) has a term of more than 90 days and that
may not be terminated by such Parent within 90 days after the delivery of a
termination notice by such Parent;
(vii) any Contract that contemplates or involves payment or
delivery of cash or other consideration by Parent in an amount or having a
value in excess of $75,000 in the aggregate;
(viii) any Contract or Plan (including, without
limitation, any stock option plan, stock appreciation plan or stock purchase
plan), any of the benefits of which will be increased, or the vesting of
benefits of which will be accelerated, by the execution of this Agreement or
the consummation of any of the transactions contemplated by this Agreement or
the value of any of the benefits of which will be calculated on the basis of
any of the transactions contemplated by this Agreement;
(ix) any Contract (not otherwise identified in clauses
"(i)" through "(viii)" of this sentence) that is or would be material to
Parent, to the business, condition, capitalization or operations of Parent or
to any of the transactions contemplated by this Agreement; and
30.
<PAGE>
(x) any other Contract, if a breach of such Contract could
reasonably be expected to have a Material Adverse Effect on Parent.
(b) Each Parent Material Contract is valid and in full force and
effect, and is enforceable by an Acquired Corporation in accordance with its
terms, subject to (i) laws of general application relating to bankruptcy,
insolvency and the relief of debtors, and (ii) rules of law governing
specific performance, injunctive relief and other equitable remedies
(c) Except where the following would not have a Material Adverse
Effect on Parent: (i) Parent has not violated or breached, or committed any
default under, any Parent Contract, and, to the knowledge of Parent, no other
Person has violated or breached, or committed any default under, any Parent
Contract; (ii) to the knowledge of Parent, no event has occurred, and no
circumstance or condition exists, that (with or without notice or lapse of
time) will, or could reasonably be expected to, (A) result in a violation or
breach of any of the provisions of any Parent Contract, (B) give any Person
the right to declare a default or exercise any remedy under any Parent
Contract, (C) give any Person the right to a rebate, chargeback, penalty or
change in delivery schedule under any Parent Contract, (D) give any Person
the right to accelerate the maturity or performance of any Parent Contract,
or (E) give any Person the right to cancel, terminate or modify any Parent
Contract; and (iii) neither Parent, nor any of its Representatives, has
received any notice or other communication regarding any actual or possible
violation or breach of, or default under any Parent Contract.
(d) There is no Parent Contract to which any Governmental Body
is a party or under which any Governmental Body has any rights or
obligations, or directly or indirectly benefiting any Governmental Body
(including any subcontract or other Contract between Parent and any
contractor or subcontractor to any Governmental Body).
(e) No Person is renegotiating, or has a right pursuant to the
terms of any Parent Material Contract to renegotiate, any amount paid or
payable to Parent under any Parent Material Contract or any other material
term or provision of any Parent Material Contract.
3.11 YEAR 2000 LIABILITIES. Parent does not have any accrued,
contingent or other liabilities of any nature, either matured or unmatured,
including, without limitation, any liabilities relating to costs associated
with insuring that all software (and related Parent Proprietary Assets)
utilized by Parent or other components of Parent's information technology
infrastructure are Year 2000 Compliant (whether or not required to be
reflected in financial statements in accordance with GAAP, and whether due or
to become due), except for: (a) liabilities identified as such in the
"liabilities" column of the Parent Balance Sheet; and (b) normal and
recurring liabilities that have been incurred by Parent since the date of the
Parent Balance Sheet in the ordinary course of business and consistent with
past practices.
3.12 COMPLIANCE WITH LEGAL REQUIREMENTS. Parent is, and has at all
times since September 15, 1997 been, in compliance with all applicable Legal
Requirements, except where the failure to comply with such Legal Requirements
has not had and will not have a Material Adverse Effect on Parent. Since
September 15, 1997, Parent has not received any notice or other communication
from any Governmental Body regarding any actual or possible violation of, or
failure to comply with, any Legal Requirement.
31.
<PAGE>
3.13 CERTAIN BUSINESS PRACTICES. Neither Parent nor any director,
officer, agent or employee of Parent has, on behalf of Parent, (i) used any
funds for unlawful contributions, gifts, entertainment or other unlawful
expenses relating to political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to foreign or
domestic political parties or campaigns or violated any provision of the
Foreign Corrupt Practices Act of 1977, as amended, or (iii) made any other
unlawful payment.
3.14 GOVERNMENTAL AUTHORIZATIONS. Parent holds all Governmental
Authorizations necessary to enable it to conduct its business in the manner
in which such business is currently being conducted. All such Governmental
Authorizations are valid and in full force and effect. Parent is, and at all
times since September 15, 1997 has been, in substantial compliance with the
terms and requirements of such Governmental Authorizations. Since September
15, 1997, Parent has not received any notice or other communication from any
Governmental Body regarding (a) any actual or possible violation of or
failure to comply with any term or requirement of any Governmental
Authorization, or (b) any actual or possible revocation, withdrawal,
suspension, cancellation, termination or modification of any Governmental
Authorization.
3.15 TAX MATTERS.
(a) All Tax Returns required to be filed by or on behalf of
Parent with any Governmental Body with respect to any taxable period ending
on or before the Closing Date ("PARENT RETURNS") (i) have been or will be
filed on or before the applicable due date (including any extensions of such
due date if properly obtained), and (ii) have been, or will be when filed,
prepared in all material respects in compliance with all applicable Legal
Requirements. All amounts shown on Parent Returns to be due on or before the
Closing Date have been or will be paid on or before the Closing Date.
(b) Parent Financial Statements fully accrue all actual and
contingent liabilities for Taxes with respect to all periods through the
dates thereof in accordance with GAAP. Parent will establish, in the
ordinary course of business and consistent with its past practices, reserves
adequate for the payment of all Taxes for the period from June 30, 1998
through the Closing Date.
(c) Except as set forth in Part 3.15(c) of Parent Disclosure
Schedule, Parent Returns have never been examined or audited by any
Governmental Body. No extension or waiver of the limitation period
applicable to any Parent Returns has been granted (by Parent or any other
Person), and no such extension or waiver has been requested from Parent.
(d) No claim or Legal Proceeding is pending or, to the knowledge
of Parent, has been threatened against or with respect to Parent in respect
of any material Tax. There are no unsatisfied liabilities for material Taxes
(including liabilities for interest, additions to tax and penalties thereon
and related expenses) with respect to any notice of deficiency or similar
document received by Parent with respect to any material Tax (other than
liabilities for Taxes asserted under any such notice of deficiency or similar
document which are being contested in good faith by Parent and with respect
to which adequate reserves for payment have been established). There are no
liens for material Taxes upon any of the assets of Parent except liens for
current Taxes not yet due and payable. Parent has not entered into or become
bound by any
32.
<PAGE>
agreement or consent pursuant to Section 341(f) of the Code. Parent has not
been, and it will not be, required to include any material adjustment in
taxable income for any tax period (or portion thereof) pursuant to Section
481 of the Code or any comparable provision under state or foreign Tax laws
as a result of transactions or events occurring, or accounting methods
employed, prior to the Closing.
(e) Except as set forth in Part 3.15(e) of Parent Disclosure
Schedule, there is no agreement, plan, arrangement or other Contract covering
any employee or independent contractor or former employee or independent
contractor of Parent that, considered individually or considered collectively
with any other such Contracts, will, or could reasonably be expected to, give
rise directly or indirectly to the payment of any amount that would not be
deductible pursuant to Section 280G or Section 162 of the Code. Parent is
not and has never been, a party to or bound by any tax indemnity agreement,
tax sharing agreement, tax allocation agreement or similar Contract.
3.16 EMPLOYEE AND LABOR MATTERS; BENEFIT PLANS.
(a) Part 3.16(a) of Parent Disclosure Schedule identifies each
salary, bonus, deferred compensation, incentive compensation, stock purchase,
stock option, severance pay, termination pay, hospitalization, medical, life
or other insurance, supplemental unemployment benefits, profit-sharing,
pension or retirement plan, program or agreement (collectively, the "PARENT
PLANS") sponsored, maintained, contributed to or required to be contributed
to by Parent for the benefit of any current or former employee of Parent.
(b) Except as set forth in Part 3.16(a) of Parent Disclosure
Schedule, Parent does not maintain, sponsor or contribute to, and it has not
at any time in the past maintained, sponsored or contributed to, any employee
pension benefit plan (as defined in Section 3(2) of the Employee Retirement
Income Security Act of 1974, as amended ("ERISA"), whether or not excluded
from coverage under specific Titles or Subtitles of ERISA) for the benefit of
employees or former employees of Parent (a "PARENT PENSION PLAN"). None of
the Parent Plans identified in Part 3.16(a) of Parent Disclosure Schedule is
subject to Title IV of ERISA or Section 412 of the Code.
(c) Except as set forth in Part 3.16(a) of Parent Disclosure
Schedule, Parent does not maintain, sponsor or contribute to any employee
welfare benefit plan (as defined in Section 3(1) of ERISA, whether or not
excluded from coverage under specific Titles or Subtitles of ERISA) for the
benefit of any employees or former employees of Parent including any
self-funded medical, dental, or other similar Parent Plan (a "PARENT WELFARE
PLAN"). None of the Parent Plans identified in Part 3.16(a) of Parent
Disclosure Schedule is a multiemployer plan (within the meaning of Section
3(37) of ERISA).
(d) With respect to each Parent Plan, Parent has delivered to
the Company: (i) an accurate and complete copy of such Parent Plan (including
all amendments thereto); (ii) an accurate and complete copy of the annual
report, if required under ERISA, with respect to such Parent Plan for the
last two years; (iii) an accurate and complete copy of the most recent
Summary Plan Description, together with each Summary of Material
Modifications, if required under ERISA, with respect to such Parent Plan,
(iv) if such Parent Plan is funded through a trust
33.
<PAGE>
or any third party funding vehicle, an accurate and complete copy of the
trust or other funding agreement (including all amendments thereto) and
accurate and complete copies of the most recent financial statements thereof;
(v) accurate and complete copies of all Contracts relating to such Parent
Plan, including service provider agreements, insurance contracts, minimum
premium contracts, stop-loss agreements, investment management agreements,
subscription and participation agreements and recordkeeping agreements; and
(vi) an accurate and complete copy of the most recent determination letter
received from the Internal Revenue Service with respect to such Parent Plan
(if such Parent Plan is intended to be qualified under Section 401(a) of the
Code).
(e) Each of the Parent Plans complies with and has been operated
and administered in all material respects in accordance with applicable Legal
Requirements, including but not limited to ERISA and the Code.
(f) Each of the Parent Plans intended to be qualified under
Section 401(a) of the Code has received a favorable determination from the
Internal Revenue Service, and Parent is not aware of any reason why any such
determination letter should be revoked.
(g) Part 3.16(g) of Parent Disclosure Schedule contains a list
of all salaried employees of Parent as of the date of this Agreement, and
correctly reflects, in all material respects, their base salaries, their
targeted annual bonus amounts, their dates of employment and their positions.
Parent is not a party to any collective bargaining contract or other
Contract with a labor union involving any of its employees. All of the
employees of Parent are "at will" employees.
(h) Parent is in compliance in all material respects with all
Contracts relating to employment, employment practices, wages, bonuses and
terms and conditions of employment, including employee compensation matters.
(i) Parent has good labor relations, and it has no knowledge of
any facts indicating that (i) the consummation of the Merger or any of the
other transactions contemplated by this Agreement will have a material
adverse effect on the labor relations of Parent, or (ii) any of the employees
of Parent intends to terminate his or her employment with Parent with which
such employee is employed.
3.17 ENVIRONMENTAL MATTERS. Parent is in compliance with all
applicable Environmental Laws, except where failure to comply would not have
a Material Adverse Effect on Parent. Parent possesses all permits and other
Governmental Authorizations required under applicable Environmental Laws to
conduct its current operations. Parent has not received any notice or other
communication (in writing or otherwise) from a Governmental Body or citizens
group that alleges that Parent is not in compliance with any Environmental
Law. To the knowledge of Parent, there are no circumstances that may prevent
or interfere with the compliance by Parent with any Environmental Law in the
future, except where failure to comply would not have a Material Adverse
Effect on Parent. To the knowledge of Parent without further inquiry, no
current or prior owner of any property leased or controlled by Parent has
received any notice or other communication (in writing or otherwise) from a
Governmental Body or citizens group that alleges that such current or prior
owner or Parent is not in compliance with
34.
<PAGE>
any Environmental Law. To the knowledge of Parent, all property that is
leased to, controlled by or used by Parent, and all surface water,
groundwater and soil associated with or adjacent to such property is in clean
and healthful condition and is free of environmental contamination of any
nature.
3.18 INSURANCE. Parent has delivered to the Company a copy of each
insurance policy relating to the business, assets or operations of Parent and
with respect to each such policy, the insurer, the amount of coverage, the
type of insurance and the period of coverage. Each such insurance policy is
in full force and effect. Part 3.18 of the Parent Disclosure Schedule also
sets forth each self insurance program relating to the business, assets or
operations of Parent. Since September 15, 1997, Parent has not received any
notice or other communication regarding any actual or possible (a)
cancellation or invalidation of any insurance policy, (b) refusal of any
coverage or rejection of any material claim under any insurance policy, or
(c) material adjustment in the amount of the premiums payable with respect to
any insurance policy. There is no pending claim (including any workers'
compensation claim) under or based upon any insurance policy of Parent; and,
to the knowledge of Parent, no event has occurred that could reasonably be
expected to (with or without notice or lapse of time) directly or indirectly
give rise to or serve as a basis for any such claim.
3.19 TRANSACTIONS WITH AFFILIATES. Except as set forth in the Parent
SEC Documents no event has occurred that would be required to be reported by
Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC. Part
3.19 of the Parent Disclosure Schedule identifies each person who is an
"affiliate" (as that term is used in Rule 145 promulgated under the
Securities Act) of Parent as of the date of this Agreement.
3.20 LEGAL PROCEEDINGS; ORDERS.
(a) Except as set forth in Part 3.20(a) of the Parent Disclosure
Schedule, there is no pending Legal Proceeding and, to the knowledge of
Parent, no Person has threatened to commence any Legal Proceeding: (i) that
involves Parent or any of the assets owned or used by Parent, including,
without limitation, Parent Proprietary Assets; or (ii) that challenges, or
that may have the effect of preventing, delaying, making illegal or otherwise
interfering with, the Merger or any of the other transactions contemplated by
this Agreement. To the knowledge of Parent, no event has occurred, and no
claim, dispute or other condition or circumstance exists, that will, or that
could reasonably be expected to, give rise to or serve as a basis for the
commencement of any such Legal Proceeding. To the knowledge of Parent, no
event has occurred, and no claim, dispute or other condition or circumstance
exists, that will, or that could reasonably be expected to, cause or provide
a basis for a director, officer or other Representative of Parent to seek
indemnification from, or commence a Legal Proceeding against or involving,
Parent.
(b) There is no order, writ, injunction, judgment or decree to
which Parent, or any of the assets owned or used by Parent, is subject. To
the knowledge of Parent, no officer or other employee of Parent is subject to
any order, writ, injunction, judgment or decree that prohibits such officer
or other employee from engaging in or continuing any conduct, activity or
practice relating to the business of Parent.
35.
<PAGE>
3.21 AUTHORITY; BINDING NATURE OF AGREEMENT. Parent has the absolute
and unrestricted right, power and authority to enter into and to perform its
obligations under this Agreement. The Board of Directors of Parent (at a
meeting duly called and held) has (a) unanimously determined that the Merger
is advisable and fair and in the best interests of Parent and its
stockholders, (b) unanimously approved the execution, delivery and
performance of this Agreement by Parent and has unanimously approved the
Merger, and (c) unanimously recommended the adoption and approval of a
proposal to issue shares of Parent Common Stock in the Merger by the holders
of Parent Common Stock and directed that such proposal be submitted for
consideration by Parent's stockholders at the Parent Stockholders' Meeting
(as defined in Section 6.3). This Agreement constitutes the legal, valid and
binding obligation of Parent, enforceable against Parent in accordance with
its terms, subject to (i) laws of general application relating to bankruptcy,
insolvency and the relief of debtors, and (ii) rules of law governing
specific performance, injunctive relief and other equitable remedies.
3.22 NON-CONTRAVENTION; CONSENTS. Neither (i) the execution, delivery
or performance of this Agreement or any of the other agreements referred to
in this Agreement, nor (ii) the consummation of the Merger or any of the
other transactions contemplated by this Agreement, will directly or
indirectly (with or without notice or lapse of time):
(a) contravene, conflict with or result in a violation of (i)
any of the provisions of the certificate of incorporation, bylaws or other
charter or organizational documents of Parent, or (ii) any resolution adopted
by the stockholders, the Board of Directors or any committee of the Board of
Directors of Parent;
(b) contravene, conflict with or result in a violation of, or
give any Governmental Body or other Person the right to challenge the Merger
or any of the other transactions contemplated by this Agreement or to
exercise any remedy or obtain any relief under, any Legal Requirement or any
order, writ, injunction, judgment or decree to which Parent, or any of the
assets owned or used by Parent, is subject;
(c) contravene, conflict with or result in a violation of any of
the terms or requirements of, or give any Governmental Body the right to
revoke, withdraw, suspend, cancel, terminate or modify, any Governmental
Authorization that is held by Parent or that otherwise relates to the
business of Parent or to any of the assets owned or used by Parent;
(d) contravene, conflict with or result in a violation or breach
of, or result in a default under, any provision of any Parent Material
Contract or (except as set forth in Part 3.22(d) of Parent Disclosure
Schedule), give any Person the right to (i) declare a default or exercise any
remedy under any such Parent Material Contract, (ii) a rebate, chargeback,
penalty or change in delivery schedule under any such Parent Material
Contract, (iii) accelerate the maturity or performance of any such Parent
Material Contract, or (iv) cancel, terminate or modify any term of such
Parent Material Contract; or
(e) result in the imposition or creation of any Encumbrance upon
or with respect to any asset owned or used by Parent (except for Permitted
Encumbrances).
36.
<PAGE>
Except as set forth in Part 3.22(d) of the Parent Disclosure Schedule or
except as may be required by the Exchange Act, the DGCL and the rules of NASD
(as they relate to the S-4 Registration Statement and the Joint Proxy
Statement/Prospectus, as defined in Section 2.27(b)), Parent was not, is not
and will not be required to make any filing with or give any notice to, or to
obtain any Consent from, any Person in connection with (x) the execution,
delivery or performance of this Agreement or any of the other agreements
referred to in this Agreement, or (y) the consummation of the Merger or any
of the other transactions contemplated by this Agreement.
3.23 VOTE REQUIRED. The only vote of Parent's stockholders required
to approve the issuance of Parent Common Stock in the Merger is the vote of a
majority of votes cast in person or by proxy as prescribed by rules of the
NASD (the "REQUIRED PARENT STOCKHOLDER VOTE").
3.24 VALID ISSUANCE. The Parent Common Stock to be issued in the
Merger will, when issued in accordance with the provisions of this Agreement,
be duly authorized, validly issued, fully paid and nonassessable.
3.25 FAIRNESS OPINION. Parent's Board of Directors has received the
written opinion of Hambrecht & Quist LLC, financial advisor to Parent, dated
as of the date of this Agreement, to the effect that the Exchange Ratio is
fair to Parent from a financial point of view. Parent has furnished an
accurate and complete copy of said written opinion to the Company.
3.26 FULL DISCLOSURE.
(a) This Agreement (including the Parent Disclosure Schedule)
does not, and the certificate referred to in Section 8.5(b) will not, (i)
contain any representation, warranty or information that is false or
misleading with respect to any material fact, or (ii) omit to state any
material fact necessary in order to make the representations, warranties and
information contained and to be contained herein and therein (in the light of
the circumstances under which such representations, warranties and
information were or will be made or provided) not false or misleading.
(b) None of the information supplied or to be supplied by or on
behalf of Parent for inclusion or incorporation by reference in the S-4
Registration Statement to be filed with the SEC by Parent in connection with
the issuance of Parent Common Stock in the Merger will, at the time the S-4
Registration Statement is filed with the SEC or at the time it becomes
effective under the Securities Act, contain any untrue statement of a
material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in the light of
the circumstances under which they are made, not misleading. None of the
information supplied or to be supplied by or on behalf of Parent for
inclusion or incorporation by reference in the Joint Proxy
Statement/Prospectus to be filed with the SEC as part of the S-4 Registration
Statement, will, at the time the Joint Proxy Statement/Prospectus is mailed
to the stockholders of the Parent, at the time of the Parent Stockholders'
Meeting or as of the Effective Time, contain any untrue statement of a
material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in the light of
the circumstances under which they are made, not misleading. The Joint Proxy
37.
<PAGE>
Statement/Prospectus will comply as to form in all material respects with the
provisions of the Exchange Act and the rules and regulations promulgated by
the SEC thereunder.
3.27 FINANCIAL ADVISOR. Except for Hambrecht & Quist LLC, no broker,
finder, investment banker or other Person is entitled to any brokerage,
finder's or other fee or commission in connection with the Merger or any of
the other transactions contemplated by this Agreement based upon arrangements
made by or on behalf of Parent. Parent has disclosed to the Company the
fees, commissions and other payments which will be paid by Parent to
Hambrecht & Quist LLC if the Merger is consummated. Parent furnished to the
Company accurate and complete copies of all agreements under which any such
fees, commissions or other amounts have been paid or may become payable and
all indemnification and other agreements relating to the engagement of
Hambrecht & Quist LLC.
3.28 INTERIM OPERATIONS OF MERGER SUB. Merger Sub was formed solely
for the purpose of engaging in the transactions contemplated hereby, has
engaged in no other business activity and has conducted its operations only
as contemplated hereby.
SECTION 4. CERTAIN COVENANTS OF THE COMPANY.
4.1 OPERATION OF THE COMPANY'S BUSINESS. During the period from the
date of this Agreement through the Effective Time (the "PRE-CLOSING PERIOD"),
the Company shall not (without the prior written consent of Parent), except
as contemplated by this Agreement:
(i) declare, accrue, set aside or pay any dividend or
make any other distribution in respect of any shares of capital stock, or
repurchase, redeem or otherwise reacquire any shares of capital stock or
other securities;
(ii) sell, issue, grant or authorize the issuance or
grant of (A) any capital stock or other security, (B) any option, call,
warrant or right to acquire any capital stock or other security except as set
forth on Part 4.1(ii) of the Company Disclosure Schedule, or (C) any
instrument convertible into or exchangeable for any capital stock or other
security (except that the Company may issue Company Common Stock upon the
valid exercise of Company Options and pursuant to Company Plans;
(iii) amend or waive any of its rights under, or
accelerate the vesting under, any provision of any of the Company's stock
option plans, any provision of any agreement evidencing any outstanding stock
option or any restricted stock purchase agreement, or otherwise modify any of
the terms of any outstanding option, warrant or other security or any related
Contract, except pursuant to written agreements outstanding, or policies
existing, on the date hereof and as previously disclosed in writing or made
available to Parent;
(iv) amend or permit the adoption of any amendment to its
certificate of incorporation or bylaws or other charter or organizational
documents, or effect or become a party to any merger, consolidation, share
exchange, business combination, recapitalization, reclassification of shares,
stock split, reverse stock split or similar transaction;
(v) form any Subsidiary or acquire any equity interest
or other interest in any other Entity;
38.
<PAGE>
(vi) make any capital expenditure (except that the
Company may make capital expenditures that, when added to all other capital
expenditures made on behalf of the Company during the Pre-Closing Period, do
not exceed $25,000 with respect to any single capital expenditure or $100,000
in the aggregate);
(vii) enter into or become bound by, or permit any of the
assets owned or used by it to become bound by, any Company Material Contract,
or amend or prematurely terminate, or waive or exercise any material right or
remedy (including any right to repurchase shares of Company Common Stock)
under, any Company Material Contract;
(viii) acquire, lease or license any material right or
other asset from any other Person or sell or otherwise dispose of, or lease
or license or encumber, any material right or other asset to any other Person
(except in each case for material rights or assets acquired, leased, licensed
or disposed of by the Company in the ordinary course of business and
consistent with past practices), or waive or relinquish any material right or
otherwise extend the term of any agreement with respect to, amend or modify
in any material respect any material rights, including rights to material
Proprietary Assets of the Company, or enter into assignments of future
rights, including rights to material Proprietary Assets of the Company, other
than non-exclusive licenses and distribution rights in the ordinary course of
business consistent with past practices;
(ix) incur any indebtedness for borrowed money (other
than (i) in connection with the financing of ordinary trade payables; (ii)
pursuant to existing credit facilities; (iii) in connection with leasing
activities in the ordinary course of business; or (iv) for tax planning
purposes in the ordinary course of business) or guarantee any indebtedness of
any Person for borrowed money, or issue or sell any debt securities or
warrants or right to acquire debt securities of the Company or guarantee any
debt securities of others.
(x) establish, adopt or amend any employee benefit plan,
pay any bonus except in accordance with the terms of existing Company Plans
or pursuant to commitments made prior to the date of this Agreement, or make
any profit-sharing or similar payment to, or increase the amount of the
wages, salary, commissions, fringe benefits or other compensation or
remuneration payable to, any of its directors, officers or employees, except
for normal periodic increases in wages and salaries made in the ordinary
course of business and consistent with past practices;
(xi) grant any severance or termination pay to any
officer or employee except payments in amounts consistent with policies and
past practices or pursuant to written agreements outstanding, or policies
existing, on the date hereof and as previously disclosed in writing or made
available to Parent, or adopt any new severance plan;
(xii) hire any new employee having an annual salary in
excess of $120,000 or as an officer of the Company or engage any consultant
or independent contractor for a period exceeding sixty (60) days;
39.
<PAGE>
(xiii) change the status, title or responsibilities,
including without limitation, termination or promotion, of any officer of the
Company or promote any employee to an officer position in the Company;
(xiv) change any of its methods of accounting or
accounting practices in any respect;
(xv) make any election with respect to Taxes;
(xvi) commence or settle any Legal Proceeding;
(xvii) enter into any material transaction or take any
other material action outside the ordinary course of business or inconsistent
with past practices;
(xviii) enter into any agreement requiring the consent or
approval of any third party with respect to the Merger; or
(xix) agree or commit to take any of the actions described
in clauses "(i)" through "(xviii)" of this Section 4.1.
4.2 NO SOLICITATION.
(a) From the date of this Agreement until the earlier of the
Effective Time or termination of this Agreement pursuant to Section 9, the
Company shall not directly or indirectly, and shall not authorize or permit
any subsidiary of the Company or any Representative of the Company directly
or indirectly to, (i) solicit, initiate, encourage or induce the making,
submission or announcement of any Acquisition Proposal or take any action
that could reasonably be expected to lead to an Acquisition Proposal, (ii)
furnish any information regarding the Company to any Person in connection
with or in response to an Acquisition Proposal, (iii) engage in discussions
with any Person with respect to any Acquisition Proposal, (iv) approve,
endorse or recommend any Acquisition Proposal or (v) enter into any letter of
intent or similar document or any Contract contemplating or otherwise
relating to any Acquisition Transaction; PROVIDED, HOWEVER, that prior to the
approval of this Agreement by the Required Company Stockholder Vote, this
Section 4.2(a) shall not prohibit the Company from (A) furnishing nonpublic
information regarding the Company to, or entering into discussions with, any
Person in response to a Superior Offer submitted by such Person (and not
withdrawn) if (1) neither the Company nor any Representative of the Company
shall have violated any of the restrictions set forth in this Section 4.2,
(2) the Board of Directors of the Company concludes in good faith, after
consultation with its outside legal counsel, that such action is required in
order for the Board of Directors of the Company to comply with its fiduciary
obligations to the Company's stockholders under applicable law, (3) prior to
furnishing any such nonpublic information to, or entering into discussions
with, such Person, the Company gives Parent written notice of the identity of
such Person and of the Company's intention to furnish nonpublic information
to, or enter into discussions with, such Person, and the Company receives
from such Person an executed confidentiality agreement that is at least as
restrictive as the Confidentiality Agreement (as hereinafter defined) with
respect to the use and disclosure of all nonpublic written and oral
information furnished to such Person by or on behalf of the Company, and (4)
prior to furnishing any such nonpublic information to such Person, the
Company furnishes such
40.
<PAGE>
nonpublic information to Parent (to the extent such nonpublic information has
not been previously furnished by the Company to Parent) or (B) taking and
disclosing to its stockholders a position contemplated by Rules 14(d)(9) and
14e-2(a) promulgated under the Exchange Act. Without limiting the generality
of the foregoing, the Company acknowledges and agrees that any violation of
any of the restrictions set forth in the preceding sentence by any
Representative of the Company, whether or not such Representative is
purporting to act on behalf of the Company, shall be deemed to constitute a
breach of this Section 4.2 by the Company. In addition to the foregoing, the
Company shall (i) provide Parent with at least twenty-four (24) hours prior
notice of any meeting of the Company's Board of Directors at which the
Company's Board of Directors is reasonably expected to consider a Superior
Offer and (ii) not recommend a Superior Offer to its stockholders for a
period of not less than the greater of two (2) business days or forty-eight
(48) hours after Parent's receipt of a copy of such Superior Offer (pursuant
to Section 4.2(b) below).
(b) The Company shall promptly advise Parent orally and in
writing of any Acquisition Proposal (including the identity of the Person
making or submitting such Acquisition Proposal and the terms thereof) that is
made or submitted by any Person during the Pre-Closing Period. The Company
shall keep Parent fully informed with respect to the status of any such
Acquisition Proposal and any modification or proposed modification thereto.
(c) The Company shall immediately cease and cause to be
terminated any existing discussions with any Person that relate to any
Acquisition Proposal.
4.3 CONVERSION OF SERIES B PREFERRED STOCK. The Company shall take
all actions necessary to effect the conversion of all of the outstanding
Series B Preferred Stock into shares of Company Common Stock in accordance
with its certificate of incorporation no later than twenty (20) days after
the date of this Agreement.
SECTION 5. CERTAIN COVENANTS OF PARENT.
5.1 OPERATION OF THE PARENT'S BUSINESS. During the Pre-Closing
Period, Parent shall not (without the prior written consent of the Company)
(i) declare, accrue, set aside or pay any dividend or make any other
distribution in respect of any shares of its capital stock, (ii) repurchase,
redeem or otherwise reacquire any shares of its capital stock or other
securities, (iii) sell, issue, grant or authorize the issuance or grant of
(A) any capital stock or other security, (B) any option, call, warrant or
right to acquire any capital stock or other security except as set forth on
Part 5.1(iii) of the Parent Disclosure Schedule or (C) any instrument
convertible into or exchangeable for any capital stock or other security
(except that Parent may issue Parent Common Stock upon the valid exercise of
Parent Options outstanding as of the date of this Agreement), (iv) amend or
permit the adoption of any amendments to its certificate of incorporation or
bylaws or other charter or organizational documents or effect or become a
party to any merger, consolidation, share exchange, business combination,
recapitalization of shares, stock split, reverse stock split or similar
transaction, (v) incur any indebtedness for borrowed money (other than (A) in
connection with the financing of ordinary trade payables; (B) pursuant to
existing credit facilities; (C) in connection with leasing activities in the
ordinary course of business; or (D) for tax planning purposes in the ordinary
course of business) in excess of $5,000,000, (vi) acquire, lease or license
any material right or other asset from any other Person
41.
<PAGE>
or sell or otherwise dispose of, or lease or license or encumber any material
right or other asset to any other Person (except in each case for material
rights or assets acquired, leased, licensed or disposed of by Parent in the
ordinary course of business and consistent with past practices), or waive or
relinquish any material right or otherwise extend the term of any agreement
with respect to, amend or modify in any material respect any material rights,
including rights to material Proprietary Assets of Parent, or enter into
assignments of future rights, including rights to material Proprietary Assets
of Parent, other than non-exclusive licenses and distribution rights in the
ordinary course of business consistent with past practice, or (vii) agree or
commit to take any of the actions described in clauses "(i)" through "(vi)"
of this Section 5.1.
SECTION 6. ADDITIONAL COVENANTS OF THE PARTIES.
6.1 REGISTRATION STATEMENT; JOINT PROXY STATEMENT/PROSPECTUS.
(a) As promptly as practicable after the date of this Agreement,
the Company and Parent shall prepare and cause to be filed with the SEC the
S-4 Registration Statement, together with the Joint Proxy
Statement/Prospectus and any other documents required by the Securities Act,
the Exchange Act or any other Federal, foreign or Blue Sky or related laws in
connection with the Merger and the transactions contemplated by this
Agreement ("OTHER FILINGS"). Each of Parent and the Company will notify the
other promptly upon the receipt of any comments from the SEC or its staff or
any other government officials and of any request by the SEC or its staff or
any other government officials for amendments or supplements to the S-4
Registration Statement, the Joint Proxy Statement/Prospectus or any Other
Filings or for additional information and will supply the other with copies
of all correspondence between such party or any of its representatives, on
the one hand, and the SEC, or its staff or any other government officials, on
the other hand, with respect to the S-4 Registration Statement, the Joint
Proxy Statement/Prospectus, any Other Filings or the Merger. Each of Parent
and the Company shall use all reasonable efforts to cause the S-4
Registration Statement (including the Joint Proxy Statement/Prospectus) and
any Other Filings to comply with the rules and regulations promulgated by the
SEC, to respond promptly to any comments of the SEC or its staff and to have
the S-4 Registration Statement declared effective under the Securities Act as
promptly as practicable after it is filed with the SEC. Parent will use all
reasonable efforts to cause the Joint Proxy Statement/Prospectus to be mailed
to Parent's stockholders and the Company will use all reasonable efforts to
cause the Joint Proxy Statement/Prospectus to be mailed to the Company's
stockholders, as promptly as practicable after the Form S-4 Registration
Statement is declared effective under the Securities Act. The Company shall
promptly furnish to Parent all information concerning the Company and the
Company's stockholders that may be required or reasonably requested in
connection with any action contemplated by this Section 6.1. If any event
relating to the Company occurs, or if the Company becomes aware of any
information, that should be set forth in an amendment or supplement to the
S-4 Registration Statement or the Joint Proxy Statement/Prospectus, then the
Company shall promptly inform Parent thereof and shall cooperate with Parent
in filing such amendment or supplement with the SEC and, if appropriate, in
mailing such amendment or supplement to the stockholders of the Company and
the stockholders of Parent.
(b) Prior to the Effective Time, Parent shall use reasonable
efforts to obtain all regulatory approvals needed to ensure that the Parent
Common Stock to be issued in the Merger
42.
<PAGE>
will be registered or qualified under the securities law of every
jurisdiction of the United States in which any registered holder of Company
Common Stock has an address of record on the record date for determining the
stockholders entitled to notice of and to vote at the Company Stockholders'
Meeting; PROVIDED, HOWEVER, that Parent shall not be required (i) to qualify
to do business as a foreign corporation in any jurisdiction in which it is
not now qualified or (ii) to file a general consent to service of process in
any jurisdiction.
6.2 COMPANY STOCKHOLDERS' MEETING.
(a) The Company shall take all action necessary under all
applicable Legal Requirements to call, give notice of, convene and hold a
meeting of the holders of Company Common Stock (the "COMPANY STOCKHOLDERS'
MEETING") to consider, act upon and vote upon the adoption of this Agreement
and approval of the Merger. The Company Stockholders' Meeting will be held
as promptly as practicable and in any event within forty-five (45) days after
the S-4 Registration Statement is declared effective under the Securities
Act; PROVIDED, HOWEVER, that notwithstanding anything to the contrary
contained in this Agreement, the Company may adjourn or postpone the Company
Stockholders' Meeting to the extent necessary to ensure that any necessary
supplement or amendment to the Joint Proxy Statement/Prospectus is provided
to the Company's stockholders in advance of a vote on the Merger and this
Agreement or, if as of the time for which Company Stockholders' Meeting is
originally scheduled (as set forth in the Joint Proxy Statement/Prospectus)
there are insufficient shares of Company Common Stock represented (either in
person or by proxy) to constitute a quorum necessary to conduct the business
of the Company Stockholders' Meeting. The Company shall ensure that the
Company Stockholders' Meeting is called, noticed, convened, held and
conducted, and that all proxies solicited in connection with the Company
Stockholders' Meeting are solicited, in compliance with all applicable Legal
Requirements; PROVIDED, HOWEVER that the Company shall not be obligated to
call, give notice of, convene and hold the Company Stockholders' Meeting in
accordance with this Section 6.2(a) if in accordance with Section 6.2(c) the
Board of Directors of the Company withdraws, amends or modifies its unanimous
recommendation in favor of the Merger and accepts or recommends to the
stockholders of the Company a Superior Offer.
(b) Subject to Section 6.2(c): (i) the Board of Directors of
the Company shall unanimously recommend that the Company's stockholders vote
in favor of and adopt and approve this Agreement and the Merger at the
Company Stockholders' Meeting; (ii) the Joint Proxy Statement/Prospectus
shall include a statement to the effect that the Board of Directors of the
Company has unanimously recommended that the Company's stockholders vote in
favor of and adopt and approve this Agreement and the Merger at the Company
Stockholders' Meeting; and (iii) neither the Board of Directors of the
Company nor any committee thereof shall withdraw, amend or modify, or propose
or resolve to withdraw, amend or modify, in a manner adverse to Parent, the
unanimous recommendation of the Board of Directors of the Company that the
Company's stockholders vote in favor of and adopt and approve this Agreement
and the Merger. For purposes of this Agreement, said recommendation of the
Board of Directors shall be deemed to have been modified in a manner adverse
to Parent if said recommendation shall no longer be unanimous.
(c) Nothing in Section 6.2(b) shall prevent the Board of
Directors of the Company from withdrawing, amending or modifying its
unanimous recommendation in favor of
43.
<PAGE>
the Merger if (i) a Superior Offer is made to the Company and is not
withdrawn, (ii) neither the Company nor any of its Representatives shall have
violated any of the restrictions set forth in Section 4.2, and (iii) the
Board of Directors of the Company concludes in good faith, after consulting
with its outside counsel, that, in light of such Superior Offer, the
withdrawal, amendment or modification of such recommendation is required in
order for the Board of Directors of the Company to comply with its fiduciary
obligations to the Company's stockholders under applicable law.
6.3 PARENT STOCKHOLDERS' MEETING.
(a) Parent shall take all action necessary to call, give notice
of, convene and hold a meeting of the holders of Parent Common Stock to
consider and vote upon the issuance of Parent Common Stock in the Merger (the
"PARENT STOCKHOLDERS' MEETING"). The Parent Stockholders' Meeting will be
held as promptly as practicable and in any event within forty-five (45) days
after the S-4 Registration Statement is declared effective under the
Securities Act; PROVIDED, HOWEVER, that notwithstanding anything to the
contrary contained in this Agreement, Parent may adjourn or postpone the
Parent Stockholders' Meeting to the extent necessary to ensure that any
necessary supplement or amendment to the Joint Proxy Statement/Prospectus is
provided to Parent's stockholders in advance of a vote on the issuance of
Parent Common Stock in the Merger or, if as of the time for which the Parent
Stockholders' Meeting is originally scheduled (as set forth in the Joint
Proxy Statement/Prospectus) there are insufficient shares of Parent Common
Stock represented (either in person or by proxy) to constitute a quorum
necessary to conduct the business of the Parent Stockholders' Meeting.
Parent shall ensure that the Parent Stockholders' Meeting is called, noticed,
convened, held and coordinated, and that all proxies submitted in connection
with the Parent Stockholders' Meeting are solicited, in compliance with all
applicable Legal Requirements.
(b) Subject to Section 6.3(c): (i) The Board of Directors of
Parent shall unanimously recommend that Parent's stockholders vote in favor
of the issuance of Parent Common Stock in the Merger; (ii) the Joint Proxy
Statement/Prospectus shall include a statement to the effect that the Board
of Directors of Parent has unanimously recommended that Parent's stockholders
vote in favor of the issuance of Parent Common Stock in the Merger; and (iii)
neither the Board of Directors of Parent nor any committee thereof shall
withdraw, amend or modify, or propose or resolve to withdraw, amend or
modify, in a manner adverse to the Company, the unanimous recommendation of
the Board of Directors of Parent that Parent's stockholders vote in favor of
the issuance of Parent Common Stock in the Merger. For purposes of this
Agreement, said recommendation of Parent's Board of Directors shall be deemed
to have been modified in a manner adverse to the Company if said
recommendation shall no longer be unanimous.
(c) Nothing in Section 6.3(b) shall prevent the Board of
Directors of Parent from withdrawing, amending or modifying its unanimous
recommendation in favor of the issuance of Parent Common Stock in the Merger
if the Board of Directors of Parent concludes in good faith, based upon the
advice of its outside counsel, that the withdrawal, amendment or modification
of such recommendation is required in order for the Board of Directors of
Parent to comply with its fiduciary obligations to Parent's stockholders
under applicable law.
44.
<PAGE>
6.4 REGULATORY APPROVALS. The Company and Parent shall use all
reasonable efforts to file, as soon as practicable after the date of this
Agreement, all notices, reports and other documents required to be filed with
any Governmental Body with respect to the Merger and the other transactions
contemplated by this Agreement, and to submit promptly any additional
information requested by any such Governmental Body. The Company and Parent
shall respond as promptly as practicable to (i) any inquiries or requests
received from any Governmental Body (including any state attorney general) in
connection with antitrust or related matters. Each of the Company and Parent
shall (1) give the other party prompt notice of the commencement of any Legal
Proceeding by or before any Governmental Body with respect to the Merger or any
of the other transactions contemplated by this Agreement, (2) keep the other
party informed as to the status of any such Legal Proceeding, and (3) promptly
inform the other party of any communication to or from any Governmental Body
regarding the Merger. The Company and Parent will consult and cooperate with
one another, and will consider in good faith the views of one another, in
connection with any analysis, appearance, presentation, memorandum, brief,
argument, opinion or proposal made or submitted in connection with any Legal
Proceeding under or any other federal or state antitrust or fair trade law. In
addition, except as may be prohibited by any Governmental Body or by any Legal
Requirement, in connection with any Legal Proceeding under or any other federal
or state antitrust or fair trade law or any other similar Legal Proceeding, each
of the Company and Parent agrees to permit authorized Representatives of the
other party to be present at each meeting or conference relating to any such
Legal Proceeding and to have access to and be consulted in connection with any
document, opinion or proposal made or submitted to any Governmental Body in
connection with any such Legal Proceeding.
6.5 STOCK OPTIONS.
(a) At the Effective Time, all rights with respect to Company
Common Stock under each Company Option then outstanding shall be converted
into and become rights with respect to Parent Common Stock, and Parent shall
assume each such Company Option in accordance with the terms (as in effect as
of the date of this Agreement) of the stock option plan under which it was
issued and the stock option agreement by which it is evidenced as same may be
amended or modified by the Company's employment agreements and severance
agreements, plans and arrangements. From and after the Effective Time, (i)
each Company Option assumed by Parent may be exercised solely for shares of
Parent Common Stock, (ii) the number of shares of Parent Common Stock subject
to each such Company Option shall be equal to the number of shares of Company
Common Stock subject to such Company Option immediately prior to the
Effective Time multiplied by the Exchange Ratio, rounding down to the nearest
whole share (with cash, less the applicable exercise price, being payable for
any fraction of a share), (iii) the per share exercise price under each such
Company Option shall be adjusted by dividing the per share exercise price
under such Company Option by the Exchange Ratio and rounding up to the
nearest cent and (iv) any restriction on the exercise of any such Company
Option shall continue in full force and effect and the term, exercisability,
vesting schedule and other provisions of such Company Option as may have been
amended or modified by the Company's employment agreements and severance
agreements, plans and arrangements shall otherwise remain unchanged;
PROVIDED, HOWEVER, that each Company Option assumed by Parent in accordance
with this Section 6.5(a) shall, in accordance with its terms, be subject to
further adjustment as
45.
<PAGE>
appropriate to reflect any stock split, stock dividend, reverse stock split,
reclassification, recapitalization or other similar transaction subsequent to
the Effective Time.
(b) Notwithstanding anything to the contrary contained in this
Section 6.5, in lieu of assuming outstanding Company Options in accordance
with Section 6.5(a), Parent may, at its election, cause such outstanding
Company Options to be replaced by issuing reasonably equivalent replacement
stock options in substitution therefor; provided however, that such
replacement options shall in any event comply with the provisions of the
second sentence of Section 6.5(a).
(c) The Company shall take all action that may be necessary (under
the plans pursuant to which Company Options are outstanding and otherwise) to
effectuate the provisions of this Section 6.5 and to ensure that, from and after
the Effective Time, holders of Company Options have no rights with respect
thereto other than those specifically provided in this Section 6.5.
6.6 FORM S-8. Parent agrees to file a registration statement on Form
S-8 for the shares of Parent Common Stock issuable with respect to assumed
Company Options as soon as reasonably practical (and in any event within
sixty (60) days) after the Effective Time.
6.7 INDEMNIFICATION OF OFFICERS AND DIRECTORS.
(a) All rights to indemnification existing in favor of the
current directors and officers of the Company for acts and omissions
occurring prior to the Effective Time, as provided in the Company's bylaws
(as in effect as of the date of this Agreement) and as provided in any
indemnification agreements between the Company and said officers and
directors (as in effect as of the date of this Agreement), shall survive the
Merger and shall be observed by the Surviving Corporation for a period of not
less than six (6) years from the Effective Time.
(b) From the Effective Time until the third anniversary of the
date on which the Merger becomes effective, the Surviving Corporation shall
maintain in effect, for the benefit of the current directors and officers of
the Company with respect to acts or omissions occurring prior to the
Effective Time, the lesser of (i) the existing amount of coverage of the
existing policy of directors' and officers' liability insurance maintained by
the Company as of the date of this Agreement (the "EXISTING POLICY") and (ii)
the amount of coverage purchased by 150% of the amount of the last annual
premium paid by the Company prior to the date of this Agreement for the
Existing Policy; PROVIDED, HOWEVER, that the Surviving Corporation may
substitute for the Existing Policy a policy or policies of comparable
coverage.
(c) In the event that Parent (i) causes the Surviving
Corporation to consolidate with or merge into any other Person and the
Surviving Corporation is not the continuing or surviving corporation or
entity of such consolidation or merger, or (ii) causes the Surviving
Corporation to transfer or convey all or substantially all of Surviving
Corporation's properties and assets to any Person, then, and in each such
case, to the extent necessary to effectuate the purposes of this Section 6.7,
proper provision shall be made so that the successors and assigns of the
Surviving Corporation assume the obligations set forth in this Section 6.7
and none of the actions described in clause (i) or (ii) shall be taken until
such provision is made.
46.
<PAGE>
6.8 TAX FREE REORGANIZATION. Each of the Company and Parent agrees
not to take any action either prior to or after the Effective Time that could
reasonably be expected to cause the Merger to fail to qualify as a
"reorganization" under Section 368(a) of the Code.
6.9 ADDITIONAL AGREEMENTS.
(a) Subject to Section 6.9(b), Parent and the Company shall use
all reasonable efforts to take, or cause to be taken, all actions necessary
to consummate the Merger and make effective the other transactions
contemplated by this Agreement. Without limiting the generality of the
foregoing, but subject to Section 6.9(b), each party to this Agreement (i)
shall make all filings (if any) and give all notices (if any) required to be
made and given by such party in connection with the Merger and the other
transactions contemplated by this Agreement, (ii) shall use all reasonable
efforts to obtain each Consent (if any) required to be obtained (pursuant to
any applicable Legal Requirement or Contract, or otherwise) by such party in
connection with the Merger or any of the other transactions contemplated by
this Agreement, and (iii) shall use all reasonable efforts to lift any
restraint, injunction or other legal bar to the Merger.
(b) Notwithstanding anything to the contrary contained in this
Agreement, Parent shall not have any obligation under this Agreement: (i) to
dispose or cause any of its subsidiaries to dispose of any assets, or to
commit to cause the Company to dispose of any assets; (ii) to license or
otherwise make available, or cause any of its subsidiaries to license or
otherwise make available, to any Person, any technology or other Proprietary
Asset, or to commit to cause the Company to license or otherwise make
available to any Person any technology or other Proprietary Asset; (iii) to
hold separate any assets or operations (either before or after the Closing
Date), or to commit to cause the Company to hold separate any assets or
operations; or (iv) to make any commitment (to any Governmental Body or
otherwise) regarding its future operations or the future operations of the
Company.
6.10 CONFIDENTIALITY. The parties acknowledge that the Company and
Parent have previously executed a Mutual Confidential Disclosure Agreement,
dated as of September 17, 1998 (the "CONFIDENTIALITY AGREEMENT"), which
Confidentiality Agreement, excluding Section 7 thereof, will continue in full
force and effect in accordance with its terms.
6.11 DISCLOSURE. Parent and the Company have agreed to the text of a
joint press release announcing the signing of this Agreement and shall
consult with each other before issuing any other press release or otherwise
making any public statement with respect to the Merger or any of the other
transactions contemplated by this Agreement. Without limiting the generality
of the foregoing, neither Parent nor the Company shall, and neither shall
permit any of its Representatives to, make any disclosure regarding the
Merger or any of the other transactions contemplated by this Agreement unless
(a) the other party shall have approved such disclosure or (b) the disclosing
party shall have been advised by its outside legal counsel that such
disclosure is required by applicable law.
6.12 TAX MATTERS.
(a) At or prior to the filing of the S-4 Registration Statement,
Parent and Merger Sub and the Company shall execute and deliver to Cooley
Godward LLP and to Heller
47.
<PAGE>
Ehrman White & McAuliffe LLP tax representation letters in the forms attached
as Exhibit C-1 and C-2, as applicable;
(b) Parent, Merger Sub and the Company shall each confirm to
Cooley Godward LLP and to Heller Ehrman White & McAuliffe LLP the accuracy
and completeness as of the Effective Time of the tax representation letters
delivered pursuant to Section 6.12(a);
(c) Parent, Merger Sub and the Company shall use all reasonable
efforts to cause the Merger to qualify as a tax free reorganization under
Section 368(a)(1) of the Code; and
(d) Following delivery of the tax representation letters
pursuant to Section 6.12(a), each of Parent and the Company shall use its
reasonable efforts to cause Cooley Godward LLP and Heller Ehrman White &
McAuliffe LLP, respectively, to deliver promptly to it a legal opinion
satisfying the requirements of Item 601 of Regulation S-K promulgated under
the Securities Act. In rendering such opinions, each of such counsel shall be
entitled to rely on the tax representation letters delivered pursuant to
Section 6.12(a).
6.13 RESIGNATION OF OFFICERS AND DIRECTORS. The Company shall use all
reasonable efforts to obtain and deliver to Parent prior to the Closing the
resignation of each officer and director of the Company.
6.14 NASDAQ LISTING. Parent shall use all reasonable efforts to have
the shares of Parent Common Stock issuable to the stockholders of the Company
pursuant to the Agreement and such other shares required to be reserved for
issuance in connection with the Merger authorized for listing on Nasdaq upon
official notice of issuance.
6.15 FIRPTA MATTERS. At the Closing, (a) the Company shall deliver to
Parent a statement (in such form as may be reasonably requested by counsel to
Parent) conforming to the requirements of Section 1.897 - 2(h)(1)(i) of the
United States Treasury Regulations, and (b) the Company shall deliver to the
Internal Revenue Service the notification required under Section 1.897 -
2(h)(2) of the United States Treasury Regulations.
6.16 PARENT BOARD OF DIRECTORS. On or prior to the Closing Date,
Parent shall take all actions necessary to nominate and appoint (i) Arthur M.
Pappas to Class I of its Board of Directors to serve until the annual meeting
of stockholders to be held in 2001; (ii) Stanley T. Crooke to Class II of its
Board of Directors to serve until the annual meeting of stockholders to be
held in 1999; and (iii) Bert W. O'Malley to Class III of its Board of
Directors to serve until the annual meeting of stockholders to be held in
2000.
6.17 ACCESS AND INVESTIGATION. During the Pre-Closing Period, the
Company and Parent shall, and shall cause their respective Representatives
to: (a) provide the Company and Parent and the Company's and Parent's
Representatives with reasonable access to the other party's Representatives,
personnel and assets and to all existing books, records, Tax Returns, work
papers and other documents and information relating to the Company and
Parent; and (b) provide Company and Parent and Company's and Parent's
Representatives with such copies of the existing books, records, Tax Returns,
work papers and other documents and information relating to the other party,
and with such additional financial, operating and other data and information
regarding the other party, as such party may reasonably request. Without
limiting
48.
<PAGE>
the generality of the foregoing, during the Pre-Closing Period, the Company
and Parent shall promptly provide the other party with copies of:
(a) any written materials or communications sent by or on behalf
of the other party to its stockholders;
(b) any material notice, document or other communication sent by
or on its behalf to any party to any Company Material Contract or Parent
Material Contract, respectively, or sent to the Company or Parent by any
party to any Company Material Contract or Parent Material Contract,
respectively, (other than any communication that relates solely to commercial
transactions between the Company or Parent and the other party to any such
Company Material Contract or Parent Material Contract, respectively, and that
is of the type sent in the ordinary course of business and consistent with
past practices);
(c) any notice, report or other document filed with or sent to
any Governmental Body in connection with the Merger or any of the other
transactions contemplated by this Agreement; and
(d) any material notice, report or other document received by
either the Company or Parent from any Governmental Body.
6.18 OPERATION OF BUSINESS.
(a) During the Pre-Closing Period: (i) both the Company and
Parent shall ensure that each of the Company and Parent, respectively,
conducts its business and operations (A) in the ordinary course of business
and in accordance with past practices and (B) in compliance with all
applicable Legal Requirements and the requirements of all Company Material
Contracts and Parent Material Contracts, respectively; (ii) each of the
Company and Parent shall use all reasonable efforts to ensure that each of
the Company and Parent preserves intact its respective business organization,
keeps available the services of its respective officers and employees and
maintains its respective relations and goodwill with all suppliers,
landlords, creditors, licensors, licensees, employees and other Persons
having business relationships with it; (iii) the Company and Parent,
respectively, shall keep in full force all insurance policies referred to in
Sections 2.18 and 3.18, respectively, or replace such policies that terminate
with comparable policies; (iv) the Company and Parent shall provide all
notices, assurances and support required by any Company Contract or Parent
Contract, respectively, relating to any Proprietary Asset in order to ensure
that no condition under such Company Contract or Parent Contract,
respectively, occurs which could result in, or could increase the likelihood
of, any transfer or disclosure by the Company or Parent, respectively, of any
Proprietary Asset; and (v) each of the Company and Parent shall (to the
extent requested by the other party) cause its officers to report regularly
to the other party concerning the status of the other party's business.
(b) During the Pre-Closing Period, each of the Company and
Parent shall promptly notify the other party in writing of: (i) the
discovery by the Company or Parent, respectively, of any circumstance that
occurred or existed on or prior to the date of this Agreement and that caused
or constitutes a material inaccuracy in any representation or warranty made
by the Company or Parent, respectively, in this Agreement; (ii) any event,
condition, fact
49.
<PAGE>
or circumstance that occurs, arises or exists after the date of this
Agreement and that would cause or constitute a material inaccuracy in any
representation or warranty made by the Company or Parent, respectively, in
this Agreement if (A) such representation or warranty had been made as of the
time of the occurrence, existence or discovery of such event, condition, fact
or circumstance, or (B) such event, condition, fact or circumstance had
occurred, arisen or existed on or prior to the date of this Agreement; (iii)
any event, condition, fact or circumstance hereafter arising which, if
existing or occurring at the date of this Agreement, would have been required
to be set forth or described in the Company Disclosure Schedule or Parent
Disclosure Schedule, respectively; (iv) any material breach of any covenant
or obligation of the Company or Parent, respectively; and (v) any event,
condition, fact or circumstance that would make the timely satisfaction of
any of the conditions set forth in Section 7 or Section 8 impossible or
unlikely or that has had or could reasonably be expected to have a Material
Adverse Effect on the Company or Parent, respectively. No notification given
to the Company or Parent, respectively, pursuant to this Section 6.18(b)
shall limit or otherwise affect any representations, warranties, covenants or
obligations of the Company or Parent, respectively, contained in this
Agreement.
(c) If any event, condition, fact or circumstance that is
required to be disclosed pursuant to Section 6.18(b) requires any change in
the Company Disclosure Schedule or Parent Disclosure Schedule, or if any such
event, condition, fact or circumstance would require such a change assuming
that the Company Disclosure Schedule or Parent Disclosure Schedule were dated
as of the date of the occurrence, existence or discovery of such event,
condition, fact or circumstance, then the Company or Parent, respectively,
shall deliver to the other party an update to the Company Disclosure Schedule
or Parent Disclosure Schedule, respectively, at least three (3) days prior to
the Effective Time, specifying such change. No such update shall be deemed
to supplement or amend the Company Disclosure Schedule or Parent Disclosure
Schedule, respectively, for the purpose of (i) determining the accuracy of
any of the representations and warranties made by the Company or Parent,
respectively, in this Agreement, or (ii) determining whether any of the
conditions set forth in Section 7 or Section 8 has been satisfied.
6.19 FINANCIAL STATEMENTS. All financial statements (including any
related notes) contained in Company SEC Documents and Parent SEC Documents filed
after the date hereof shall meet the conditions set forth in (i), (ii) and (iii)
of Sections 2.4(b) or 3.4(b), respectively.
SECTION 7. CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB.
The obligations of Parent and Merger Sub to effect the Merger and
otherwise consummate the transactions contemplated by this Agreement are
subject to the satisfaction, at or prior to the Closing, of each of the
following conditions, and upon consummation of the Closing, all conditions
herein shall be deemed satisfied and any liability for failure to satisfy any
condition herein shall be precluded:
7.1 ACCURACY OF REPRESENTATIONS. The representations and warranties
of the Company contained in this Agreement shall have been accurate in all
material respects as of the date of this Agreement and shall be accurate in
all material respects as of the Closing Date, as if made on and as of the
Closing Date, except representations and warranties that refer specifically
50.
<PAGE>
to "the date of this Agreement" or a specific date prior to the date of this
Agreement, and except that any inaccuracies in such representations and
warranties shall be disregarded if the circumstances giving rise to such
inaccuracies (individually and collectively) do not constitute a Material
Adverse Effect on the Company (it being understood that, for purposes of
determining the accuracy of such representations and warranties, (i) all
"Material Adverse Effect" or other materiality qualifications and (ii) any
update or modification to the Company Disclosure Schedule made or purported
to have been made after the date of this Agreement shall be disregarded).
7.2 PERFORMANCE OF COVENANTS. Each covenant or obligation that the
Company is required to comply with or to perform at or prior to the Closing
shall have been complied with and performed in all material respects.
7.3 EFFECTIVENESS OF REGISTRATION STATEMENT. The S-4 Registration
Statement shall have become effective in accordance with the provisions of
the Securities Act, and no stop order shall have been issued by the SEC with
respect to the S-4 Registration Statement.
7.4 STOCKHOLDER APPROVAL. This Agreement and the Merger shall have
been duly approved by the Required Company Stockholder Vote, and the issuance
of Parent Common Stock in the Merger shall have been duly approved by the
Required Parent Stockholder Vote.
7.5 CONSENTS. The Consents identified in Part 2.24(d) of the Company
Disclosure Schedule shall have been obtained and shall be in full force and
effect.
7.6 AGREEMENTS AND DOCUMENTS. Parent shall have received the following
agreements and documents, each of which shall be in full force and effect:
(a) the statement referred to in Section 6.15(a), executed by the
Company;
(b) a legal opinion of Cooley Godward LLP, dated as of the Closing
Date and addressed to Parent in a form substantially similar to the opinion
delivered pursuant to Section 8.5(a), to the effect that the Merger will
constitute a reorganization within the meaning of Section 368 of the Code (it
being understood that, in rendering such opinion, Cooley Godward LLP may rely
upon the tax representation letters referred to in Section 6.12);
(c) a certificate executed on behalf of the Company by an executive
officer of the Company confirming that the conditions set forth in Sections 7.1,
7.2, 7.4 (with respect to the Company only), 7.5, 7.7, 7.8, 7.10 (with respect
to the Company only), 7.11 (with respect to the Company only) and 7.12 have been
duly satisfied; and
(d) the written resignations of all officers and directors of the
Company, effective as of the Effective Time.
7.7 NO MATERIAL ADVERSE CHANGE. There shall have been no material
adverse change in the business, assets, liabilities, financial condition or
results of operations performance of the Company since the date of this
Agreement.
51.
<PAGE>
7.8 FIRPTA COMPLIANCE. The Company shall have filed with the Internal
Revenue Service the notification referred to in Section 6.15(b).
7.9 LISTING. The shares of Parent Common Stock to be issued in the
Merger shall have been authorized for listing on Nasdaq, subject to notice of
issuance.
7.10 NO GOVERNMENTAL LITIGATION. There shall not be pending or
threatened any Legal Proceeding in which a Governmental Body is or is
threatened to become a party or is otherwise involved: (a) challenging or
seeking to restrain or prohibit the consummation of the Merger or any of the
other transactions contemplated by this Agreement; (b) relating to the Merger
and seeking to obtain from Parent or any of its subsidiaries any damages that
may be material to Parent; (c) seeking to prohibit or limit in any material
respect Parent's ability to vote, receive dividends with respect to or
otherwise exercise ownership rights with respect to the stock of the
Surviving Corporation; or (d) which would materially and adversely affect the
right of Parent, the Surviving Corporation or any subsidiary of Parent to own
the assets or operate the business of the Company.
7.11 NO OTHER LITIGATION. There shall not be pending any Legal
Proceeding in which there is a reasonable possibility of an outcome that
would have a Material Adverse Effect on the Company or on Parent: (a)
challenging or seeking to restrain or prohibit the consummation of the Merger
or any of the other transactions contemplated by this Agreement; (b) relating
to the Merger and seeking to obtain from Parent or any of its subsidiaries
any damages that may be material to Parent; (c) seeking to prohibit or limit
in any material respect Parent's ability to vote, receive dividends with
respect to or otherwise exercise ownership rights with respect to the stock
of the Surviving Corporation; or (d) which would affect adversely the right
of Parent, the Surviving Corporation or any subsidiary of Parent to own the
assets or operate the business of the Company.
7.12 CONVERSION OF SERIES B PREFERRED STOCK. All outstanding shares of
Series B Preferred Stock shall be converted into Company Common Stock in
accordance with the provisions of Section 4.3 and the Company's certificate of
incorporation.
SECTION 8. CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY.
The obligation of the Company to effect the Merger and otherwise consummate
the transactions contemplated by this Agreement are subject to the satisfaction,
at or prior to the Closing, of the following conditions, and upon consummation
of the Closing, all conditions herein shall be deemed satisfied and any
liability for failure to satisfy any condition herein shall be precluded:
8.1 ACCURACY OF REPRESENTATIONS. The representations and warranties of
Parent and Merger Sub contained in this Agreement shall have been accurate in
all material respects as of the date of this Agreement and shall be accurate in
all material respects as of the Closing Date, except representations and
warranties that refer specifically to "the date of this Agreement" or a specific
date prior to the date of this Agreement, and except that any inaccuracies in
such representations and warranties shall be disregarded if the circumstances
giving rise to such inaccuracies (individually and collectively) do not
constitute a Material Adverse Effect on Parent
52.
<PAGE>
(it being understood that, for purposes of determining the accuracy of such
representations and warranties, (i) all "Material Adverse Effect" or other
materiality qualifications and (ii) any update or modification to the Company
Disclosure Schedule made or purported to have been made after the date of
this Agreement shall be disregarded).
8.2 PERFORMANCE OF COVENANTS. Each covenant and obligation that the
Parent are required to comply with or to perform at or prior to the Closing
shall have been complied with and performed in all material respects.
8.3 EFFECTIVENESS OF REGISTRATION STATEMENT. The S-4 Registration
Statement shall have become effective in accordance with the provisions of the
Securities Act, and no stop order shall have been issued by the SEC with respect
to the S-4 Registration Statement.
8.4 STOCKHOLDER APPROVAL. This Agreement and the Merger shall have
been duly approved by the Required Company Stockholder Vote, and the issuance of
Parent Common Stock in the Merger shall have been duly approved by the Required
Parent Stockholder Vote.
8.5 DOCUMENTS. The Company shall have received the following
documents:
(a) a legal opinion of Heller Ehrman White & McAuliffe LLP,
dated as of the Closing Date and addressed to the Company in a form
substantially similar to the opinion delivered pursuant to Section 7.6(b), to
the effect that the Merger will constitute a reorganization within the
meaning of Section 368 of the Code (it being understood that, in rendering
such opinion, Heller Ehrman White & McAuliffe LLP may rely upon tax
representation letters including those referred to in Section 6.12);
(b) a certificate executed on behalf of Parent by its Chief
Executive Officer, confirming that conditions set forth in Sections 8.1, 8.2,
8.3, 8.4 (with respect to Parent only), 8.6, 8.7, 8.8 (with respect to Parent
only), 8.9 (with respect to Parent only) and 8.10 have been duly satisfied.
8.6 NO MATERIAL ADVERSE CHANGE. There shall have been no material
adverse change in Parent's business, assets, liabilities, financial condition or
results of operations since the date of this Agreement (it being understood that
a decline in the price of Parent Common Stock shall not constitute, in and of
itself, a material adverse change).
8.7 LISTING. The shares of Parent Common Stock to be issued in the
Merger shall have been authorized for listing on Nasdaq, subject to notice of
issuance.
8.8 NO GOVERNMENTAL LITIGATION. There shall not be pending or
threatened any Legal Proceeding in which a Governmental Body is or is threatened
to become a party or is otherwise involved: (a) challenging or seeking to
restrain or prohibit the consummation of the Merger or any of the other
transactions contemplated by this Agreement; (b) relating to the Merger and
seeking to obtain from the Company any damages that may be material to the
Company; or (c) seeking to prohibit or limit in any material respect Parent's
ability to vote, receive dividends with respect to or otherwise exercise
ownership rights with respect to the stock of the Surviving Corporation; or (d)
which would materially and adversely affect the right of
53.
<PAGE>
Parent, the Surviving Corporation or any subsidiary of Parent to own the
assets or operate the business of the Company.
8.9 NO OTHER LITIGATION. There shall not be pending any Legal
Proceeding in which there is a reasonable possibility of an outcome that
would have a Material Adverse Effect on Parent or on the Company: (a)
challenging or seeking to restrain or prohibit the consummation of the Merger
or any of the other transactions contemplated by this Agreement; (b) relating
to the Merger and seeking to obtain from the Company or any of its
subsidiaries any damages that may be material to the Company; (c) seeking to
prohibit or limit in any material respect Parent's ability to vote, receive
dividends with respect to or otherwise exercise ownership rights with respect
to the stock of the Surviving Corporation; or (d) which would affect
adversely the right of Parent, the Surviving Corporation or any subsidiary of
Parent to own the assets or operate the business of the Company.
8.10 DIRECTORS. Parent shall have taken all actions necessary to
cause the number of authorized directors to be nine and Board of Directors of
Parent to include Drs. Pappas, Crooke and O'Malley in accordance with the
procedures set forth in Section 6.16.
SECTION 9. TERMINATION.
9.1 TERMINATION. This Agreement may be terminated prior to the
Effective Time, whether before or after approval of the Merger by the
stockholders of the Company:
(a) by mutual written consent of the Parent and the Company;
(b) by either Parent or the Company if the Merger shall not have
been consummated by February 28, 1999 (unless the failure to consummate the
Merger is attributable to a failure on the part of the party seeking to
terminate this Agreement to perform any material obligation required to be
performed by such party at or prior to the Effective Time);
(c) by either Parent or the Company if a court of competent
jurisdiction or other Governmental Body shall have issued a final and
non-appealable order, decree or ruling, or shall have taken any other action,
having the effect of permanently restraining, enjoining or otherwise
prohibiting the Merger;
(d) by either Parent or the Company if (i) the Company
Stockholders' Meeting shall have been held (either on the date for which such
Meeting was originally scheduled or pursuant to any permissible adjournment
or postponement) and (ii) this Agreement and the Merger shall not have been
adopted and approved at such meeting by the Required Company Stockholder Vote
(PROVIDED that the right to terminate this Agreement under this Section
9.1(d) shall not be available to the Company where the failure to obtain
Company stockholder approval shall have been caused by the action or failure
to act of the Company and such action or failure to act constitutes a
material breach by the Company of this Agreement);
(e) by Parent (at any time prior to the adoption and approval of
this Agreement and the Merger by the Required Company Stockholder Vote) if a
Triggering Event shall have occurred;
54.
<PAGE>
(f) by the Company if in accordance with Section 6.2(c) hereof
the Board of Directors of the Company withdraws, amends or modifies its
unanimous recommendation in favor of the Merger and accepts or recommends to
the Stockholders of the Company a Superior Offer.
(g) by either Parent or Company if (i) the Parent Stockholders'
Meeting shall have been held (either on the date for which such Meeting was
originally scheduled or pursuant to any permissible adjournment or
postponement) and (ii) issuance of the Parent Common Stock in the Merger
shall not have been approved at such meeting by the Required Parent
Stockholder Vote (provided that the right to terminate this Agreement under
this Section 9.1(g) shall not be available to Parent where the failure to
obtain Parent stockholder approval shall have been caused by the action or
failure to act of Parent and such action or failure to act constitutes a
material breach by Parent of this Agreement);
(h) by Parent if any of the Company's representations and
warranties contained in this Agreement shall be or shall have become
materially inaccurate, or if any of the Company's covenants contained in this
Agreement shall have been breached in any material respect and such
inaccuracy or breach (individually and collectively) will cause a Material
Adverse Effect on the Company; PROVIDED, HOWEVER, that if an inaccuracy in
the Company's representations and warranties or a breach of a covenant by the
Company is curable by the Company and the Company is continuing to exercise
all reasonable efforts to cure such inaccuracy or breach, then Parent may not
terminate this Agreement under this Section 9.1(h) on account of such
inaccuracy or breach; or
(i) by the Company if any of Parent's representations and
warranties contained in this Agreement shall be or shall have become
materially inaccurate, or if any of Parent's covenants contained in this
Agreement shall have been breached in any material respect and such
inaccuracy or breach (individually and collectively) will cause a Material
Adverse Effect on Parent; PROVIDED, HOWEVER, that if an inaccuracy in
Parent's representations and warranties or a breach of a covenant by Parent
is curable by Parent and Parent is continuing to exercise all reasonable
efforts to cure such inaccuracy or breach, then the Company may not terminate
this Agreement under this Section 9.1(i) on account of such inaccuracy or
breach.
9.2 NOTICE OF TERMINATION; EFFECT OF TERMINATION. Any termination
under Section 9.1 above will be effective immediately upon the delivery of
written notice of the terminating party to the other parties hereto. In the
event of the termination of this Agreement as provided in Section 9.1, this
Agreement shall be of no further force or effect; PROVIDED, HOWEVER, that (i)
this Section 9.2, Section 9.3 and Section 10 shall survive the termination of
this Agreement and shall remain in full force and effect, (ii) the
termination of this Agreement shall not relieve any party from any liability
for any breach of this Agreement and (iii) no termination of this Agreement
shall affect the obligations of the parties contained in the Confidentiality
Agreement, all of which obligations shall survive termination of this
Agreement in accordance with their terms.
9.3 EXPENSES; TERMINATION FEES.
(a) Except as set forth in this Section 9.3, all fees and
expenses incurred in connection with this Agreement and the transactions
contemplated by this Agreement shall be
55.
<PAGE>
paid by the party incurring such expenses, whether or not the Merger is
consummated; PROVIDED, HOWEVER, that Parent and the Company shall share
equally all fees and expenses, other than attorneys' fees, incurred in
connection with the printing and filing of the S-4 Registration Statement and
the Joint Proxy Statement/Prospectus and any amendments or supplements
thereto.
(b) If this Agreement is terminated by Parent pursuant to
Section 9.1(e), then the Company shall pay to Parent, in cash, a
nonrefundable fee equal to one million four hundred thousand dollars
($1,400,000) (the "TERMINATION FEE") in cash within three (3) business days
of such termination.
(c) If this Agreement is terminated by Company or Parent
pursuant to Section 9.1(d) and an Acquisition Transaction is publicly
announced at any time within six (6) months after the date of termination and
consummated within twelve (12) months after the date of termination, the
Company shall pay to Parent a nonrefundable fee equal to three percent (3%)
of the aggregate consideration received by the Company in such Acquisition
Transaction contemporaneously with the consummation of such Acquisition
Transaction.
(d) If this Agreement is terminated by the Company pursuant to
Section 9.1(f), then the Company shall pay to Parent the Termination Fee
contemporaneously with the written notice of termination.
SECTION 10. MISCELLANEOUS PROVISIONS.
10.1 AMENDMENT. This Agreement may be amended with the approval of
the respective boards of directors of the Company and Parent at any time
(whether before or after approval of this Agreement and the Merger by the
stockholders of the Company; and whether before or after approval of the
issuance of Parent Common Stock in the Merger by Parent's stockholders);
PROVIDED, HOWEVER, that (i) after any such approval of this Agreement and the
Merger by the Company's stockholders, no amendment shall be made which by law
or NASD regulation requires further approval of the stockholders of the
Company without the further approval of such stockholders, and (ii) after any
such approval of the issuance of Parent Company Stock in the Merger by
Parent's stockholders, no amendment shall be made which by law or NASD
regulation requires further approval of Parent's stockholders without the
further approval of such stockholders. This Agreement may not be amended
except by an instrument in writing signed on behalf of each of the parties
hereto.
10.2 WAIVER.
(a) No failure on the part of any party to exercise any power,
right, privilege or remedy under this Agreement, and no delay on the part of
any party in exercising any power, right, privilege or remedy under this
Agreement, shall operate as a waiver of such power, right, privilege or
remedy; and no single or partial exercise of any such power, right, privilege
or remedy shall preclude any other or further exercise thereof or of any
other power, right, privilege or remedy.
(b) No party shall be deemed to have waived any claim arising
out of this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of
56.
<PAGE>
such claim, power, right, privilege or remedy is expressly set forth in a
written instrument duly executed and delivered on behalf of such party; and
any such waiver shall not be applicable or have any effect except in the
specific instance in which it is given.
10.3 NO SURVIVAL OF REPRESENTATIONS AND WARRANTIES. None of the
representations and warranties contained in this Agreement or in any
certificate (except as provided in the Tax Representation Letters attached as
Exhibits C-1 and C-2 hereto) delivered pursuant to this Agreement shall
survive the Merger.
10.4 ENTIRE AGREEMENT; COUNTERPARTS. This Agreement and the other
agreements referred to herein constitute the entire agreement and supersede
all prior agreements and understandings, both written and oral, among or
between any of the parties with respect to the subject matter hereof and
thereof. This Agreement may be executed in several counterparts, each of
which shall be deemed an original and all of which shall constitute one and
the same instrument.
10.5 APPLICABLE LAW; JURISDICTION. THIS AGREEMENT IS MADE UNDER, AND
SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF
CALIFORNIA APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED SOLELY THEREIN,
WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAW. In any action
between or among any of the parties, whether arising out of this Agreement or
otherwise, (a) each of the parties irrevocably and unconditionally consent in
the State of California; (b) if any such action is commenced in a state
court, then, subject to applicable law, no party shall object to the removal
of such action to any federal court located in the law, no party shall object
to the removal of such action to any federal court located in the State of
California; (c) each of the parties irrevocably waivers the right to trial by
jury; and (d) each of the parties irrevocably consents to service of process
by first class certified mail, return receipt requested, postage prepaid, to
the address at which such party is to receive notice in accordance with
Section 10.9.
10.6 DISCLOSURE SCHEDULE. Each of the Company Disclosure Schedule and
the Parent Disclosure Schedule shall be arranged in separate parts
corresponding to the numbered and lettered sections contained in Sections 2
and 3, respectively, and the information disclosed in any numbered or
lettered part shall be deemed to relate to and to qualify only the particular
representation or warranty set forth in the corresponding numbered or
lettered section in Section 2 or 3, respectively, and shall not be deemed to
relate to or to qualify any other representation or warranty.
10.7 ATTORNEYS' FEES. In any action at law or suit in equity to
enforce this Agreement or the rights of any of the parties hereunder, the
prevailing party in such action or suit shall be entitled to receive a
reasonable sum for its attorneys' fees and all other reasonable costs and
expenses incurred in such action or suit.
10.8 ASSIGNABILITY. This Agreement shall be binding upon, and shall
be enforceable by and inure solely to the benefit of, the parties hereto and
their respective successors and assigns; PROVIDED, HOWEVER, that neither this
Agreement nor any of the other party's rights hereunder may be assigned by
any party without the prior written consent of the other party, and
57.
<PAGE>
any attempted assignment of this Agreement or any of such rights by a party
without such consent shall be void and of no effect. Except as set forth in
Section 6.7 with respect to the current directors and officers of the
Company, nothing in this Agreement, express or implied, is intended to or
shall confer upon any Person any right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement.
10.9 NOTICES. Any notice or other communication required or permitted
to be delivered to any party under this Agreement shall be in writing and
shall be deemed properly delivered, given and received when delivered (by
hand, by registered mail, by courier or express delivery service or by
facsimile) to the address or facsimile telephone number set forth beneath the
name of such party below (or to such other address or facsimile telephone
number as such party shall have specified in a written notice given to the
other parties hereto):
<TABLE>
<S> <C>
if to Parent: Megabios Corp.
863A Mitten Road
Burlingame, CA 94010
Attn: Benjamin F. McGraw III, Pharm.D.
Facsimile: (650) 652-1990
with a copy to: Cooley Godward LLP
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Attn: Patrick A. Pohlen
Facsimile: (650) 849-7400
if to Merger Sub: Montana Acquisition Sub, Inc.
863A Mitten Road
Burlingame, CA 94010
Attn: Benjamin F. McGraw III, Pharm.D.
Facsimile: (650) 652-1990
if to the Company: GeneMedicine, Inc.
8301 New Trails Drive
The Woodlands, TX 77381-4248
Attn: Eric Tomlinson
Facsimile: (281) 419-0795
with a copy to: Heller Ehrman White & McAuliffe
525 University Avenue
Palo Alto, CA 94301
Attn: Stephen C. Ferruolo
Facsimile: (650) 324-0638
</TABLE>
10.10 COOPERATION. The Company agrees to cooperate fully with Parent
and to execute and deliver such further documents, certificates, agreements
and instruments and to take such
58.
<PAGE>
other actions as may be reasonably requested by Parent to evidence or reflect
the transactions contemplated by this Agreement and to carry out the intent
and purposes of this Agreement.
10.11 CONSTRUCTION.
(a) For purposes of this Agreement, whenever the context
requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine
gender shall include the masculine and neuter genders; and the neuter gender
shall include masculine and feminine genders.
(b) The parties hereto agree that any rule of construction to
the effect that ambiguities are to be resolved against the drafting party
shall not be applied in the construction or interpretation of this Agreement.
(c) As used in this Agreement, the words "include" and
"including," and variations thereof, shall not be deemed to be terms of
limitation, but rather shall be deemed to be followed by the words "without
limitation."
(d) Except as otherwise indicated, all references in this
Agreement to "Sections" and "Exhibits" are intended to refer to Sections of
this Agreement and Exhibits to this Agreement.
59.
<PAGE>
IN WITNESS WHEREOF, the parties have caused this AGREEMENT AND PLAN OF
MERGER AND REORGANIZATION to be executed as of the date first above written.
MEGABIOS CORP.
By: /s/ Benjamin F. McGraw, III
------------------------------------
Printed Name: Benjamin F. McGraw, III
--------------------------
Title: Chairman, President & CEO
---------------------------------
MONTANA ACQUISITION SUB, INC.
By: /s/ Benjamin F. McGraw, III
------------------------------------
Printed Name: Benjamin F. McGraw, III
--------------------------
Title: Chairman, President & CEO
---------------------------------
GENEMEDICINE, INC.
By: /s/ Eric Tomlinson
------------------------------------
Printed Name: Eric Tomlinson
--------------------------
Title: Vice Chairman, Board of Directors
---------------------------------
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
SIGNATURE PAGE
EXECUTION COPY
<PAGE>
EXHIBIT INDEX
<TABLE>
<S> <C>
Exhibit A. . . . . . .Certain Definitions
Exhibit B-1. . . . . .Form of Surviving Corporation Certificate of Incorporation
Exhibit B-2. . . . . .Form of Surviving Corporation Bylaws
Exhibit C-1. . . . . .Form of Tax Representation Letter to be delivered by Parent and
Merger Sub
Exhibit C-2. . . . . .Form of Tax Representation Letter to be delivered by Company
</TABLE>
i
<PAGE>
EXHIBIT A
CERTAIN DEFINITIONS
For purposes of the Agreement (including this Exhibit A):
ACQUISITION PROPOSAL. "ACQUISITION PROPOSAL" shall mean any offer or
proposal (other than an offer or proposal by Parent) contemplating or
otherwise relating to any Acquisition Transaction.
ACQUISITION TRANSACTION. "ACQUISITION TRANSACTION" shall mean any
transaction or series of related transactions involving:
(a) any merger, consolidation, share exchange, business combination,
issuance of securities, acquisition of securities, tender offer, exchange
offer or other similar transaction (i) in which the Company is a constituent
corporation, (ii) in which a Person or "group" (as defined in the Exchange
Act and the rules promulgated thereunder) of Persons directly or indirectly
acquires the Company or more than fifty percent (50%) of the Company's
business or directly or indirectly acquires beneficial or record ownership of
securities representing more than twenty percent (20%) of the outstanding
securities of any class of voting securities of the Company, or (iii) in
which the Company issues securities representing more than twenty percent
(20%) of the outstanding securities of any class of voting securities of the
Company;
(b) any sale, lease (other than in the ordinary course of business),
exchange, transfer, license (other than in the ordinary course of business),
acquisition or disposition of more than 50% of the assets of the Company; or
(c) any liquidation or dissolution of the Company.
AGREEMENT. "AGREEMENT" shall mean the Agreement and Plan of Merger and
Reorganization to which this Exhibit A is attached, as it may be amended from
time to time.
COMPANY COMMON STOCK. "COMPANY COMMON STOCK" shall mean the Common
Stock, $.001 par value per share, of the Company.
COMPANY CONTRACT. "COMPANY CONTRACT" shall mean any Contract: (a) to
which the Company is a party; (b) by which the Company or any asset of the
Company is or may become bound or under which the Company has, or may become
subject to, any obligation; or (c) under which the Company has or may acquire
any right or interest.
COMPANY PROPRIETARY ASSET. "COMPANY PROPRIETARY ASSET" shall mean any
Proprietary Asset owned by or licensed to the Company or otherwise used by
the Company.
CONSENT. "CONSENT" shall mean any approval, consent, ratification,
permission, waiver or authorization (including any Governmental
Authorization).
A-1.
<PAGE>
CONTRACT. "CONTRACT" shall mean any written, oral or other agreement,
contract, subcontract, lease, understanding, instrument, note, option,
warranty, purchase order, license, sublicense, insurance policy, benefit plan
or legally binding commitment or undertaking of any nature.
ENCUMBRANCE. "ENCUMBRANCE" shall mean any lien, pledge, hypothecation,
charge, mortgage, security interest, encumbrance, claim, infringement,
interference, option, right of first refusal, preemptive right, community
property interest or restriction of any nature (including any restriction on
the voting of any security, any restriction on the transfer of any security
or other asset, any restriction on the receipt of any income derived from any
asset, any restriction on the use of any asset and any restriction on the
possession, exercise or transfer of any other attribute of ownership of any
asset).
ENTITY. "ENTITY" shall mean any corporation (including any non-profit
corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any limited
liability company or joint stock company), firm or other enterprise,
association, organization or entity.
ENVIRONMENTAL LAW. "ENVIRONMENTAL LAW" means any federal, state, local
or foreign Legal Requirement relating to pollution or protection of human
health or the environment (including ambient air, surface water, ground
water, land surface or subsurface strata), including any law or regulation
relating to emissions, discharges, releases or threatened releases of
Materials of Environmental Concern, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or
handling of Materials of Environmental Concern.
EXCHANGE ACT. "EXCHANGE ACT" shall mean the Securities Exchange Act of
1934, as amended.
GOVERNMENTAL AUTHORIZATION. "GOVERNMENTAL AUTHORIZATION" shall mean
any: (a) permit, license, certificate, franchise, permission, clearance,
registration, qualification or authorization issued, granted, given or
otherwise made available by or under the authority of any Governmental Body
or pursuant to any Legal Requirement; or (b) right under any Contract with
any Governmental Body.
GOVERNMENTAL BODY. "GOVERNMENTAL BODY" shall mean any: (a) nation,
state, commonwealth, province, territory, county, municipality, district or
other jurisdiction of any nature; (b) federal, state, local, municipal,
foreign or other government; or (c) governmental or quasi-governmental
authority of any nature (including any governmental division, department,
agency, commission, instrumentality, official, organization, unit, body or
Entity and any court or other tribunal).
LEGAL PROCEEDING. "LEGAL PROCEEDING" shall mean any action, suit,
litigation, arbitration, proceeding (including any civil, criminal,
administrative, investigative or appellate proceeding), hearing, inquiry,
audit, examination or investigation commenced, brought,
A-2.
<PAGE>
conducted or heard by or before, or otherwise involving, any court or other
Governmental Body or any arbitrator or arbitration panel.
LEGAL REQUIREMENT. "LEGAL REQUIREMENT" shall mean any federal, state,
local, municipal, foreign or other law, statute, constitution, principle of
common law, resolution, ordinance, code, edict, decree, rule, regulation,
ruling or requirement issued, enacted, adopted, promulgated, implemented or
otherwise put into effect by or under the authority of any Governmental Body.
MATERIAL ADVERSE EFFECT. An event, violation, inaccuracy, circumstance
or other matter will be deemed to have a "Material Adverse Effect" on the
Company if such event, violation, inaccuracy, circumstance or other matter
(considered together with all other matters that would constitute exceptions
to the representations and warranties set forth in the Agreement but for the
presence of "Material Adverse Effect" or other materiality qualifications, or
any similar qualifications, in such representations and warranties) would
have a material adverse effect on (i) the business, assets, liabilities,
financial condition or results of operations of the Company taken as a whole,
(ii) the ability of the Company to consummate the Merger or any of the other
transactions contemplated by the Agreement or to perform any of its
obligations under the Agreement, or (iii) Parent's ability to vote, receive
dividends with respect to or otherwise exercise ownership rights with respect
to the stock of the Surviving Corporation. An event, violation, inaccuracy,
circumstance or other matter will be deemed to have a "Material Adverse
Effect" on Parent if such event, violation, inaccuracy, circumstance or other
matter (considered together with all other matters that would constitute
exceptions to the representations and warranties set forth in the Agreement
but for the presence of "Material Adverse Effect" or other materiality
qualifications, or any similar qualifications, in such representations and
warranties) would have a material adverse effect on (i) the business, assets,
liabilities, financial condition or results of operations of Parent and its
subsidiaries taken as a whole, (ii) the ability of Parent to consummate the
Merger or any of the other transactions contemplated by the Agreement or to
perform any of its obligations under the Agreement, or (iii) Parent's ability
to vote, receive dividends with respect to or otherwise exercise ownership
rights with respect to the stock of the Surviving Corporation.
MATERIALS OF ENVIRONMENTAL CONCERN. "MATERIALS OF ENVIRONMENTAL
CONCERN" include chemicals, pollutants, contaminants, wastes, toxic
substances, petroleum and petroleum products and any other substance
regulated by any Environmental Law.
NASDAQ. "NASDAQ" shall mean the Nasdaq National Market.
PARENT COMMON STOCK. "PARENT COMMON STOCK" shall mean the Common Stock,
$.001 par value per share, of Parent.
PARENT CONTRACT. "PARENT CONTRACT" shall mean any Contract: (a) to
which Parent is a party; (b) by which Parent or any asset of Parent is or may
become bound or under which Parent has, or may become subject to, any
obligation; or (c) under which Parent has or may acquire any right or
interest.
A-3.
<PAGE>
PARENT PROPRIETARY ASSET. "PARENT PROPRIETARY ASSET" shall mean any
Proprietary Asset owned by or licensed to Parent or otherwise used by Parent.
PERSON. "PERSON" shall mean any individual, Entity or Governmental Body.
PERMITTED ENCUMBRANCES. "PERMITTED ENCUMBRANCES" means such of the
following as to which no enforcement, collection, execution, levy or
foreclosure proceeding shall have been commenced: (a) liens for taxes,
assessments and governmental charges or levies not yet due and payable which
are not in excess of $50,000 in the aggregate; (b) Encumbrances imposed by
law, such as materialmen's, mechanics', carriers', workmen's and repairmen's
liens and other similar liens arising in the ordinary course of business
securing obligations that (i) are not overdue for a period of more than 30
days and (ii) are not in excess of $5,000 in the case of a single property or
$50,000 in the aggregate at any time; (c) pledges or deposits to secure
obligations under workers' compensation laws or similar legislation or to
secure public or statutory obligations; and (d) minor survey exception,
reciprocal easement agreements and other customary Encumbrances on title to
real property that (i) were not incurred in connection with any indebtedness,
(ii) do not render title to the property encumbered thereby unmarketable and
(iii) do not, individually or in the aggregate, materially adversely affect
the value or use of such property for its current and anticipated purposes.
PROPRIETARY ASSET. "PROPRIETARY ASSET" shall mean any: (a) patent,
patent application, trademark (whether registered or unregistered), trademark
application, trade name, fictitious business name, service mark (whether
registered or unregistered), service mark application, copyright (whether
registered or unregistered), copyright application, maskwork, maskwork
application, trade secret, know-how, customer list, franchise, system,
computer software, computer program (in source and executable form),
algorithm, invention, design, blueprint, engineering drawing, proprietary
product, technology, proprietary right or other intellectual property right
or intangible asset in any jurisdiction in the world; or (b) right to use or
exploit any of the foregoing in any jurisdiction in the world.
REPRESENTATIVES. "REPRESENTATIVES" shall mean officers, directors,
employees, agents, attorneys, accountants, advisors and representatives.
RIGHTS AGREEMENT. "RIGHTS AGREEMENT" shall mean the Rights Agreement by
and between the Company and American Stock Transfer & Trust Company dated as
of January 16, 1996, as amended January 31, 1998 (or similar plan commonly
referred to as a "poison pill").
SEC. "SEC" shall mean the United States Securities and Exchange
Commission.
SECURITIES ACT. "SECURITIES ACT" shall mean the Securities Act of 1933,
as amended.
SUBSIDIARY. An entity shall be deemed to be a "Subsidiary" of another
Person if such Person directly or indirectly owns, beneficially or of record,
an amount of voting securities of other interests in such Entity that is
sufficient to enable such Person to elect at leased a majority of the members
of such Entity's Board of Directors or other governing body.
A-4.
<PAGE>
SUPERIOR OFFER. "SUPERIOR OFFER" shall mean an unsolicited, bona fide
written offer made by a third party to consummate any of the following
transactions: (i) the purchase of more than 50% of the outstanding shares of
Company Common Stock or (ii) a sale or other disposition by the Company of
all or substantially all of its assets, on terms that the Board of Directors
of the Company determines, in its reasonable judgment, after consultation
with its financial advisor, to be more favorable to the Company's
stockholders than the terms of the Merger; PROVIDED, HOWEVER, that any such
offer shall not be deemed to be a "Superior Offer" if any financing required
to consummate the transaction contemplated by such offer is not committed or
is not likely to be obtained by such third party on a timely basis.
TAX. "TAX" shall mean any tax (including any income tax, franchise tax,
capital gains tax, gross receipts tax, value-added tax, surtax, excise tax,
AD VALOREM tax, transfer tax, stamp tax, sales tax, use tax, property tax,
business tax, withholding tax or payroll tax), levy, assessment, tariff, duty
(including any customs duty), deficiency or fee, and any related charge or
amount (including any fine, penalty or interest), imposed, assessed or
collected by or under the authority of any Governmental Body.
TAX RETURN. "TAX RETURN" shall mean any return (including any
information return), report, statement, declaration, estimate, schedule,
notice, notification, form, election, certificate or other document or
information filed with or submitted to, or required to be filed with or
submitted to, any Governmental Body in connection with the determination,
assessment, collection or payment of any Tax or in connection with the
administration, implementation or enforcement of or compliance with any Legal
Requirement relating to any Tax.
TRIGGERING EVENT. A "TRIGGERING EVENT" shall be deemed to have occurred
if: (i) the Board of Directors of the Company shall have failed to
recommend, or shall for any reason have withdrawn or shall have amended or
modified in a manner adverse to Parent its unanimous recommendation in favor
of, the adoption and approval of the Agreement or the approval of the Merger;
(ii) the Company shall have failed to include in the Joint Proxy
Statement/Prospectus the unanimous recommendation of the Board of Directors
of the Company in favor of the adoption and approval of the Agreement and the
approval of the Merger; (iii) the Board of Directors of the Company fails to
reaffirm its unanimous recommendation in favor of the adoption and approval
of the Agreement and the approval of the Merger within five (5) business days
after the Parent request in writing that such recommendation be reaffirmed;
(iv) the Board of Directors of the Company shall have approved, endorsed or
recommended any Acquisition Proposal; (v) the Company shall have entered into
any letter of intent or similar document or any Contract relating to any
Acquisition Proposal; (vi) the Company shall have failed to hold the Company
Stockholders' Meeting as promptly as practicable and in any event within 45
days after the Form S-4 Registration Statement is declared effective under
the Securities Act; (vii) a tender or exchange offer relating to securities
of the Company shall have been commenced and the Company shall not have sent
to its securityholders, within five (5) business days after the commencement
of such tender or exchange offer, a statement disclosing that the Company
recommends rejection of such tender or exchange offer; (viii) an Acquisition
Proposal is publicly announced, and the Company (A) fails to issue a press
release announcing its opposition to such Acquisition Proposal within five
business days after such Acquisition Proposal is announced or
A-5.
<PAGE>
(B) otherwise fails to actively oppose such Acquisition Proposal; or (ix) the
Company shall have breached in any material respect any of its obligations under
Section 4.2 of the Agreement.
A-6.
